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Abstract 
Myogenesis is the process by which mesodermal progenitor cells are committed to 
a myogenic fate and differentiate to form myofibers via a complex transcriptional 
network largely controlled by Myogenic Regulatory Factors (MRFs). One such 
MRF, MyoD, has been extensively investigated and its regulatory network shown 
to include not only protein-coding mRNAs, but non-coding RNAs and epigenetic 
modifications too, leading to highly coordinated transcriptional activation of target 
genes. The advances in high-throughput and small-RNA sequencing have 
revealed that transcriptional output by RNA Polymerase III, like Polymerase II, is 
differentially regulated between tissues and during development. This indicates 
that developmental transcriptional networks are potentially more complex than 
previously thought, involving cross-talk between multiple polymerases. 
Polr3G is a subunit unique to RNA Polymerase III, is associated with maintaining 
pluripotency and proliferation in hESCs and exists in 2 distinct forms in mammals 
and in Xenopus. This thesis presents the distinct expression profiles of Polr3G and 
its paralog Polr3gL during Xenopus tropicalis development, the specific expression 
of Polr3G in the skeletal muscle lineage and investigation into its regulation by 
myogenic factors. Custom tRNA Xenopus microarrays show the regulation of 
tRNAs by Polr3G at the earliest point of embryonic transcriptional activation, and 
the differential regulation of tRNAs in the muscle lineage in response to changes in 
expression of Polr3G and Polr3gL and expression changes to RNA Polymerase III 
targets and transcriptional machinery in animal caps undergoing myogenic 
differentiation. This thesis also presents finding from an RNA-seq study analysing 
founder (F0) embryos where MyoD was disrupted using CRISPR/Cas9 methods to 
determine early gene targets of MyoD. Together, this thesis proposes that a 
conserved downregulation of RNA Polymerase III activity during differentiation is 
shared between this model and previous cell culture studies but that the novel 
factors, Polr3G and Polr3gL, may be implicated in its mediation. 
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The central dogma of molecular biology is that the flow of genetic information from 
DNA to Protein involves a two-step process of transcription and translation. 
Transcriptional and translational outputs define a cell’s function, and there are 
multiple levels of regulation controlling these processes, that regulate and define 
overall gene expression levels within a cell.  
During embryonic development, cells become restricted to particular lineages by 
activating the expression of specific sets of genes. In animals, 3 RNA 
Polymerases transcribe DNA; RNA Polymerase I transcribes Ribosomal RNAs; 
RNA Polymerase II transcribes protein coding mRNAs, microRNAs and other long 
non-coding RNAs and RNA Polymerase III synthesises small structural RNAs 
including 5S ribosomal RNA, U6 spliceosomal RNA and tRNAs. Much is known 
about the regulation of RNA Polymerase II activity during development, and recent 
advances in high-throughput sequencing has meant that transcriptional networks 
can be studied even at the single cell level (Briggs et al., 2018; Ramsköld et al., 
2012). The regulation of the activity of RNA Polymerases I and III and their roles in 
development and differentiation however, have received less attention- particularly 
with regards to their role in development.  
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1.1. Regulation of Myogenesis by RNA Polymerase II products 
Myogenesis is the process of converting multipotent mesodermal cells into 
terminally differentiated myofibers through a complex network of transcriptional 
regulation. This program of differentiation is driven largely by a family of closely 
related transcription factors known as Myogenic Regulatory Factors; MyoD, Myf5, 
MRF4 and Myogenin (Pownall et al., 2002). Extensive study of the regulation of 
myogenesis by these four factors has revealed the level of complexity through 
which their activity is activated, enhanced and also modulated in early 
development.  
 
Identification of MRFs 
Transfection experiments on 10T1/2 fibroblasts were used to determine the factors 
capable of converting them to myoblasts and revealed that transfection of a single 
locus could convert cells to a myogenic fate (Pinney et al., 1988) and other studies 
identified a single cDNA, MyoD, capable of converting a number of different cell 
types to myoblasts, categorizing it as the first candidate master regulator of 
myogenesis (Davis et al., 1987). 
MyoD is a member of a family of transcription factors including Myf5, MRF4 and 
Myogenin that all containing a basic helix-loop-helix (bHLH) domain (Pownall et 
al., 2002). These factors show highly regulated temporal and spatial expression 
patterns, specific to the muscle lineage, and function in the specification of 
myogenic lineage and driving terminal differentiation of skeletal muscle.  
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Knock-out studies in mice have been particularly important in characterising the 
roles of these factors and during development as well as revealing their partial 
redundancy. Myf5 and MyoD both act as specification factors of multipotent 
myogenic progenitors located in the somites. Typically, Myf5 is the earliest MRF to 
be expressed in the muscle lineages (Hopwood et al., 1991; Ott et al., 1991) and 
is expressed early in the dorsal-medial somites whilst MyoD expression is induced 
soon after in the dorsal-lateral somites, giving rise to the trunk/intercostal muscles 
and body wall/limb muscles respectively. Myf5/MyoD null mice fail to generate 
skeletal muscle, however, expression of either Myf5 or MyoD alone is sufficient to 
partially restore determination of skeletal muscle myoblasts, although both 
individual null mutations result in defects within different muscle lineages (Haldar 
et al., 2008; Rudnicki et al., 1993).  
More recent cell culture studies have also shown that Myf5 and MyoD genome-
wide binding patterns are largely similar, and that binding of both factors is 
associated with histone acetylation. But because Myf5 is expressed first, their 
model predicts that binding of Myf5 is more associated with histone acetylation 
and chromatin reorganisation rather than transcriptional activation of targets, whilst 
ChIP revealed that MyoD recruits RNA Polymerase II to target genes and 
activates gene expression. This suggests that Myf5 may act prior to MyoD in order 
to specify the myogenic programme before myogenic differentiation is activated by 
MyoD once it is expressed (Conerly et al., 2016). 
In contrast, Myogenin null mice show defects in development and differentiation of 
skeletal muscle tissues, despite normal specification of myoblasts (Hasty et al., 
1993; Nabeshima et al., 1993). This evidence suggests that Myogenin is crucial in 
driving terminal differentiation of myoblasts, but is not required for initial 
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specification of myogenic progenitors. Myogenin is activated later in development 
than the other factors, is directly activated by MyoD and acts to drive terminal 
differentiation. 
The role of Mrf4 is less well defined- initially being expressed in mice soon after 
induction of Myf5, its expression decreases before second induction later during 
myogenesis (Jennings, 1992). Therefore permitting it to potentially have roles in 
both myogenic determination and differentiation. The expression of an Mrf4 
transgene controlled by a Myogenin promoter partially restores full myogenesis 
supporting its’ role in terminal differentiation (Zhu and Miller, 1997). Moreover, the 
close localisation of Mrf4 to the Myf5 locus meant that in initial null experiments 
mutation of Myf5 also resulted in disruption of the mrf4 gene and in Myf5/MyoD 
null mice with maintained expression of Mrf4, skeletal muscle differentiation is 
preserved (Kassar-Duchossoy et al., 2004). This indicates that, whilst the MRFs 
have distinct roles during myogenesis, there is also a level of redundancy among 
factors (Figure 1.1). 
 
Figure 1.1. Schematic overview of myogenesis and the key bHLH factors that drive specification and 
differentiation as “master regulators”. 
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As well as their distinct temporal expression patterns during development; MRFs 
have different molecular features within their functional domains, defining them as 
either specification factors or differentiation factors. Substitution of the Myogenin 
coding sequence into the Myf5 locus alone is not sufficient to restore specification 
of myoblasts and normal development of skeletal muscle indicating that timing 
alone is not a sole determinant of the role of an MRF (Wang and Jaenisch, 1997). 
A later study revealed that structural differences between factors enable MRFs to 
act as specification factors or differentiation factors. A specific motif within the 
MyoD protein with high sequence conservation throughout vertebrate species was 
revealed to be key to its function as a myogenic specification factor. The motif is 
located within the carboxy-terminal domain of alpha Helix III of MyoD, and is also 
conserved to Myf5. Whilst Helix III of Myogenin has some sequence similarity to 
this motif, substitution of the Myogenin sequence into a chimeric MyoD protein is 
not able to recapitulate MyoD activity. Moreover, substitution of the MyoD motif is 
sufficient to convert Myogenin into a specification factor (Bergstrom and Tapscott, 
2001). Therefore, whilst some redundancy is present between these factors, clear 
structural differences enable them to function distinctly and work collaboratively to 
induce a wide myogenic transcriptional programme. 
 
1.1.1. The MyoD transcriptional network.  
 
Interaction between MRFs and E-proteins 
As part of the bHLH family of transcription factors, the MRFs require dimerization 
in order to bind to DNA at target promoter regions. They can form both homo-
dimers with themselves, or hetero-dimers with other factors such as E-proteins, 
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which are expressed throughout development in different tissues. The basic 
domain of bHLH factors is required for DNA binding at target sites whilst the HLH 
domain facilitates dimerization with partnering E proteins. Together, these dimers 
bind the specific consensus sequence CANNTG in the DNA, known as E boxes. 
During Myogenesis, MyoD associates with E12/E47 resulting in activation of 
transcription of myogenic genes (Lluís et al., 2005). The crucial role of dimerization 
between MyoD and E47 in the activation of MyoD target genes was shown by 
tethering of these proteins to force dimerization. Transfection of the MyoD-E47 
fusion into 10T1/2 cells is sufficient to both overcome negative regulation and 
greatly enhances expression of myogenic genes (Neuhold and Wold, 1993). 
Importantly, binding at two E-box sites located in close proximity to one another is 
necessary for activation of transcription by MyoD (Weintraub et al., 1990). 
Surprisingly however, it has been reported in C2C12 cells that MyoD binding sites 
are detected at E-boxes throughout the genome, and not just specifically at 
myogenic target gene promoters (Cao et al., 2010). Moreover, another study 
revealed that the overall genome binding patterns of MyoD identified through 
ChIP-Seq are conserved between endogenous MyoD in myotubes and 
overexpressed lenti-MyoD expressed in MyoD-/- Myf5-/- MEFs (Yao et al., 2013b). 
Additionally, overexpression of MyoD in MEFs does not result in promiscuous 
binding of additional sites in the genome from the reported binding in myotubes, 
and the introduced MyoD protein still requires the formation of heterodimers with 
E-proteins in order to bind DNA. This indicates that there is a biological measure 
to ensure that MyoD binding at the genome-wide sites observed in C2C12 cells is 
regulated (Yao et al., 2013b).  
22 
 
Interestingly, MyoD binding is not always associated with activation of gene 
transcription (Cao et al., 2010). This therefore indicates that MyoD occupancy 
alone is not sufficient to drive gene expression, and that therefore additional 
regulation exists to activate expression exclusively at target genes. Comparisons 
of the binding patterns of MyoD and the bHLH neurogenic factor NeuroD2 
identified that, whilst both factors bind to shared E-box sites in the genome with a 
GC core of the consensus, only factor specific binding at private E-box sites is 
accompanied by activation of lineage specific gene expression and driving of 
differentiation programs. For MyoD the sequences are CAGGTG and CAGCTG 
whereas for NeuroD2 this sequence is CAGATG. Private binding at these specific 
sites is driven both by chromatin accessibility and the presence of co-factor 
binding motifs i.e. Meis sites are located at MyoD preferred sites (Fong et al., 
2012). In addition, by replacing the bHLH domain of MyoD with that of NeuroD2, 
its role becomes that of a Neurogenic factor, activating NeuroD2 target genes, 
indicating that MyoD’s function as a master regulator of myogenic differentiation 
depends largely on its protein sequence defining binding site specificity (Fong et 
al., 2015).  
 
Id proteins (Id1, Id2, and Id3) are HLH factors capable of binding both bHLH 
proteins and their co-factors and preventing the formation of dimer complexes. Id 
proteins therefore act as a mechanism of repression of bHLH transcriptional 
activation (Benezra et al., 1990; Wang and Baker, 2015). In myogenesis, Id 
proteins interact with both MRFs and E proteins to inhibit differentiation. Evidence 
exists to suggest that all three Id proteins bind to E-proteins but only two proteins 
interact with MRFs, specifically Myf5 and MyoD. Therefore suggesting that the 
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regulation by these proteins is important for early myogenic specification rather 
than terminal differentiation (Langlands et al., 1997). Expression of Id1 is depleted 
in terminally differentiated muscle cells, and its overexpression in C2C12 cells 
causes delays in myogenic differentiation (Jen et al., 1992). Therefore, direct 
inhibition of E protein-MRF dimerisation is a possible negative regulator of MRF 
activity during development. However, this requires further investigation. 
 
Interaction between MyoD and co-factors 
Alone, MyoD is sufficient to drive myogenic specification in many cell types and in 
subpopulations of myoblasts in vivo (Haldar et al., 2008), but full differentiation and 
expression of contractile proteins requires its interaction with additional factors 
(Hopwood and Gurdon, 1990; Tapscott, 2005). Therefore, in order to direct full 
myogenic differentiation, MyoD must activate a wide network of target genes 
through interaction with assistance through a number of co-factors.  
Mef2 
The Mef2 family of MADS-box containing transcription factors assists the MRFs in 
activating transcription of myogenic genes during muscle differentiation. Some 
factors belonging to this family, mef2c for example, are activated directly by MRFs 
early in myogenic differentiation and subsequently act in coordination with MRFs 
to drive full myogenic differentiation (Dodou et al., 2003; Naidu et al., 1995; Wang 
et al., 2001). Unlike MRFs, MEF expression is not restricted to skeletal muscle and 
Mef overexpression alone cannot convert fibroblasts (Gossett et al., 1989). 
Despite this, in co-operation with Mef factors, MyoD increases its efficiency of 
conversion to myoblasts (Molkentin et al., 1995) and at myogenic target genes, 
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Mef2 binding sites are located close to E-boxes (Wasserman and Fickett, 1998). 
Activation of target genes by MyoD binding shows distinct temporal regulation, 
which is in part, controlled by interaction of MyoD with primary target genes, such 
as Mef2 (Penn et al., 2004). 
Pbx 
Another family shown to interact with MyoD family members; the Pbx TALE-class 
homeodomain proteins, form complexes with an additional homeodomain protein, 
Meis, and act as ‘pioneer” factors which are able to bind to DNA in repressive 
chromatin in order to mark MyoD target genes such as Myogenin and enable 
activation transcription by MyoD (Berkes et al., 2004). This is achieved through 
binding of the protein complex to DNA at specific motifs of target gene promoters 
(of note the Myogenin promoter), prior to the activation of transcription, and the 
recruitment of MyoD through cooperative binding via its conserved bHLH H/C and 
Helix III domains (Knoepfler et al., 1999; Sartorelli, V; Caretti, 2005). In studies 
comparing the binding activities of MyoD and NeuroD2, MyoD specific binding 
sites are shown to be enriched for Pbx/Meis binding sites, whilst sites specific for 
NeuroD2, a neurogenic bHLH factor, are enriched for a different Pbx complex 
(Fong et al., 2012). Pbx/Meis sites are crucial to the maintenance of MyoD as a 
myogenic factor, and only in deleting these sequences is MyoD converted to a 
fully neurogenic factor (Fong et al., 2015). It has been shown that Pbx proteins 
have a particular role in the differentiation of fast-muscle by MyoD (Maves et al., 
2007; Yao et al., 2013a). The Pbx-Meis complex also has roles in other 
differentiation pathways and interacts with other bHLH factors all through their 
conserved domains. Thus indicating a conserved mechanism of regulating bHLH 
factor activity in development. 
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p38 
Factors such as p38 Mitogen Activated Protein Kinase (MAPK) can act as 
limitation factors to MyoD-dependent transcription, resulting in waves of target 
gene activation. This is achieved through p38-dependent phosphorylation of E47 
which promotes heterodimerisation with MyoD and occupancy at target gene 
promoters, like that of muscle creatine kinase (MCK) (Lluís et al., 2005). p38 also 
facilitates MyoD/Mef2 complex assembly and binding to late target gene 
promoters, which can be activated early through overexpression of p38. This is a 
regulatory mechanism known as a ‘feed-forward’ circuit. The MyoD-induced Feed-
Forward circuit means some direct targets are activated within 6 hours of MyoD 
expression, while later targets don’t show activation of expression for days after, 
despite still being directly bound by MyoD (Bergstrom et al., 2002; Tapscott, 
2005). The existence of multiple waves of transcriptional activation by MyoD was 
also shown during myogenic differentiation of P19 cells. Early targets activated by 
MyoD were identified as premyogenic mesoderm factors Meox1, Six1, and Pax7 
and their expression preceded activation of both Mef2c and Myf5. MyoD was 
shown to bind directly to both early and late targets such as Myogenin, indicating 
its ability to temporally regulate gene expression through induction of other 
transcriptional regulators (Gianakopoulos et al., 2011). Together, this data shows 
that MyoD is capable of activating a complex transcriptional network by interacting 
with a multitude of cofactors to direct myogenesis in a tightly regulated temporal 
pattern. 
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1.2. MicroRNAs  
In addition to protein coding genes, RNA Polymerase II activity in myogenesis also 
results in specific expression of regulatory non-coding RNAs, microRNAs (miRs). 
These include miR-1, miR-206 and miR-133. MiRs are typically around 22bp long 
and act to negatively regulate target genes through binding of miRs to sites in 
UTRs of target genes resulting in either mRNA degradation or translational 
disruption. miR-1, miR-206 and miR-133 are expressed in the somites of Chick, 
Xenopus and Zebrafish embryos during development (Chen et al., 2006; Goljanek-
Whysall et al., 2012; Mishima et al., 2009; Sweetman et al., 2006; Sweetman et 
al., 2008). Studies in Chick revealed that miR-1 and miR-206 are positively 
regulated by both Myf5 and Myogenin, whilst MyoD and Mrf4 upregulate miR-206 
(Sweetman et al., 2008). The disruption of expression of any one of these miRs 
leads to disorganisation of muscle structures and downregulated expression of 
contractile protein genes. Importantly, miR-133 has recently been shown to have a 
role in regulation of the Shh related effector, Gli3 during chick myogenesis (Mok et 
al., 2018). In amniotes, Shh signals from axial structures induce somitic 
expression of myogenic factors. In miR-133 knockdown embryos, Myogenin 
expression in posterior somites is reduced, and many components of the Shh 
pathway are significantly downregulated. This effect can be rescued by activation 
of Shh signalling, therefore indicating that miR-133 is an important mediator of 
myogenic signals. Together, these data identify that non-coding RNAs act 
cooperatively with protein-coding RNAs as important regulators of muscle 
development and further investigation into the roles of additional families of non-
coding RNAs might reveal novel mechanisms regulating myogenesis. 
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1.3. Transcription by RNA Polymerase I 
RNA Polymerase I is a 14-subunit complex that transcribes 18S, 28S and 5.8S 
ribosomal RNAs. These ribosomal RNAs play a catalytic roles within the core of 
the ribosome and interact with transcripts of RNA Polymerase III, 5S rRNAs 
(Laferté et al., 2006). As ribosomal RNAs make up the majority of all RNAs within 
a cell (60%), the rate of RNA Polymerase I activity has a great deal of control over 
cellular growth and proliferation, and dysregulation of activity is linked with 
oncogenesis.  
Enhanced ribosomal biogenesis is a common feature of transformed cells (White, 
2004) and RNA polymerase I activity is activated by oncogenes such as c-Myc, 
and mitogenic signals such as Erk (White, 2008). It has been shown in paediatric 
patients with Rhabdomyosarcoma, a cancer affecting the connective tissue, that 
levels of pre-rRNA transcripts increase in cancer progression giving an indication 
for tumour prognosis (Williamson et al., 2006). Moreover, whilst RNA Polymerase I 
activity is required for the maintenance of cell growth and survival, it is regulated 
by multiple tumour suppressors in normal development. This indicates the 
importance of tight regulation on RNA Polymerase I activity and ribosome 
biogenesis for normal cellular function. However, regulation of RNA Polymerase I 
activity in myogenesis is outside of the scope of this thesis. 
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1.4 Transcription by RNA Polymerase III  
The third of the three nuclear RNA Polymerases in Eukarya, RNA Polymerase III, 
consists of 17 subunits and is responsible for the transcription of tRNAs, ribosomal 
5S RNAs, U6 snRNA, 7SK RNA as well as many other small non-coding RNAs 
(White, 2011). 
The core promoter machinery of Polymerase III consists of a transcription factor 
TFIIIB. TFIIIB consist of 3 subunits; TATA binding protein (TBP) also utilised by 
RNA Polymerase I and II, BDP1 and Brf1 or Brf2. Brf1 is required for transcription 
of tRNAs, which have promoter elements located within the transcribed region, 
whilst Brf2 is required for transcription of targets such as U6 RNA with promoter 
elements upstream of the transcription initiation site. ChIP-Seq studies support 
this, as they show no overlap in the peaks of Brf1 and Brf2 binding (Moqtaderi et 
al., 2010). It is also interesting to note that Brf1 targets, tRNAs, are much more 
abundant than Brf2.  
In addition to TFIIIB, the transcription factor complex TFIIIC is also required for 
transcription activation. TFIIIC consists of six subunits, and transcription is 
dependent on molecular interactions between TFIIIB subunits Brf1/Brf2 with TFIIIC 
and with RNA Polymerase III itself. The TFIIIC complex recognizes A and B block 
sequences at target gene promoters, binds and then recruits TFIIIB via protein-
protein interactions (Paule and White, 2000).  
Protein-protein interactions of these subunits and the recruitment of transcriptional 
machinery are regulated by a number of embryonic signalling pathways and 
proteins, and modulates the transcription of RNA Polymerase III target genes 
during development and differentiation. 
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Figure 1.2. Basal transcriptional machinery of RNA Polymerase III at tRNA gene promoters. The RNA 
Polymerase III enzyme interacts with 2 transcription factor complexes TFIIIB (orange) and TFIIIC (blue). 
TFIIIC recognizes target gene promoters, binds the DNA, and recruits TFIIIB. TFIIIB consists of the TATA 
Binding Protein (TBP) which binds TATA boxes recognized at transcriptional target promoters, BDP1 and 
either Brf1 or Brf2. In activation of transcription at tRNA genes, TFIIIB recruits Brf1 to its complex 
 
1.4.1. Regulation of RNA Polymerase III transcription 
mTOR 
The protein kinase Target of Rapamycin (TOR) is a regulator of a number of 
cellular processes and responds to extracellular signals such as stress induced 
signals, growth factors (IGFs) and nutrient levels. It is conserved throughout 
eukaryotes, in yeast as TOR1 and TOR2 proteins, through to mammals (mTOR). 
The activation of mTOR through a number of signalling pathways and external 
signals initiates a complex downstream signal cascade, resulting in wide cellular 
responses including altered transcription, enhanced ribosome biogenesis, 
changes in the microtubule organisation and the actin cytoskeleton, and 
mitochondrial metabolism (Laplante and Sabatini, 2009; Laplante and Sabatini, 
2012). 
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TOR is a conserved positive regulator of RNA Polymerase III activity throughout 
eukaryotes. In Drosophila, TOR signalling is inhibited through starvation of larvae 
and results in decreased expression of RNA Polymerase III targets including 
tRNAs, 5S rRNA and 7SL RNA. This was matched in TOR-null drosophila larvae. 
In Drosophila larvae overexpressing TOR, increases in expression of targets was 
observed along with cell growth. TOR directly interacts with the Brf subunit of 
TFIIIB in Drosophila to mediate these changes in response to nutrient levels 
(Marshall et al., 2012). TOR regulation of RNA Polymerase III outputs in response 
to nutrient availability is a conserved mechanism also found in yeast (Therapy et 
al., 1999). 
In mammals, the homologue mTOR is found bound to tRNA and 5S rRNA genes 
therefore indicating that conserved TOR mediated regulation of RNA Polymerase 
III is also important for cell growth control in mammalian development (Kantidakis 
et al., 2010; Tsang et al., 2010). In mammals however, mTOR associates with 
TFIIIC in the nucleus, and it is indicated that TFIIIC recruits mTOR to promoters of 
target genes where it then activates transcription indirectly via phosphorylation-
induced inhibition of RNA Polymerase III repressors (Kantidakis et al., 2010; Shor 
et al., 2010). This mechanism of regulation of RNA Polymerase III activty is crucial 
for the modulation of cell growth in response to extracellular signals such as 
stress. 
 
Maf1 
RNA Polymerase III transcription is negatively regulated by the conserved protein 
Maf1 (Kantidakis et al., 2010; Shor et al., 2010). In its active form, Maf1 binds 
directly to RNA Polymerase III, altering the conformation of its clamp domain sub-
31 
 
complex, and also binds Brf1 preventing assembly of the TFIIIB complex and 
recruitment of Polymerase III (Reina et al., 2006). Disruption of basal 
transcriptional machinery interactions leads to reduced association of RNA 
Polymerase III with, and activation of its target genes (Desai et al., 2005; Vannini 
et al., 2010). Repression by Maf1 occurs as a response to multiple cellular 
signalling pathways including DNA damage and nutrient depletion and in Maf1 
mutant cells this repression of RNA Polymerase III targets is abolished (Upadhya 
et al., 2002).  
The ability of Maf1 to repress Polymerase III transcription is regulated by the 
phosphorylation state of Maf1. The phosphorylated form of Maf1 is unable to 
relocate to the nucleus and interact with Polymerase III machinery. PKA and TOR 
signalling both have roles in regulation of Maf1 repression by facilitating the 
phosphorylation of Maf1 at its site used for RNA Polymerase III interaction 
(Kantidakis et al., 2010; Moir et al., 2006; Oficjalska-Pham et al., 2006; Shor et al., 
2010). Therefore, Polymerase III transcription is closely regulated under normal 
cellular conditions and is altered accordingly to a number of environmental triggers 
such as nutrient availability and this becomes dysregulated in cancers (Laplante 
and Sabatini, 2012; Shor et al., 2010). This indicates that transcription by 
Polymerase III is under tight regulation during the cell cycle and development, and 
that this regulation is well coordinated with cellular cues from RNA Polymerase II 
transcriptional products. 
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MAPK-ERK signalling 
The MAPK-ERK pathway also activates RNA Polymerase III transcription. MAPK 
is activated by a wide number of external signals and promotes cellular growth, 
and embryo patterning much like TOR signalling. Inhibition of MAPK-ERK 
signalling reduced expression of RNA Polymerase III targets whilst inducible 
overexpression of Raf alone (a component of the MAPK signalling pathway) is 
sufficient to stimulate enhanced expression of RNA polymerase III transcripts in 
3T3 cells (Felton-Edkins et al., 2003a). This is achieved through promotion of 
TFIIIB interaction with both TFIIIC and the RNA Polymerase III complex, 
specifically through phosphorylation of the Brf1 subunit, enhancing its activity 
(Felton-Edkins et al., 2003a). A recent study identified that MAPK-ERK signalling 
also promoted Brf1-dependent tRNA synthesis in Drosophila cultured S2 cells, and 
this upregulation enhanced rates of protein synthesis and proliferation in 
Drosophila epithelial and stem cells. The study revealed that MAPK-ERK 
signalling also upregulates RNA Polymerase III activity through inhibition of 
nuclear localisation of the RNA Polymerase III inhibitor Maf1 and its repressor 
activity (Sriskanthadevan-Pirahas et al., 2018). This indicates that Erk signalling 
may have multiple roles promoting the regulation of RNA Polymerase III activity 
during development, however, the context of these roles during embryogenesis 
and differentiation has still not been investigated. This is an interesting route of 
investigation for this thesis as the earliest MAPK-ERK activity present during 
Xenopus development is the result of FGF signalling, and results in mesoderm 
induction and, amongst other differentiation programmes, the activation of 
myogenic differentiation. It could therefore be that MAPK-ERK mediated activity of 
RNA Polymerase III has a role indirecting myogenesis. 
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1.5. Regulation of RNA Polymerase III activity is important for normal cell 
growth and division 
1.5.1. Regulation of TFIIIB- interaction with Rb and p53 
Rb 
Transcription by RNA Polymerase III is regulated by a number of signalling 
pathways and directly by transcription factors. Importantly, the tumour suppressors 
Rb and p53, regulated by mitogenic signalling pathways, have been shown to 
directly regulate RNA Polymerase III activity by disrupting protein-protein 
interactions between components of the basal transcription machinery.  
Rb is a cell cycle regulator with a role in regulating cell division through G1 phase 
progression, and also has a role in differentiation pathways (Giacinti and 
Giordano, 2006). Rb is part of a tumour-suppressor pathway which is dysregulated 
so frequently in cancers that it is recognized as a “hallmark” of oncogenesis 
(Hanahan and Weinberg, 2000; Sherr and McCormick, 2002). Rb has been shown 
to bind directly to the BRF1 subunit of TFIIIB (Felton-Edkins et al., 2003b; Sutcliffe 
et al., 2000), resulting in disruption of protein-protein interactions between the 
RNA Polymerase III enzyme and its transcriptional machinery, causing reduced 
transcription of target genes (Figure 1.3.). 
 
p53 
The transcription factor p53 is induced in response to DNA damage and stress 
and acts as a driver of both cell cycle arrest and/or apoptosis. p53 regulates the 
cell cycle through inducing expression of the CDK inhibitor p21Cip1, and activates 
expression of pro-apoptotic proteins (Shaw, 1996; Sherr and McCormick, 2002). 
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p53 interacts with the TBP subunit of TFIIIB and disrupts its’ interaction with TFIIIC 
(Figure 1.3). TFIIIB recruitment to target genes is therefore diminished, leading to 
reduced TFIIIB occupancy at tRNA genes and reduced target gene expression- an 
effect that can be reversed by overexpression of TBP (Crighton et al., 2003; 
Felton-Edkins et al., 2003b; Sutcliffe et al., 2000).  
The activity of both of these tumour suppressors results in decreased transcription 
by RNA Polymerase III in normal cells. In most cancers, one or both of these 
proteins are mutated, which may underlie the increased activity of Polymerase III 
observed in cancer cells and could explain why activity of RNA Polymerase III is 
deregulated and more active in most, if not all cancers.  
 
 
Figure 1.3. Regulation of RNA Polymerase III transcription by tumour suppressors Rb and p53 and the 
proto-oncogene Myc. Induced by mitogenic signals (anti-growth), transcription by RNA Polymerase III is 
modulated by Rb and p53. Rb directly associates with Brf subunits of TFIIIB and p53 interacts with the TBP 
subunit to disrupt protein-protein interactions with the Polymerase III complex and TFIIIC respectively. Myc 
has a role in the promotion of transcription by RNA Polymerase III during cancer transformation and recruits 
RNA Polymerase III to target genes through interaction with TFIIIB. Red pentagons represent negative 
regulation and green indicate positive regulation. 
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1.5.2. Dysregulation of the RNA Polymerase III core promoter machinery in 
cancer 
In transformed cells and cancers, dysregulation of RNA Polymerase III activity and 
the hyper-activation of RNA Polymerase III target genes is common. This can be 
achieved through overexpression and enhanced activity of core promoter 
elements. The proto-oncogene c-Myc is a transcription factor with roles in cell 
growth and proliferation. Under normal conditions, developmental signalling 
pathways tightly regulate activity of c-Myc, and the unstable nature of c-Myc, 
means that sustained positive regulation of expression is required (Miller et al., 
2012). However, dysregulation of c-Myc through over-activation, mutations of the 
c-myc gene itself, and chromosomal translocations, is found in a number of 
different cancers (Dang, 1999; Schmidt, 1999).  
c-Myc directly interacts with TFIIIB in vivo (Figure 1.3), resulting in enhanced 
recruitment of RNA Polymerase III to target promoters and activation of RNA 
Polymerase III transcription- overexpression of tRNA and 5S rRNA targets. This is 
supported by the observation using ChIP, that endogenous c-Myc is located at 
RNA Polymerase III target gene promoters such as tRNAs and 5S rRNA (Felton-
Edkins et al., 2003b; Gomez-Roman et al., 2003).  However, not all genes 
occupied by RNA Polymerase III were also occupied by c-Myc. Therefore 
indicating that, whilst these factors interact directly, occupancy by RNA 
Polymerase III does not completely dictate c-Myc occupancy. 
Other studies have also shown that components of the core RNA Polymerase III 
transcription machinery have elevated activity in transformed cells and in primary 
cancer cells (Marshall and White, 2008; White, 2004). The Brf1 and Brf2 subunits 
of TFIIIB are differentially regulated in some cancer cell lines, and whilst Brf2 
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activity is enhanced specifically much more-so than Brf1, Brf1 dependent 
expression of VA1 RNA is elevated higher than Brf2-dependent transcription of U6 
RNA (Cabarcas et al., 2008). U6 RNA is however, upregulated in some cancers 
such as breast cancer (Appaiah et al., 2011), and as a Brf2 target of RNA 
Polymerase III, this could therefore be a direct effect of enhanced Brf2 activity.  
It has been found in some human ovarian cancers that the activity of subunit 
complex TFIIIC is also upregulated (Winter et al., 2000). Although the study was 
limited to only nine samples, TFIIC was upregulated in all nine, and all 5 tested 
subunits of TFIIIC were overexpressed. TFIIIC binds to DNA at target gene sites 
and recruits TFIIIB to activate transcription, therefore suggesting that elevated 
activity of this factor alone also results in increased and dysregulated 
transcriptional output. In breast cancer for example, analysis of tRNA expression 
levels shows significantly elevated overall levels when compared with non-cancer 
samples (Pavon-Eternod et al., 2009). 
 
1.5.3. Elevated RNA Polymerase III activity drives cancer progression 
Moreover, it has been indicated that overexpression of RNA Polymerase III activity 
and expression of particular target genes drives cancer progression, with wider 
transcriptional effect. Overexpression of the tRNA initiator Methionine (tRNAiMet) 
has been shown to alter expression of other tRNAs when overexpressed in cancer 
cell lines, increasing expression of tRNAs for charged amino acids, and also 
increases cellular proliferation relative to non-tumour derived cells (Pavon-Eternod 
et al., 2013). Although this study was based on a single overexpression clone, 
these data suggest that RNA Polymerase III transcription is necessary for correct 
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cellular function, however must be modulated in order to maintain normal 
proliferation levels. 
A more recent study identified particular tRNA isoacceptors as promoters of 
cancer metastasis when overexpressed. tRNAGluUUC and tRNAArgCCG in particular 
were elevated in metastatic cells compared with parental cells. When these tRNAs 
were overexpressed in non-metastatic cells, increased cell invasiveness and 
promotion of metastasis was observed (Goodarzi et al., 2016). These results 
indicate that dysregulation of tRNAs is important for multiple stages of cancer 
progression, therefore making RNA Polymerase III activity a good target for novel 
therapeutics in treating cancer (Grewal, 2015). 
 
1.6. tRNAs and the genetic code 
Quantitatively, the most significant role of RNA Polymerase III activity is the 
transcription of tRNAs. tRNAs are small non-coding RNAs generally consisting of 
between 70-100 base pairs in length. tRNAs contain an amino acceptor stem, 
which functions to recruit amino acids to translation machinery and importantly, an 
anticodon loop, which pairs with mRNA using Watson-Crick base pairing enabling 
tRNAs to convert transcriptional messages into translational output. 
There are 64 codons in the genetic code of which 61 encode amino acids and 
three encode stop signals. Due to wobble pairing, whereby the 3rd base in an 
mRNA codon can undergo non-Watson-Crick base pairing with the 1st base of a 
tRNA anticodon, the number of codons outweighs the number of specific tRNAs 
encoded by a genome. Multiple tRNA anticodon families (isoacceptors) encode 
each amino acid isotype- in Xenopus there are 54 isoacceptor families encoding 
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the 20 standard amino acid isotypes. Each anticodon isoacceptor in turn is 
encoded for by multiple tRNA genes. In Xenopus tropicalis, it is estimated that 
there are 2638 tRNA genes (Chan and Lowe, 2016; Chan, P.P. & Lowe, 2009). As 
a result of gene duplication, up to hundreds of tRNA genes with identical 
sequences can encode the same triplet anticodon. 
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Table 1.1. Summary of predicted tRNA isoacceptors encoding the 20 amino acid isotypes 
predicted by the Xenopus tropicalis genome (adapted from Lowe et al. gtRNA db) 
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1.7. Regulation of tRNA transcription by RNA Polymerase III during 
development 
1.7.1. mRNA Codon Usage Bias 
Usage bias of mRNA codons refers to the selective usage of specific codons more 
than others in translation. This phenomenon is evolutionarily conserved, however 
particular codon usage biases vary between species (Behura and Severson, 
2013). mRNA codon usage bias can arise through genetic mutation and selection 
in particular species whereby weak selective pressures drive usage of 
translationally favoured codons.  
One of the most striking examples of codon-usage bias in invertebrates is that of 
the silkworm bombyx mori. The silk glands of B.mori develop rapidly and produces 
almost exclusively the silk proteins fibroin and sericin. There are two parts to the 
silk gland, the middle and the posterior. The middle produces the protein sericin 
which is made up of 31% Serine whereas the posterior produces fibroin which is 
made up of 46% Glycine, 29% Alanine and 12% Serine. Fibroin sequence analysis 
revealed the amino acids sequence is significantly enriched for Serine, Glycine 
and Alanine codons. The mRNAs expressed in the posterior part of the silk gland 
were shown to be enriched in particular codons for each amino acid: GCU for 
Alanine; CGA and GGU for Glycine and UCA for Serine (Hentzen et al., 1981; 
Suzuki and Brown, 1972).  
Codon usage bias is also suggested in Caenorhabditis elegans whereby the 
amount of bias in codon usage within genes is skewed by the level at which a 
gene is expressed. Low levels of usage bias occur in genes with low expression 
levels whilst high levels of bias is present in genes that are most highly expressed. 
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Moreover, this bias appears to select only a few translationally favourable mRNA 
codons (Stenico et al., 1994).  
 
1.7.2. Evidence of tRNA usage bias - lessons from prokaryotes 
A common theme throughout both eukaryotes and prokaryotes is that codon 
usage is driven by selective pressure from translation- the notion that translation 
efficiency and tRNA levels would drive selection of a few codons that are most 
favourable for translation through wobble-pairing.  The coordination of mRNA 
codon usage with abundance of specific tRNA pools has been observed in a 
number of models including both prokaryotes and eukaryotes, however, 
understanding of the drivers and responders within this relationship is still unclear. 
In E.coli, biased abundance of particular tRNA isoacceptors was observed 
throughout different growth rates and a correlation with mRNA codon usage 
frequency was identified (Dong et al., 1996). tRNAs most abundant at slowest 
growth rates appear to show increased expression moreso than tRNAs expressed 
at low levels, though this appears to be modest in size of change. The study also 
revealed that tRNA genes, even when existing in a single operon, showed different 
transcriptional control in response to changes in codon usage with growth rate 
increase.  
A relationship between codon usage and tRNA levels was also observed in 
another bacterial species Bacillus subtilis, but it was observed that tRNA levels 
correlated with their gene copy number rather than mRNA codon usage changes. 
This study argued that mRNA codon usage was in fact determined by a drive for 
translational efficiency, determined by tRNA abundance (Kanaya et al., 1999). 
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1.7.3. Evidence of tRNA usage bias - Lessons from invertebrates 
The silk gland of the silkworm Bombyx mori, due to its striking mRNA codon usage 
patterns, has been studied in order to elucidate possible correlation between the 
codon usage observed from mRNAs, and the expression of particular tRNA 
isoacceptor families. The tRNA isoacceptor families enriched in B.mori during silk 
gland development correlate with the amino acids most abundant in the silk 
proteins expressed. It was also found that specific Serine tRNA isoacceptors with 
more favourable translational capacity due to wobble pairing were more highly 
abundant (Garel and Hentzen, 1974; Hentzen et al., 1981). These data identify 
that tRNA transcription is modulated by a driving force of amino acid usage and 
that particular isoacceptors capable of encoding multiple anticodons by wobble 
pairing rules is favoured to ensure optimal translational efficiency. 
A study in C.elegans revealed that co-ordination of tRNA abundance with amino 
acid codon usage bias within mRNA transcripts is present in other organisms too, 
but that gene copy number of tRNAs also has influence over tRNA abundance 
(Duret, 2000; Stenico et al., 1994). 
In Drosophila, all amino acids contribute to codon usage bias and show preference 
to one of their synonymous codons. This usage bias correlated with predicted 
highest translational efficiency based on availability of tRNA anticodons. Moreover, 
when tRNA isoacceptors are more significantly changed in abundance across 
Drosophila development, their corresponding mRNA codons show less biased 
usage (Moriyama and Powell, 1997). This data suggests that, in lower eukaryotic 
systems, a number of factors determine tRNA regulation and mRNA codon usage 
bias but that an overriding driver of coordination is selective pressure from the 
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need for efficient translation, which is altered under different conditions or at 
different developmental stages. 
 
1.7.4. Evidence of tRNA usage bias - Lessons from vertebrates 
In humans, evidence exists to support the notion that tRNA expression is altered 
during development to best match the need for efficient translation, and that this 
demand is set by mRNA codon usage. An initial study into codon usage bias in 
human genes revealed that tissue specific mRNAs can be distinguished from each 
other based on their synonymous codon usage (Plotkin et al., 2004). Studies 
utilising customized tRNA microarrays have shown that tRNA expression is also 
differentially regulated between tissue types. Comparing reproductive tissues 
(testes, ovary) with immune tissue (thymus and lymph node) with expression 
levels in the brain as a control revealed that expression of tRNAs encoding 
isoacceptors for hydrophobic amino acids are greatly increased and charged 
amino acid isoacceptor expression is decreased. Reproductive tissues however 
show notably decreased expression of hydrophobic amino acid isoacceptors and 
increased expression of those encoding small amino acids (Dittmar et al., 2006). 
When a comparison to the predicted codon-usage of highly translated tissue 
specific mRNAs was carried out, a significant correlation was also found in a few 
anticodon families. This study therefore indicates that RNA Polymerase III activity 
is differentially regulated between tissues, but that this is independent of mRNA 
codon bias.  
A more recent study used tRNA microarrays coupled with RNA-Seq analysis of 
mRNAs to determine the differences in regulation between proliferative cells from 
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primary tumours, cancer cell lines and immortalized cell lines and differentiated 
normal tissue and embryonic stem cells post-induction of differentiation (Gingold et 
al., 2014). The results showed that expression of specific tRNA genes is 
significantly altered in proliferative cells over differentiated, and that some tRNA 
genes of the same isoacceptor family show opposing trends. This change 
happens gradually as shown by transitioning cells from proliferative to senescent 
indicating a steady alteration of RNA Polymerase III activity in distinct cellular 
programs. Interestingly, mRNAs highly expressed in either proliferating or 
differentiated cells are enriched in different codons respectively and these codons 
match with the anticodons of tRNA genes upregulated in each cell type. Together, 
these results suggest that in human tissues, there exists a coordinated regulation 
of mRNAs and tRNAs such that changes in tRNA levels match the demand of 
mRNA codon bias to ensure the high expression of required proteins in each cell 
type (Topisirovic and Sonenberg, 2014). 
 
1.7.5 Evidence of a stable tRNA-mRNA interface  
A recent study using ChIP-Seq to analyse RNA Polymerase III binding in multiple 
mammalian species determined the level of conservation in binding patterns 
throughout millions of years of evolution. In the species studied (from mouse to 
marsupial), RNA Polymerase III binding at individual tRNA genes varied by several 
orders of magnitude, but this variation was less significant at the isoacceptor level 
where overall binding appears directly correlated with the number of other 
isoacceptor families encoding the same amino acid isotype. Patterns of overall 
occupancy at the isotype level were conserved across the six species, and even 
across different tissues within a single species. Accompanying RNA-Seq data 
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revealed that mRNA codon usage across the mammalian species is also well 
conserved and is unvarying for overall abundance of individual codons (Kutter et 
al., 2011). This evidence indicates an evolutionarily conserved, coordinated 
regulation of the mRNA-tRNA interface, in which relative tRNA abundance at 
individual gene level is significantly varied between diverse tissues throughout 
mammalian species. Yet, as a result of redundancy of the genetic code and 
regulatory cross-talk between isoacceptor families, this converts to a stable pool of 
tRNAs coding for each amino acid isotype between diverse tissues and species 
throughout millions of years of evolution. This conservation is closely mirrored in 
mRNA codon usage, therefore suggesting that an underlying mechanism of 
coordinated regulation is crucial for development and correct cellular function. 
 
During development, regulation of tRNA gene expression shows dynamic 
regulation. An analysis of tRNA expression in mouse brain and liver at different 
developmental stages showed that individual genes undergo significant changes 
in expression throughout their development. However, on observations of overall 
binding at the isoacceptor level, this is equilibrated as increased expression of a 
tRNA gene matches a simultaneous decreased expression of another gene in the 
same isoacceptor family, resulting in a stable pool of tRNAs for each amino acid 
throughout development (Schmitt et al., 2014). This therefore suggests that 
developmental cues act to regulate specific tRNA genes to maintain an 
equilibrated pool of tRNA isotypes rather than to change the expression of tRNA 
isoacceptor families. This work is supported by a more recent study, which 
showed that whilst mRNA codon usage differs between proliferative and quiescent 
cells, tRNA anticodon abundance did not significantly correlate with or differ 
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between the two cell types (Rudolph et al., 2016). Together, this data shows that 
as yet, no clear relationship between RNA Polymerase II activity and RNA 
Polymerase III transcription has been determined across vertebrates. Yet, as 
many signals, which result in altered transcription of RNA Polymerase II, also lead 
to changes in the activity of RNA polymerase III, exploring this relationship in vivo 
is of interest. 
During myogenesis, a transcriptional network is activated by the MRFs, resulting in 
the rapid upregulation of multiple large proteins; most significantly Myosins, Actins 
and Troponins. The transcription of these factors occurs almost simultaneously 
during tailbud stages in Xenopus development and it is therefore likely that 
myogenic cells undergo a change in demand from translation as a result of the 
expression of these genes. Therefore, Xenopus myogenesis provides a useful 
model in which to investigate the role of novel factors in regulating both mRNA and 
tRNA expression to drive differentiation of muscle cells in vivo. 
 
1.8. Polr3G. A Polymerase III subunit with distinct developmental regulation 
RNA Polymerase III consists of 17 subunits, which are highly evolutionarily 
conserved from yeast to humans. Most subunits show structural similarity to 
subunits of RNA Polymerases I and II, with 5 subunits showing no homology to 
any subunits of RNA Polymerase I or II. Three of these subunits in humans 
(RPC32, RPC39 and RPC62) form a dissociable sub-complex which directs gene 
specific transcription initiation through interaction between RPC39 and TFIIIB 
(Wang and Roeder, 1997).  
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The subunit RPC32 (Polr3G) is unique to Polymerase III, showing no homology to 
any Polymerase I or II subunits. It interacts with RPC62 via two alpha-Winged-
Helices, and binding causes conformational change to expose Polr3G to the 
remaining Polymerase III subunits, forming a stable transcriptional complex 
(Boissier et al., 2015).   
As a result of gene duplication, RPC32 exists as two isoforms; RPC32α (Polr3G) 
and RPC32β (Polr3gL). Proteins with significant homology to Polr3G were 
identified throughout Eukaryotic species, however only one gene exists in species 
such as Saccharomyces cerevisiae and C.elegans, which more closely resembles 
Polr3gL than Polr3G. It was concluded therefore that Polr3G evolved as a result of 
a gene duplication event. However, surprisingly it appears that in Chicken (Gallus 
gallus), only one Polr3G gene exists with homology closer to Polr3G than Polr3gL 
(Renaud et al., 2014). 
  
1.8.1. Distinct functions of Polr3G and Polr3gL 
The existence of two distinct isoforms of Polymerase III; α or β, was determined by 
the inclusion of either Polr3G or Polr3gL into its dissociable sub-complex. Polr3G 
and Polr3gL show different expression profiles, as Polr3G is expressed at higher 
levels in embryonic stem cells, and expression then decreases during 
differentiation. Conversely, Polr3G expression also increases during cell 
transformation. Polr3gL levels, on the other hand, remain constant throughout 
differentiation and transformation. siRNA knockdown of each subunit and cell 
growth assays in hESCs revealed that Polr3gL expression is essential for cell 
survival, whilst Polr3G is non-essential and that the two factors were non-
48 
 
redundant (Haurie et al., 2010). These distinct Polymerase III isoforms may have 
different roles in development, with distinct repertoires of target genes. 
Each isoform appears to have a distinct function in embryonic stem cells; ectopic 
expression of Polr3G results in increased resistance to retinoic acid-induced 
differentiation (Wong et al., 2011), and its targeting by siRNAs results in 
decreased anchorage-independent cell growth. Conversely, Polr3gL targeting 
results in inhibited general cell growth, and ectopic expression results in 
decreased expression of the cell cycle genes Aurora A kinase, Cyclin E and p27 
(Haurie et al., 2010). This suggests that Polr3G is a proliferative, pluripotent 
isoform while Polr3gL is a differentiation related isoform. However, global ChIP-
Seq revealed that, these subunits appear to show few unique targets, and their 
binding patterns were largely overlapping leaving the defined role of each isoform 
unclear (Renaud et al., 2014). 
More recently, a study in cancer and hESC lines showed that telomerase reverse 
transcriptase (TERT), a key promoter of oncogenesis and proliferation, directly 
interacts with the Polr3G subunit of RNA Polymerase III through both its N and C-
terminal domains. Interaction with TERT in transformed cells enhanced RNA 
Polymerase III recruitment to tRNA genes, resulting in increased expression of 
tRNAs. Moreover, expression levels of TERT positively correlate with increased 
expression of tRNA genes in cancer cells (Khattar et al., 2016) and transformation 
of IMR90 cells results in the upregulation of Polr3G along with few other subunits 
of RNA Polymerase III (Durrieu-Gaillard et al., 2017). These results suggest that 
Polr3G has a direct role in regulating tRNA gene expression during stem cell 
proliferation and differentiation, and is dysregulated in cancer through interaction 
with key oncogenes. 
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1.8.2. Regulation of Polr3G in cell lines 
There has been little study into the regulators of Polr3G expression during 
vertebrate development and differentiation, with studies limited to hESC cell 
culture only. Wong et al. conducted promoter analysis using binding site prediction 
matrices and located two Nanog target sites upstream of the Polr3G transcriptional 
start site. Subsequent siRNA targeting of Oct4 and Nanog in hESCs resulted in 
downregulation of Polr3G therefore suggesting that Polr3G is a downstream target 
of the pluripotency factors it is coexpressed alongside (Wong et al., 2011). Using 
the ERK signalling inhibitor U0126, evidence also indicated that Polr3G is 
positively regulated by the MAPK signalling pathway. However, as this pathway is 
used by multiple signalling factors, identification of specific regulators to place this 
regulation into developmental context requires more in-depth study. 
Polr3G is also negatively regulated by the micro-RNA miR-1305 in stem cells. 
Overexpression of miR-1305 in hESCs results in upregulated expression of 
differentiation markers from the primary germ layers (notably, endoderm markers 
appear downregulated), which was coordinated with downregulation of 
pluripotency factors. Conversely, inhibition of miR-1305 results in larger colony 
formation consistent with maintained high proliferation rates. This indicates that 
expression of miR-1305 is a positive driver of differentiation and reduced cell 
division in stem cell populations (Jin et al., 2016). Polr3G was identified through 
target scanning software as a predicted target of miR-1305, which was confirmed 
through RT-PCR and Western blotting in miR-1305 overexpressing and siRNA 
targeted cells. In cells overexpressing miR-1305, Polr3G expression is 
downregulated and Polr3G is upregulated when miR-1305 is inhibited. Further 
experiments identified that the role for this regulation is in promoting hESC 
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differentiation as knocking-down of miR-1305 and Polr3G together resulted in 
increased expression of differentiation markers, whereas miR-1305 knock-down 
alone did not (Jin et al., 2016). 
Together, these findings indicate that Polr3G expression is regulated by different 
factors during pluripotency and differentiation programs, however it is unclear how 
cell culture findings relate to in vivo differentiation, and if so, whether regulation of 
Polr3G differs between cell lineages. 
 
 
1.9. This thesis 
The central hypothesis under investigation in this thesis is whether transcription by 
RNA Polymerase III is regulated during myogenic differentiation, and if the well-
known RNA Polymerase II regulator, MyoD, contributes to coordinated regulation 
of RNA Polymerase II and III activity during skeletal muscle differentiation. 
Polr3G is a highly regulated RNA Polymerase III subunit and is the focus of three 
of the five results chapters presents (Chapters 4, 5 and 6). Chapter 3 investigates 
transcriptional targets of MyoD using CRISPR/Cas9 targeting and acts as a 
standalone chapter. Chapter 7 investigates the regulation of RNA polymerase III 
transcription during myogenic differentiation in animal caps. 
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The core aims of this thesis are: 
1. To determine whether the use of CRISPR/Cas9 as a means of gene 
targeting in founder populations was sufficiently effective to use as an 
alternative to, and to enhance results of Antisense Morpholino Oligos in 
Xenopus studies using MyoD as an example. 
2. To characterise the temporal and spatial expression profiles of Polr3G and 
Polr3gL during Xenopus development. 
3. To characterise the regulation of Polr3G and Polr3gL by mesodermal 
signalling pathways (FGF, Wnt) and myogenic factors (MyoD) in vivo. 
4. To determine the regulation of tRNAs by Polr3G and Polr3gL during 
Xenopus development and myogenesis. 
5. To determine the regulation of RNA polymerase III targets in response to 
growth factor induced myogenic differentiation in animal caps. 
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 2.  Materials and Methods 
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2.1. Molecular Biology Methods 
2.1.1. Gel electrophoresis 
DNA and RNA samples were run on 1-2% Agarose gels stained with Ethidium 
Bromide in either TAE (50X: 242g/L Tris, 57.1ml/L Glacial Acetic acid, 100ml/L 
0.5M EDTA pH8.0) or TBE (10X:  1X buffer at 150-180V. Samples were loaded 
with 6X gel loading buffer (NEB) alongside 4µl of 2-log DNA ladder (NEB). 
 
2.1.2. Standard RT-PCR setup 
Total RNA was extracted and purified as outlined in 2.1.8. cDNA was synthesised 
using 1µg of RNA and Superscript IV (Thermo-Fisher) as per manufacturer’s 
instructions with random hexamers. 
20µl reactions are assembled using 2X PCR Mastermix (Promega): 
10µl 2X PCR Mastermix 
1µl 10µM Forward Primer 
1µl 10µM Reverse Primer 
1µl cDNA 
7µl H2O 
A 30 cycle PCR is carried out after initial denaturation of 2 minutes at 95˚C 
Cycling conditions:    95˚C – 30 seconds 
     __˚C – 30 seconds (5˚c below Tm˚) 
     72˚C – 60 seconds/kb product 
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A final extension of 72˚c for 10 minutes is included. 
Primers are listed: 
Name Forward Reverse Use 
MyoD 
genomic 
TTACTTTGCGCCGTTGCTAT GTTGCGCAAAATCTCCACTT CRISPR 
validation 
Polr3G GGGCTGCCTTTACATTTGACAT CTCGCCCTCCTCCTCTTCC RT-PCR and 
ISH Probe 
Polr3gL AGCGGTCGGGGCCAACTGACC 
TT 
TTTGGGGAGGACAACGGCGG RT-PCR and 
ISH Probe 
Polr3G-HA GAGAGACTCGAGACCATGGACTA
CCCATACGATGTTCCAGATTACG
CTGCCAAAGGGAGGGGAAGG 
AGAGAGTCTAGATTAGTAGGTGCTT
CATCCAT 
Full length 
cloning CS2+ 
Polr3gL-HA GAGAGAGAATTCACCATGGACTA
CCCATACGATGTTCCAGATTACG
CTGCTGGAAAAGCAGAGGTAGC 
AGAGAGTCTAGATCAGTAGGTGCT
TCATCCAT 
Full length 
cloning CS2+ 
tRNAiMet AGCAGAGTGGCGCAGCGGAAG TAGCAGAGGATGGTTTCGATCCAT
CGA 
RT-PCR 
tRNAeMet GCCTCGTTAGCGCAGTCGGTA TGCCCCGTGTGAGGATCGAAC RT-PCR 
tRNALeu GTCAGGATGGCCGAGTGGTCT TGTCAGAAGTGGGATTTGAACCCA RT-PCR 
tRNATyr CCTTCGATAGCTCAGCTGGTA TCCTTCGAGCCGGAATTGAAC RT-PCR 
tRNAAla(AGC) GGGGGATTAGCTCAAATGG TGGAGGATGCAGGCATCG RT-PCR(q) 
tRNAAla(CGC) GGGGATGTAGCTCAGTGGT TGGAGATGCCGGGGATTG RT-PCR(q) 
tRNAAla(TGC) GGGGATGTAGCTCAGTGGT TGGAGATGCTGGGGATTGA RT-PCR(q) 
tRNASer(GCT) GACGAGGTGGCCGAGTGG GACGAGGATGGGATTCGAAC RT-PCR(q) 
5S rRNA  GCCATACCACCCTGAAAG AGGTATTCCCAGGCGGTCT RT-PCR(q) 
U6 RNA GTGCTTGCTTCGGCAGCACAT AAAAATATGGAACGCTTCACGAAT RT-PCR 
28S rRNA GGCGCCCCGGCTGAGGTG TGAGATCGTTTCGGCCCCAAGAC RT-PCR 
Wt1 AGGCACACAGGCATTAAACC TGTTGTGGTGACGAACCAAT RT-PCR  
Table 2.1. Primer sequences for RT-PCR analysis of Xenopus tropicalis embryos. 
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2.1.3. Plasmid Transformation 
Dcm-/Dam- competent cells were used for transformation as per the 
manufacturer’s instructions (heat shock at exactly 42˚C for 30 seconds, incubate 
on ice for 2 minutes, incubate at 37˚C for 1 hour). The media used was LB broth 
(1L: 5g yeast extract, 10g tryptone, 10g NaCl). 
 
2.1.4. DNA minipreps 
Plasmid DNA was prepared by overnight growth of single transformed colonies in 
3ml LB with 1µg/ml ampicillin. Colonies were incubated at 37˚C with agitation. 
Preparations were incubated on ice for a minimum of 20 minutes prior to 
centrifugation at 10,000rpm for 10 minutes to pellet the bacteria and plasmid 
extraction was carried out using the QiaPrep® Spin Miniprep kit (Qiagen). DNA 
was eluted in 50µl volume and concentration was determined by Nanodrop® 
ND1000. 
 
2.1.5. Purification of DNA 
The volume of sample was made up to 200ul using molecular grade H2O. An 
equal volume of water-saturated phenol-chloroform was added and the samples 
were vortexed briefly. Samples were centrifuged for 5 minutes at 13,000rpm and 
the top aqueous phase was collected. An equal volume of chloroform-isoamyl was 
added, vortexed, and a second 5 minute spin was carried out. The top phase was 
collected in a new tube, 0.1 volumes of 3M sodium acetate and 2.5 volumes of 
100% ethanol were added and the sample vortexed to mix. The samples were left 
at -20˚C° for 1 hour-overnight to precipitate. Precipitated DNA was centrifuged for 
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20 minutes at 4˚C and supernatant was removed. Resulting pellet was washed in 
70% ethanol and vacuum dried for 5-10 minutes and resuspended in the required 
volume of H2O (30µl-50µl) and stored at -20˚C. 
 
2.1.6. Quantification of DNA, RNA and gRNA by spectrophotometry 
The concentration was determined using the Nanodrop® ND1000 
spectrophotometer. After initialisation with water, the equipment was blanked on 
the DNA, RNA or ssDNA setting for DNA, RNA and gRNA samples respectively. 
1µl of product was measured to determine concentration in ng/µl. 
 
2.1.7. Western Blot analysis 
For analysis of protein expression both endogenous and overexpressed, 20-25 
X.tropicalis embryos were collected and homogenised in 30µl Phosphosafe™ 
Extraction Reagent by pipetting. 5µl of 7X cOmplete™, Mini EDTA-free Protease 
Inhibitor cocktail (Roche) was added to the mix and embryos were immediately 
incubated at -80˚C for 10 minutes. Samples were centrifuged at 13,000rpm for 20 
minutes and resulting supernatants (~40µl) were collected into new tubes and 
boiled at 95˚C for 5 minutes in 1X volume 2X sample buffer to denature the 
protein. After boiling, samples were vortexed and particular embryo values were 
loaded onto 15% Acrylamide/SDS PAGE gels (For 20ml 15% resolving gel: 4.6ml 
H2O, 5ml 1.5M Tris-HCl pH8.8, 10.05ml 30% Acrylamide mix, 200µl 10% SDS, 
100µl 10% APS, 50µl TEMED) (For 10ml 5% stacking gel: 6.1ml H2O, 2.5ml 0.5M 
Tris-HCl pH6.8, 1.3ml 30% Acrylamide mix, 100µl 10% SDS, 50µl 10% APS, 25µl 
TEMED).  
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Embryo values: 
6. Overexpression/HA tag/GAPDH: 5 embryos 
7. Endogenous/Morpholino/GAPDH: 10-12.5 embryos 
Samples were run out at 180V for 2 hours alongside 10µl PageRuler™ Prestained 
Protein Ladder 26616 (ThermoFisher) in Tris-Glycine gel running buffer (3g/l Tris, 
14.4g/l Glycine, 10ml/l 10% SDS). After completion, gels were soaked for 10-20 
minutes in gel Tris-Glycine transfer buffer (3g/l Tris, 14.4g/l Glycine, 10ml/l 10% 
SDS, 100ml/l methanol). Gels were then transferred at 90V for 2.5hours at room 
temperature, or 30V overnight at 4˚C onto a PVDF membrane pre-soaked in 
methanol for 15 seconds and equilibrated in transfer buffer. Membranes were 
blocked for 1 hour in 5% Marvel milk powder/PBST (1L: 100ml PBS, 5ml 20% 
Tween). Primary antibody dilutions were made up in blocking solution and 
incubation was carried out by rolling at 4˚C overnight. Membranes were washed 
four times in PBST for 15 minutes and a second block for 30 minutes preceded 1 
hour incubation with secondary antibodies at room temperature. Membranes were 
washed 4 times for 15 minutes and developed using the BM® Chemiluminescence 
(Roche) substrate kit. The membranes were exposed to Hyperfilm™ECL® 
(Amersham) until expression was visualised.  
Once developed, membranes were stripped by rocking for 30-45 minutes at 55˚C 
in stripping buffer (For 100ml buffer: 20ml 10% SDS, 12.5ml 0.5M Tris-HCl pH6.8, 
800µl β-Mercaptoethanol, 67.5ml H2O). Membranes were washed extensively in 
H2O, followed by multiple (5 minimum) 5 minute PBST washes. Membranes were 
then placed back into 5% Marvel/PBST blocking solution for 1 hour. 
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Target Primary antibody dilution Secondary antibody dilution 
Polr3G (Eurogentec) 
(EIEAERKLQREWT) 
1:10,000 affinity purified 1:2000 anti-rabbit HRP 
GAPDH 1:10,000 (Sigma) 1:4000 anti-mouse HRP 
Anti-HA 1:1000 (Sigma) 1:4000 anti-mouse HRP 
Table 2.2. Primary and secondary antibody dilutions for protein detection by western blot of 
endogenous and overexpressed samples. 
 
2.1.8. Total RNA extraction 
For extraction of total RNA from tissue samples, 10-15 embryos/20 explants were 
snap frozen using dry ice. Frozen samples were homogenised in a sterile RNase 
free tube using a tissue homogeniser treated with RNaseZAP™ (Sigma) on ice. 
Samples were centrifuged for 10 minutes at 13,000rpm to remove excess fatty 
tissue and yolk. Approximately 1ml supernatant was collected in a new tube. A 5 
minute room temperature incubation preceded addition of 200µl chloroform 
(Sigma). The samples were shaken for 15 seconds and left to stand for 10 
minutes. Samples were centrifuged at 13,000rpm for 15 minutes to separated 
RNA, DNA and protein phases and the RNA phase (top aqueous) was collected. 
An equal volume of isopropanol was added to the samples, followed by vortexing 
and 5-10 minute incubation at room temperature to precipitate the RNA. Samples 
were centrifuged at 13,000rpm for 10 minutes to pellet the RNA. Pellets were 
washed with 75% ethanol and centrifuged for 10 minutes at 13,000rpm. RNA was 
dried for 5-10 minutes under vacuum and resuspended in 40µl of nuclease free 
water. RNA was then purified using the Zymo-Spin™ Clean and Concentrator™ 
Kit as per the manufacturer’s instructions. 
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2.1.8.2. DNase I treatment of RNA 
To remove DNA, RNA samples were incubated at room temperature for 20 
minutes with 5ul DNA digestion buffer and 5ul DNase I (Zymo). 100ul RNA binding 
buffer and 150µl 100% ethanol were mixed with samples and samples were run 
through Zymo-Spin™ columns. Columns were washed with 400µl RNA Wash 
Buffer followed by a 30 second centrifuge at 13,000rpm before an additional in-
column DNase treatment was carried out by adding 5µl DNase I and 75µlDNA 
digestion buffer to the column for more rigorous removal of DNA. RNA purification 
was then continued as per the manufacturer’s instructions. Final elution was in 20-
50µl H2O as needed and RNA was stored at -80˚C until required. 
 
2.1.8.3. Zymo-Spin™ Clean and Concentrator™ purification of total RNA 
DNase I in-tube treated samples (50µl) were mixed with 100µl (2X volume) of RNA 
binding buffer and 150µl (1X total volume) 100% ethanol. Samples were loaded 
into collection columns and centrifuged for 30 seconds at 13,000rpm. After in 
column DNase I treatment (as above), 400µl RNA Prep buffer was added to the 
samples and tubes were centrifuged at 13,000rpm for 30 seconds. Columns were 
washed twice with RNA Wash Buffer, 700µl and 400µl consecutively and the 
second wash step was followed by a 2 minute spin to ensure the columns were 
completely dry. Samples were eluted in 20µl of nuclease free H2O. Sample 
concentration was measured using the ND-1000 spectrophotometer. For RNA-Seq 
and microarray samples, RNA Integrity Numbers were measured by running 
samples on an Agilent® 2100 Bioanalyzer™. RIN scores of 6.5 (Microarray) or 7.0 
(RNA-Seq) were determined suitable quality for high-throughput methods. 
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2.1.9. Design and in vitro synthesis of a MyoD gRNA. 
The design tool ChopChop (https://chopchop.rc.fas.harvard.edu/) was used to 
scan the input sequence for suitable Cas9 target sequences including a PAM site. 
Any off-targets with up to 2 mismatches in the first 20bp of sequence were 
searched for using the Xenopus tropicalis genome version 
(xenTro3/GCA_000004195.1).  
2.1.9.1. gRNA template synthesis 
A sequence spanning 71-89bp in the first exon of the XtMyoD coding sequence  
(5’-TCGTCGTAGAAGTCATCGG-3’) on the reverse strand was selected as no off-
targets were predicted for this sequence. The 5’ primer was designed to include an 
increased efficiency promoter for transcription by T7 RNA Polymerase as 
described by (Nakayama et al. 2014), and an added 5’ G nucleotide to fit 
requirements of the T7 polymerase. The resulting forward primer consisted of the 
sequence: 
5′-GCAGCTAATACGACTCACTATAGG TCGTCGTAGAAGTCATCGG 
GTTTTAGAGCTAGAAATA-3′    
An additional gRNA for the Tyrosinase was also designed and synthesised using 
the forward primer sequence:  
5’-GCAGCTAATACGACTCACTATAGGGAAAGGAACATGGTCCCTC 
GTTTTAGAGCTAGAAATA-3’ 
The reverse primer used is common to all gRNAs: 
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC 
TTATTT TAACTTGCTATTTCTAGCTCTAAAAC-3’ (Nakayama et al., 2014). 
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2.1.9.2. gRNA transcription 
Phusion polymerase was used to amplify the template using 5µM of each primer, 
annealing at 60°C and extending for 15 seconds for 35 cycles. The resulting 
templates were checked on a 2% Agarose/TBE gel and 2µl were taken directly 
from the PCR reaction for in vitro transcription. Transcription reactions were 
carried out using the Megashortscript® T7 Transcription Kit (Life Technologies) 
following the manufacturers guidelines: 
2µl-8µl template DNA 
2µl ATP 
2µl CTP 
2µl UTP 
2µl GTP 
2µl T7 enzyme mix 
2µl 10X transcription buffer 
_µl H2O (to final volume of 20µl) 
 
Transcription reactions were incubated at 37˚C overnight and were followed by a 
15 minute TURBO DNase treatment at 37˚C. gRNA transcripts were purified by 
phenol-chloroform extraction (add 180µl of H2O and 200µl phenol-chloroform, 
centrifuge at 13,000rpm for 5 minutes.) and chloroform extraction (add equal 
volume of chloroform-isoamyl to samples and centrifuge at 13,000rpm for 5 
minutes). Samples were precipitated using NH4OAc (0.1 volume)/ethanol (2 
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volumes). gRNA was resuspended in a final volume of 20µl. RNA quality was 
measured by gel electrophoresis and spectrophotometry reading using the 
ND1000 analyser. (NB- An optimal concentration of 1.8µg/µl is desired for Cas9 
co-injection mixtures). 
 
2.1.9.3 Cas9 protein production (carried out by Olga Moroz, Wilson Lab, 
Department of Chemistry, York) 
Cas9 protein was made using a plasmid (Addgene) by expression in Rosetta-2 
cells (Novagen) at 30˚C in kanamycin/chloramphenicol substituted autoinduction 
media (Studier F.W., Protein Expression and Purification, 2005). Pelleted cells 
were resuspended in lysis buffer (buffer A (50mM Tris-HCl pH 8.0, 500mM NaCl, 
10mM imidazole) with cOmplete™,Mini EDTA-free Protease Inhibitor cocktail 
(Roche) and lysed by sonication. GE Healthcare HiTrap Nickel NTA column was 
equilibrated in 50mM Tris-HCl pH 8.0, 500mM NaCl, 10mM imidazole) and 
washed before a gradient of Buffer B (Buffer A + 500mM Imidazole) was applied to 
elute the protein. The peak eluted between 7- 30% buffer B. The fractions 
containing Cas9 were pooled and concentrated before size-exclusion 
chromatography in 20mM Tris, 200mM KCl, 10mM MgCl2 (Superdex 200 16/60; 
Amersham Pharmacia Biotech). The purified Cas9 was concentrated to 50 mg/ml 
using ultrafiltration in Amicon centrifugation filter units (Millipore). Aliquots were 
flash-frozen and stored at −80°C. 
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2.1.10. Amplification and cloning of genomic DNA for CRISPR sequencing 
To assess the efficiency of Cas9 targeting, single embryos were collected at NF 
Stage 25 and transferred to 0.5ml PCR tubes containing 200ul of TAD lysis buffer 
(50mM Tris pH7.0, 50mM NaCl, 5mM EDTA, 0.5% SDS, 10% Chelex, fresh 
250ug/ml Proteinase K) and incubated at 55 C̊ for 1 hour followed by 95 ̊C for 15 
minutes to deactivate the Proteinase K. Samples were vortexed to disrupt the cell 
membranes. Samples were centrifuged for 10 minutes at 13,000rpm, and the top 
100µl of clear supernatant (genomic DNA) was collected. The DNA was diluted 
1:10 and amplified by PCR reaction using primers flanking the Cas9 target site 
(Primers included in table in section 2.1).  
PCR products were cloned into the pGEM®-T Easy vector system as per 
manufacturer’s guidelines and transformed into E.coli. Minipreps of individual 
clones were sequenced by GATC Biotech using an SP6 primer. Sequences from 
3-10 clones from each embryo were aligned alongside the wild type amplicon 
sequence using DNAStar SeqMan to identify INDELs. 
 
2.1.11. Linearisation of plasmid DNA 
Plasmid linearization was carried out by restriction digest to produce templates for 
sense transcription of mRNA by SP6 and antisense labelled RNA for in situ 
hybridisation. For both cases, a 100µl reaction was set up: 
1-5µg plasmid DNA 
10µl necessary restriction enzyme buffer 
2µl restriction enzyme (see table) 
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_µl (to 100 total) H2O 
Restriction reactions were incubated at 37˚C for a minimum of 90 minutes and 
linearization was checked by gel electrophoresis alongside 0.5µl of uncut product. 
Resulting products were then purified as per 2.1.5. 
 
Clone Enzyme Polymerase Source Use 
pSP64T- MyoD XbaI SP6 Cloned in lab mRNA 
eFGF BamHI SP6 Cloned in lab mRNA 
CS2+-Polr3G NotI SP6 Cloned in lab mRNA 
CS2+-Polr3gL NotI SP6 Cloned in lab mRNA 
pSP73-XMyoD BamHI SP6 Harvey 1991 In situ probe 
α-cardiac actin EcoRI SP6 Gurdon 1985. In situ probe 
Polr3G NcoI SP6 Cloned in lab In situ probe 
Polr3gL SalI T7 Cloned in lab In situ probe 
Table 2.3. Clone information, restriction enzyme and polymerases used for in situ probes and 
synthetic mRNA transcripts. 
 
2.1.12. In vitro transcription of synthetic mRNA 
Full length clones were linearised as per 2.1.11. Both MEGAscript® SP6 and 
mMESSAGEmMACHINE® SP6 kits were used as per manufacturer’s instructions: 
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20ul MEGAscript® SP6 reaction: 
2µl 10X MEGAscript transcription buffer 
2µl 40mM ATP 
2µl 40mM CTP 
2µl 40mM UTP 
2µl 5mM GTP 
2.5µl 40mM Methyl-GTP (Ambion) 
2µl SP6 enzyme mix 
1-2µl template DNA 
_µl H2O (to 20µl total) 
 
20µl mMESSAGEmMACHINE® SP6 reaction: 
3µl template DNA 
10µl 2X NTP/Cap 
2µl 10X Reaction buffer 
2µl SP6 enzyme mix 
_µl H2O (to 20µl total) 
 
Transcription reactions took place at 37˚C for the specified time as per 
manufacturer’s instructions. Transcriptions were checked by gel electrophoresis of 
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a 1-2µl sample and successful reactions were treated for 15 minutes with 
TURBO™ DNase at 37˚C followed by purification and isopropanol precipitation. 
RNA was resuspended in 20µl and stored at -80˚C in 2µl aliquots until use. 
 
 
2.1.13. Digoxigenin labelled in vitro transcription of antisense probes 
Labelled probes were synthesised for use in In situ hybridisation. The 20µl 
reaction was assembled as follows: 
4µl 4X Transcription buffer (Promega) 
2µl 10X DIG NTP mix (Roche) 
2µl 100mM Dithiothreitol (DTT) 
1µl Polymerase (SP6, T7, T3) (Thermo-Scientific) 
3µl DNA template 
7µl H2O 
Transcriptions were incubated overnight at 37˚C. 
After checking for product, samples were purified by ethanol/ammonium acetate 
precipitation at -20˚C for 1 hour minimum (add 50µl H2O, 50µl 5M Ammonium 
Acetate and 300µl 100% ethanol). Samples were centrifuged at 13,000rpm for 15 
minutes and pellets were washed in 70% ethanol. Samples were dried under 
vacuum and resuspended in 50ul H2O. Probes were checked on a 1.5% 
Agarose/TAE gel run at 180V. Probes were stored at -80˚C until use. 
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2.1.14. Polr3G antisense morpholino oligonucleotide (AMO) design 
Translation blocking Morpholinos 1 and 2 were designed by Gene Tools® LLC. 
The sequences used for design were 
Polr3G MO1: 
CTAGTTTTTCATTTTGTTTCTCTTCCCATGCATTAG[TA(ATG)GCTGCCAAAGG
GAGGGGAAG]GG 
Polr3G MO2: 
CCACGCGTCCGGCAGATTTGGTGAATCAGCGAGTTCTATGTTTGATTCATCA
GCGAGAAATTATATCAGA[CTGAAGTA(ATG)GCTGCCAAAGGGAG]GGGAAGG 
Sequences are of the sense strand. (ATG) indicates the transcriptional start site of 
the mRNA coding sequence and the sequences targeted by the MOs are in 
square brackets. Lower case indicates the coding sequence. 
Morpholinos were ordered with the sequence reading 5’ to 3’: 
AMO 1: CTTCCCCTCCCTTTGGCAGCCATTA 
AMO 2: CTCCCTTTGGCAGCCATTACTTCAG 
A splice-blocking Morpholino was also designed to disrupt splicing of the intron 
between coding exons 2 and 3: 
AMO 3: AATGCGTACACAGTACCTACTTTGT 
 
In addition, Gene Tools gives a 5 base-pair mismatch control morpholino (CMO) 
sequence for each design to use as a specificity control. The CMO for MO2 was 
used with the sequence:  
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CMO: GACAACAAAGTTCATCTTCGCTTGA 
Morpholinos were diluted to stock concentrations of 3mM in nuclease free H2O 
and stored at 4˚c. They were diluted to working concentrations immediately before 
injection. 
 
2.1.15. qRT-PCR 
Total RNA was extracted and purified as outlined in 2.1.8. cDNA was synthesised 
using 1µg of RNA and Superscript IV (Thermo-Fisher) as per manufacturer’s 
instructions with random hexamers. 
Primers were designed using Integrated DNA Technologies PrimerQuest tool. 
Products were designed to be between 75 and 110 base pairs in length and 
primers were designed across exon junctions to prevent amplification of any 
residual genomic DNA. 
A list of primers is given: 
Name Forward Reverse 
Xt MyoD CCGATGGCATGACAGACTAT ATTTGGGCTGTCGCTGTA 
Xt Rbm24 GGCTATGGCTTTGTCACGAT ACATTTGCTTTCCTGCCATCTA 
Xt FoxC1 CAGGGCTTCAGTGTGGAT TGTCCTGGAAGAGGAGATGA 
Xt Rbm20 GAACTCAATGACTTTCATGGC AACTCCCAGTCCTTCAGATTG 
Xt Gli2 GCAGAAGTGGCCCATGA GCCATTTGGTGGCAGTATTC 
Xt Zeb2 GAGGAAGATGAACTGAGGGAAAG CCTCCTTCATGTCATCAGAACC 
Xt Polr3G  AGCTGACAAACAAAGCATTGAA CAGCTTTCATCTCCCTTGGAA 
Xt Polr3gL TGTTCCCGAACCTGGAATAC CTTGATGAAGTACGGGAGAGTC 
Xt Dicer GGCTTTTACACATGCCTCTTACC GTCCAAAATTGCATCTCCAAG 
Xt α-cardiac GTCACCAGGGTGTCATGG TATCCTGACCCTGAAGTACCC 
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actin 
Xl Polr3G GCTGCCTTCACATTTGACATC TCTATAGAAGGAAAGATTGGCAAGG 
Xl Polr3gL GTTGTTCCCGAGCCTAGAATAC GCTCCTCGAAGTTCCTGTTT 
Xl α-cardiac 
actin 
CGTACCACAGGTATCGTTCTTG GGGCAGAGCATAACCTTCATAG 
Xl ODC AAAGCTTGTTCTACGCATAGCAACT AGGGTGGCACCAAATTTCAC 
Xl MyoD AAGGCCGCCACTATGAGGGAGAG GCTGGGGCTTTGGGTGGAG 
Table 2.4. Primer sequences for qPCR analysis of X.tropicalis and X.laevis samples 
 
Analysis was carried out on a minimum of three biological replicates. Average Ct 
normalisation to the housekeeping gene dicer, pairwise t-tests were carried out 
comparing the mean relative expression for control and experimental sets for each 
gene. When more than two conditions were compared, ANOVA analysis was 
carried out. Graphs were constructed in GraphPad Prism5. Error bars represent 
SEM, * = p<0.05, ** = p<0.01. 
 
2.1.16. ChIP-PCR (Adapted from Maguire et al., 2012) 
50 tailbud stage embryos were demembraned and fixed for 1 hour in 5ml of 1% 
formaldehyde/NAM media (NAM/10 premixed with 135 μL 37% formaldehyde) with 
gentle agitation. Embryos were quenched in 125mM glycine/NAM solution for 10 
minutes at room temperature, snap frozen on dry ice and stored at -80°C until use. 
Embryos were homogenised in 600μl sonication buffer (20 mM Tris–HCl pH 8.0, 
70 mM KCl, 1 mM EDTA, 10% glycerol, 5 mM DTT, 0.125% Nonidet P40 and PIC) 
and were centrifuged for 10 minutes at 13,000rpm to pellet DNA. Pellets were 
washed gently in sonication buffer before resuspension in 2ml of sonication buffer. 
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Chromatin was sonicated in 30 bursts of 20 seconds (50% on/off, 35% max 
power) with incubation on ice for 30 seconds in between rounds. After sonication, 
samples were split into two 1.5ml tubes and centrifuged at 13,000rpm for 5 
minutes. Supernatant was collected in 100μl aliquots, snap frozen on dry ice and 
stored at -80°C until use. 
80μl of chromatin was incubated in 100μl ChIP incubation buffer (50 mM Tris–HCl 
pH 8.0, 100 mM NaCl, 2 mM EDTA, 1 mM DTT, 1% Nonidet P40, and PIC) and 
either 200μl D7F2 MyoD or 10μl goat anti-mouse IgG for 2 hours at 4°C. 20μl of 
chromatin was kept as input sample and stored at -20°C. Protein G magnetic 
beads were prepared during this time. 50μl bead suspension was added to 50μl of 
ChIP incubation buffer + 0.1% BSA and incubated at 4°C with rotation for 1 hour. 
Beads were collected and washed twice in 1ml ChIP incubation buffer for 5 
minutes at 4°C. Supernatant was removed from beads and beads were added to 
ChIP samples. Samples were incubated at 4°C overnight with rotation. 
Beads were collected and washed in 1ml wash buffer 1 (50 mM Tris–HCl (pH 8.0), 
100 mM NaCl, 2 mM EDTA, 1 mM DTT, 1% Nonidet P40, 0.1% deoxycholate, and 
PIC) for 5 minutes at 4°C with rotation. Beads were collected and wash step was 
repeated with 1ml wash buffer 2 (50 mM Tris–HCl pH 8.0, 500 mM NaCl, 2 mM 
EDTA, 1 mM DTT, 1% Nonidet P40, 0.1% deoxycholate, and PIC), 1ml wash 
buffer 3 (50 mM Tris–HCl pH 8.0, 100 mM NaCl, 250 mM LiCl, 2 mM EDTA, 1 mM 
DTT, 1% Nonidet P40, 0.1% deoxycholate, and PIC), 1ml wash buffer 1, and 1ml 
TE buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA). Beads were collected, 
resuspended in 200μl Elution buffer (0.1 M NaHCO3 pH 8.8 and 1% SDS) and 
incubated on rotation at room temperature for 15 minutes. Supernatant was 
collected and Elution buffer step was repeated. 200μl supernatant was added to 
71 
 
first collected supernatant. Input samples were thawed on ice and 380μl elution 
buffer was added. 400μl of elution buffer was also added to collected beads. 16μl 
of 5M NaCl was added to all samples and reverse crosslinking was carried out at 
65°C for 5 hours with agitation.  
Samples with beads were collected and supernatant moved to new 1.5ml tube. 
400μl phenol-chloroform was added to samples and samples were centrifuged at 
13,000rpm for 5 minutes. 400μl Chloroform-Isoamyl alcohol (24:1) was added to 
aqueous phase and samples were centrifuged at 13,000rpm for 5 minutes. 
Aqueous phase was collected to new 1.5ml tubes and precipitated at -20°C 
overnight in 40μl 3M NaOAc, and 1200μl 100% ethanol with 2μl glycoblue added 
for pellet visualisation. 
Samples were centrifuged at 13,000rpm for 25 minutes. Supernatant was removed 
and pellets washed gently in 500μl 70% ethanol for 10 minutes. Pellets were 
vacuum dried for 5 minutes and pellets were resuspended in 30μl nuclease-free 
H2O. 
ChIP-PCR analysis was carried out as below. For visualisation of ChIP samples, 
nested PCR was required. All primers are included in table 2.5. 
 
1μl final sample was added to 20μl PCR reaction mix: 
10μl Promega PCR mastermix (2X) 
1μl 10μM forward primer (1) 
1μl 10μM reverse primer (2) 
1μl  ChIP sample 
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7μl  H2O 
 
A 30 cycle PCR was carried out with the conditions: 
95°C      30 seconds 
40-50°C 30 seconds 
72°C      20 seconds 
 
5μl of PCR product was added to the following PCR mix: 
10μl Promega PCR mastermix (2X) 
1μl 10μM forward primer (3) 
1μl 10μM reverse primer (4) 
3μl H2O 
 
An additional 30 cycle PCR reaction was carried out with the conditions: 
95°C      30 seconds 
40-50°C 30 seconds 
72°C      15 seconds 
 
6μl product was run out on a 2% Agarose/TBE gel. 
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Polr3G_
Region 
1 
(1)CCCATTGTGGCTTTAAAAGGA 
(3)GGAAAAAGTTAACATTCAGATG 
(2)CAACATTAAGCAGATCCCAGTG 
(4)ACTATCAGCAGTTAGCTC 
Polr3G_
Region 
2 
(1)TGGCAGACATCCTTTTGAAT 
(3)ATGTTGCCTTTGCCCCTTC 
(2)CCCTTTAAGTGGCCACAATG 
(4)CCTGCTGGGGTCTGCACCT 
Polr3G_
Region 
3 
(1)GAGCGACCGCTAAGGTTTAAT(
3)CAGTATGGAACACCAATATGCA
C 
(2)GTGCTGCCCTGTCCTGTTA 
(4)CTACCCAGTTCCCTGAACCA 
Polr3G_
Region 
4 
(1)TGGTGTGCTTCTGGATTTTG 
(3)AGTGCAGATGTGCAAACAGG 
(2)TGTGTTATAAGGTTTGTGCAGGA 
(4)TTGAGCAATCAAGTGGCTTC 
Polr3G_
Region 
5 
(1)CTCCAAAGAGTTGGGTTTGA 
(3)TATTCCTGGCCCCTAACTGA 
(2)GCCATGGGAATTATCGTTCA 
(4)CCCCTTTGAAGCAACATT 
Polr3G_
Region 
6 
(1)TTCCTTGGAACAGCTTTGCT 
(3)TCTAGTACAACTAGGGTCCT 
(2)GATAACAGGCCCCATACCTG 
(4)TTCCAAGGATATGTTAAGAC 
Polr3G_
Region 
7 
(1)CGACTTCCAGGAGATTCTAG 
(3)TGGTGTGCTTAAATAGGTG 
(2)GGTGTGCCCTAAATGCAGC 
(4)GCTCTTCAATTACATAGCTT 
Polr3G_
Region 
8 
(1)GAACTGCACAGGAGACGTTG 
(3)GTAACAGCACTCAACATCAC 
(2)AGGTCCTGAGCATTCTGGAT 
(4)GGATAACAGATCCTATACCTG 
Rbm24
_Regio
n 1 
(1) GGAGCGCCACGACTTGT  AT        
(3)CAGCCTCATGTTTTTATATG 
(2)GTGTCCTCGAAGTTATTGAGGA   AT 
(4)CTGTGACAATATCTGGACTG 
Rbm24
_Regio
n 2 
(1)CCGTCGCTCAACACTCACT 
(3)GAGACAAAGGGGTGGGGAA 
(2)GGGTAACCAGAGAGCCACAC 
(4)GCTCCTCCCACCAAAGGGG 
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Rbm24
_Regio
n 3 
(1)AACAAGACCAGTTCCCCAAG 
(3)TAGAAGGCAGGCTTTTGAGC 
(2)GGGATTAAGTGGGGTGGTTC 
(4)AGCTCTGGGGGTTAGAGAGC 
Table 2.5. Primer sequences for ChIP-PCR analysis of X.laevis embryos. 
 
2.1.17. Northern Blot Analysis 
Total RNA was extracted from a Xenopus tropicalis embryo stage series using 
Sigma Tri Reagent. 5µg of RNA was added to a mix of H2O to a final volume of 
10µl and equal volume of NEB 2X loading buffer was added. Samples were 
incubated at 90˚C for 5minutes before loading onto 10% Acrylamide/7.5M 
Urea/TBE gels. 
10% Acrylamide/ 7.5M Urea/ TBE gel mix: 
to 500ml H2O (filter) 
225g Urea 
125ml 40% Acrylamide (19:1) 
50ml 10XTBE 
(Make 20ml with 120µl 10%APS (fresh), 40µl TEMED) Gels were pre-run at 170V 
for 15minutes before sample loading and running at 180V for 65-70minutes until 
Xylene blue is approximately 1cm from the bottom of the gel. Gels were stained in 
Ethidium Bromide solution (10ul 10mg/ml EtBr in 200ml TBE) for 15minutes. Gels 
were photographed with a ruler zeroed at the top to measure the distance the 
bands of the molecular weight ladder migrated (in Xenopus rRNA bands run at: 
28S/4kb, 18S/1.8kb, 5S/121bases). 
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 RNA was transferred by electroblotting onto a HydrobondN membrane in 1X TBE 
for 75minutes at 100V and crosslinked using Stratalinker UV crosslinker for 2 
bursts of autocrosslinking, followed by baking at 80˚C. 
Church and Gilbert phosphate buffer for hybridisations (2X PB): 
to 500ml H2O 
67g Na2HPO4 
2ml H3PO4 
Membranes were pre-hybridised at 40˚C for 30minutes in a 50ml Falcon tube. 
(30ml Hybridisation buffer: 15ml 2X PB (see above), 2.1g SDS, 0.3g BSA, to 30ml 
with H2O, 300µl 10mg/ml ssDNA (boil+add to warm buffer)). 
Radioactive probes were synthesised by reaction at 37˚C for 45min, the reaction 
was stopped by adding 1µl 0.5M EDTA and heating to 60˚C.   
50µl probe reaction: 
1µl 24-mer oligo 100ng/µl (complimentary to 3’end or intron seq) 
5µl kinase buffer 
5µl P32 gamma ATP (3000mCi/ml) 
2µl T4 polynucleotide kinase (Promega) 
37µl H2O 
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Name Sequence 5’-3’ 
tRNATyr  intron ACCTAAGGATTGCTGTATCACACC 
tRNATyr 3’ TCCTTCGAGCCGGAATTGAACCAG 
tRNALeu 3’ TGTCAGAAGTGGGATTCGAACCCA 
Table 2.6. 24-mer probe sequences for Northern Blot analysis of X.tropicalis 
 
Excess P32 was removed from probes using a G25 spin column. 1µl of probe was 
blotted onto paper to determine cpm (should be at least 1 million/ml). Probes were 
heated to 80-90˚C and added to hybridisation buffer. Blots were hybridised 
overnight at 40˚C. Blots were washed twice in 2X SSC/0.05% SDS for 30minutes 
at room temperature and exposed to film overnight and at different lengths of time 
as necessary. 
 
  
2.2. Embryological methods 
2.2.1. Fertilisation and culture of Xenopus tropicalis embryos. 
Females were primed overnight with a subcutaneous injection of 10 units of 
Human Chorionic Gonadotropin (HCG; Chorulon). Females were induced using 
100units HCG 3-4 hours prior to laying. The eggs were fertilised on L15+10% 
foetal calf serum layered plates with sperm suspension obtained from male. The 
testes were dissected and homogenised in 1ml L15+10% foetal calf serum. 
Embryos were flooded with MRS/9 and cultured. Media is replaced 3-4 hours post-
fertilisation with MRS/20. Embryos were kept in petri dishes lined with 3ml 1.5% 
agarose. Prior to first cleavage (25-30 minutes post-fertilisation), embryos were 
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de-jellied in 3% L-Cysteine (Sigma) solution in MRS/9, pH7.8-7.9. Embryos were 
kept between 22˚C and 27˚C and staged according to Nieuwkoop and Faber (NF 
stage). 
 
2.2.2. Fertilisation and culture of Xenopus laevis embryos. 
Females were induced overnight by subcutaneous injection of 250 units of HCG 
and kept in the dark at 19˚c. Eggs were fertilised with a suspension of testes 
crushed in water. Embryos were cultured in NAM/10 (Normal Amphibian Medium) 
at 14-15˚C in Petri dishes lined with 1.5% agarose. Prior to first cleavage, embryos 
were de-jellied in 2.5% L-cysteine hydrochloride monohydrate (Sigma) pH7.8. 
Embryos were staged according to NF. 
 
2.2.3. Microinjections 
X.tropicalis embryos were injected at the one to two cell stage (in both 
blastomeres at two cell) into either the marginal zone or animal poles with 
maximum of 2nl per cell of mRNA at the appropriate concentration. Embryos were 
injected in MRS/9+3% ficoll and transferred into MRS/20 2-3 hours after injection.  
For gRNA/Cas9 injections, X.tropicalis embryos were injected as soon as possible 
at the one cell stage with 1nl of 300pg gRNA/ 1ng Cas9/300mM KCl mixture. 
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2.2.4. Animal caps 
Animal caps were dissected using mounted tungsten needles to remove the 
animal pole cells at late blastula stage (NF Stage 8-9) of X.laevis or X.tropicalis 
embryos. The dissections were carried out in NAM/2 and animal caps were then 
cultured in NAM/2 until the required stage. 
 
2.2.5. NF Stage 25 somite explants 
X.tropicalis Embryos were left to develop in MRS/20 until NF Stage 25. At stage 
25, embryos were transferred into NAM/2 for dissections. Embryos were removed 
from their vitelline membranes and allowed to rest briefly. Somite explants were 
dissected using mounted tungsten needles by removing the head and ventral 
sections. Sections were snap-frozen using dry ice and stored at -80˚C until use. 
Confirmation of somite presence was performed by carrying out RT-PCR for MyoD 
expression in all three sections. 
 
2.2.6. Whole-mount in situ hybridisation 
Antisense Digoxigenin (DIG) labelled probes were synthesised as described in 
2.1.14. Vitelline membranes of X.tropicalis embryos were removed manually using 
forceps and embryos were pierced in the ventral cavity or animal hemisphere to 
prevent collection of probe. Embryos were fixed in MEMFA (0.1M MOPS pH7.4, 
2mM EGTA, 1mM MgSO4, 3.7% formaldehyde) for one hour and stored in 100% 
methanol at -20˚C until use. 
Embryos were rehydrated through a series of washes of a gradient of 
methanol/PBST (75% methanol/ 25% PBST, 50% methanol/ 50% PBST, 100% 
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PBST). Embryos were then permeabilised with PBST + 10mg/ml Proteinase K 
(Roche). Embryos were washed twice in 5ml Triethanolamine pH7.8 for 5 minutes 
per wash, 12.5µl acetic anhydride (Sigma) was added to the second wash for 5 
minutes and then a second 12.5µl was added for another 5 minutes. Embryos 
were then washed in PBST for 5 minutes and refixed in 10% formaldehyde for 20 
minutes before a series of 5 minute PBST washes. Embryos were then transferred 
into 50% PBSAT/ 50% hybridisation buffer (50% formamide, 5X SSC, 1mg/ml total 
yeast RNA, 100µg/ml heparin, 1X Denhart’s, 0.1% Tween-20, 0.1% CHAPS, 
10mM EDTA) at 60˚C for 10 minutes. The solution was replaced with 100% 
hybridisation buffer and rocked in the hybridisation over for two hours minimum. 
Embryos were then transferred into 1ml Hybridisation buffer + 2-3µl DIG probe 
and rocked overnight at 60˚C. 
Embryos were washed twice in hybridisation buffer for 10 minutes at 60˚C. They 
were then washed three times for 20 minutes in 2X SSC + 0.1% Tween-20, and 
three times for 30 minutes in 0.2X SSC + 0.1% Tween-20 at 60˚c. The embryos 
were then washed twice for 15 minutes at room temperature in Maleic Acid Buffer 
(MAB: 100mM maleic acid, 150mM NaCl, 0.1% Tween-20 ph7.8). They were 
preincubated in 1ml of MAB + 20% Heat treated lamb serum (60˚C for 30 minutes) 
+ 2% Boehringer Mannheim Blocking Reagent (BMB) for two hours. This was 
replaced with fresh blocking solution containing a 1:2000 dilution of affinity purified 
anti-DIG fragments coupled to alkaline phosphatase (Roche) and rolled overnight 
at 4˚C. 
Embryos were washed briefly three times in MAB. Embryos were subsequently 
washed three times for one hour in 20ml scintillation vials in MAB. MAB solution 
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was replaced with 1ml of BM Purple™ staining solution (Roche) and left until 
colour developed. Embryos were fixed in 10% formalin and photographed. 
 
2.2.7. Photography 
Embryos were photographed using a SPOT SP401-230 camera (Diagnostic 
Instruments Inc.) attached to a Leica MZFLIII microscope and a PC running SPOT 
advanced software. Image files were then formatted using Adobe Photoshop™ 
CS3® (Adobe Systems Incorporated). 
 
2.3. RNA-seq analysis 
RNA integrity was measured by the Bioanalyzer-2000 in the Technology Facility. 
mRNA libraries were prepared for sequencing using the NEBNext® UltraTM RNA 
Library Prep Kit for Illumina, using the NEBNext Poly(A) mRNA Magnetic Isolation 
Module to isolate Poly(A) mRNA from total RNA. HiSeq3000 2 x 150 bp paired 
end sequencing was performed by the University of Leeds Next Generation 
Sequencing Facility. 
 
2.3.1. Computational analysis of RNA-seq data 
Illumina deep sequencing resulted in ~440 million reads across the 6 samples. 
Raw RNA-Seq reads were mapped using the Xenopus tropicalis genome version 
9.0 (Xenbase). FPKM (fragments per kilobase of transcript per million mapped 
reads) values were calculated to normalise the number of reads per fragment to 
the length of the fragment in order to avoid bias towards longer fragments. FPKM 
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values for three biological replicates were analysed by pairwise t-tests comparing 
expression in control and MyoD CRISPR-targeted samples. 655 genes showed 
differential expression based on paired t-tests (p<0.05). Expression data for target 
genes was extracted from RNA-seq data available (Tan et al 2013) and uploaded 
to https://software.broadinstitute.org/morpheus/ creating a heatmap of expression 
and hierarchical clustering. Euclidean distance was used as the metric of linkage 
for complete samples. 
 
2.4. Microarray methods 
2.4.1. Microarray Design 
A custom microarray for tRNA isoacceptor families and also some mRNAs of 
interest was designed using the Agilent eArray software to create 8X15K arrays 
that measure tRNAs and mRNAs simultaneously. Human and Cricetulus griseus 
cell line (CHO-K1) tRNAs were included as controls for species specificity and for 
use in a collaborative study. 
 
2.4.2. Xenopus tRNAs probe sequences. 
2638 predicted tRNA genes within the Xenopus tropicalis genome version 4.0 
were identified from the Lowe Lab GtRNAdb (Chan, P.P. & Lowe, 2009) 
http://gtrnadb.ucsc.edu/. These were downloaded as a single FASTA file. 
Using Agilent eArray design tools, 60mer sense probes with eArray’s Base 
Composition and Best Probe Methodology were designed. 5 probes were 
designed per sequence for 48 of the 54 tRNA anticodon isoacceptor families as 
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well as probes for suppressor tRNA and Selenocysteine, resulting in a total of 285 
probes. The probe sequences were filtered against Agilent’s Xenopus tropicalis 
transcriptome which acts as a similarity index to remove probes with significant 
cross-hybridisation potential. 6 isoacceptor families did not pass filtering by 
Agilent, however; in order to include them in the design, 30 additional probe 
sequences were designed manually and uploaded to eArray. 
 
2.4.3. CHO-K1 tRNA probe sequences. 
As eArray did not contain transcriptome data for the CHO-K1 cell line, 3 60mer 
probes per tRNA anticodon isoacceptor family were designed manually for the 5’ 
end, 3’ end and intermediate sequences. For some isoacceptor families with 
greater variation in sequences, or with introns, 3 additional probes were designed. 
The CHO transcriptome was uploaded manually as a similarity index and the 
probe quality control check identified a high number (254) of probes with cross-
hybridisation potential; however, no probes were indicated as poor quality. 3 
probes for 13 human tRNA isoacceptor families were also designed as controls. 
 
2.4.4. Xenopus mRNA and other Polymerase III target probe sequences. 
In addition to tRNA sequences, 5 probes each for 244 selected mRNAs and small 
ncRNAs were designed using the same criteria as Xenopus tRNAs. Coding 
sequences were downloaded to form a single FASTA file for each probeset for 
upload to eArray. mRNAs included myogenic genes, bHLH transcription factors, 
known FGF targets, and mesodermal genes. 
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A total of 2058 probes were selected for Agilent’s standard 8X15K array type 
design. Agilent’s eArray probe check highlighted 102 Xenopus probes with cross-
hybridisation potential, but no probes were classified as poor in the quality control 
check. To fill the array, 7 replicates for each probe group were selected. 
 
 2.4.5. Microarray sample preparation, RNA labelling and array scanning. 
Total RNA was extracted from whole embryos or explants at the desired NF stage 
using Tri Reagent followed by DNase I in tube and on column treatment using 
ZymoSpin RNA Clean and Concentrator columns. RNA was labelled using the 
Agilent Low Input Quick Amp WT labelling kit as per the manufacturer’s 
instructions. 100ng of DNase treated RNA was combined with spike-in mix, WT 
primer mix and First strand synthesis was carried out to make cDNA by combing 
the mix with 5x First Strand Buffer, 0.1M DTT, dNTP mix and was incubated for 2 
hours at 40°C before 70°C for 15 minutes. Cyanine 3-CTP Labelled cRNA was 
synthesised from the cDNA and was subsequently purified prior to hybridisation 
using ZymoSpin columns. Array hybridisation was carried out for 17 hours at 65°C. 
The microarray was processed using a high resolution laser scanner resulting in a 
TIFF image. The TIFF file was uploaded to Agilent’s Feature Extraction software 
for quality control assessment and quantification of signal intensity for each 
individual spot compared to background signals (Processed Signal Values). 
The replicate spot intensity for each individual probe across the array were 
averaged using Agilent’s GeneSpring software to give a Raw Processed Signal for 
each Probe ID (gProcessedSignal). Raw values and values normalised to both 
75th centile shift and between individual samples for each probe across the 
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arrays. (gProcessedSignal (normalized)) were exported into an Excel spreadsheet. 
Mean values for control and experimental samples, and fold changes were 
calculated from log2 normalised values between control and experimental samples 
from sibling matched biological replicates. 
 
2.4.6. Microarray result processing and statistical analyses 
GraphPad Prism5 software was used to carry out statistical tests (t-tests) on the 
mean fold change for each isoacceptor family and each amino acid isotype for 
paired samples, and to construct graphs of mean fold changes. It was decided that 
a threshold of 1.2 and 0.8 would be used as a guide for up/downregulation of 
transcription of tRNA families. Each column includes error bars indicating SEM 
and * indicates the level of significance from the statistical analyses after 
Bonferroni Correction.  
 
2.5. Correlating tRNA expression with mRNA codon usage (Katherine 
Newling, Technology Facility, University of York) 
'codon usage scores’  were determined by calculating the number of times a 
particular codon appears in the coding sequence of all mRNAs included on the 
microarray, and multiplying it by the intensity value for that mRNA. A sum of these 
values was then calculated for each mRNA (number of codons in particular mRNA 
X intensity value of mRNA) for each mRNA that has a microarray intensity value of 
above 10. tRNA expression values were taken as the intensity values on the array. 
Correlation was calculated using Spearman’s Rho assessment for monotonic 
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relationship between variables. Correlation coefficients between 0 and 1 were 
calculated and p-values presented. 
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3. Analysis of MyoD transcriptional targets using 
CRISPR/Cas9 targeting 
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3.1. Introduction 
 
3.1.1. Methods of targeting gene expression in Xenopus 
Post-transcriptional methods of inhibiting gene activity 
Genes regulated by MyoD have been previously investigated using myoblasts 
derived from mouse knockouts and targets in both myoblasts and myocytes have 
been identified (Cao et al., 2010; Yao et al., 2013b). These studies were carried 
out in cell culture and may not identify all genes regulated by MyoD in vivo. This 
chapter describes an in vivo transcriptional analysis of genes that require MyoD in 
the Xenopus gastrula. 
SiRNAs and Morpholino Antisense Oligos are widely used methods to post-
transcriptionally inhibit gene function and morpholinos are mostly used in frog and 
fish studies. They are nucleotide based and pair to target mRNA through 
complimentary base-pairing, but possess a morpholine ring structure which is 
incorporated rather than the sugar-phosphate backbone of nucleotides. The 
morpholine structure is resistant to nucleases and therefore persists in a cell for 
relatively long time periods after introduction.  
MOs are designed to block either translation or splicing from occurring (Wagner et 
al., 2004).Translation-blocking Morpholino Oligos are usually designed as 25mers 
and are complementary to a sequence of the mRNA including the translational 
start site (ATG). MOs bind to the target sequence with high affinity and interferes 
with translational machinery (Summerton and Weller, 1997).  
Splice blocking morpholinos in contrast, are designed to target splice donor/splice 
acceptor sites of pre-mRNA, resulting in a mis-spliced mRNA and a truncated 
protein of interest (Draper et al., 2001).  
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Morpholino Oligos have been particularly useful in the study of Xenopus gene 
functions due to the method of microinjections as a means of introduction. MOs 
offered a specific knock-down protocol for Xenopus which was previously 
unavailable to use, limiting studies to overexpression methods only (Heasman et 
al., 2000; Rana et al., 2006). Morpholinos are non-toxic to embryos and long 
lasting during development meaning they can be applicable to both maternal and 
zygotic mRNAs. One of the many advantages of Xenopus as a model organism is 
the ease, and the speed at which experiments can be carried out. Direct micro-
injection of morpholinos perfectly compliment overexpression methods and can be 
carried out in the same time windows. For almost two decades therefore, 
morpholinos have remained the most commonly used targeting method in 
Xenopus and are considered reliable, providing the correct experimental controls 
are included (Eisen and Smith, 2008; Heasman, 2002). 
 
3.1.2. Identifying novel targets of MyoD in vivo using Morpholino Oligos. 
A previous study carried out in the Pownall lab (Maguire et al., 2012) utilised 
microarray technology alongside morpholino targeting of MyoD at NF Stage 11.5 
(mid-gastrula) in order to identify genes regulated by MyoD at this timepoint. This 
early timepoint was selected as MyoD is present in the embryo, but myogenic 
differentiation has not started and analysing this time window would identify early 
genes involved in myogenic determination. Morpholino targeting in Xenopus is 
particularly advantageous as similar experiments can also be carried out using 
mRNA rescue experiments in order to validate identified target genes from 
screens. Genes found to be significantly downregulated in targeted embryos were 
subsequently also shown to have developmentally relevant spatial expression 
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patterns and many were co-expressed with MyoD. This resulted in the 
identification of novel target genes regulated by MyoD early during myogenesis. 
Identified targets included genes involved in promotion of muscle differentiation 
(Rbm24) and somitogenesis (FoxC1, Esr1 and Esr2). These targets have roles in 
somitogenesis which was supported by observed disruption of somite formation in 
MyoD morpholino targeted embryos. However, the requirement for MyoD for the 
expression of the identified targets was argued to be transient as their expression 
at neurula stages was largely recovered. 
 
This study showed that during gastrulation, MyoD directly regulated genes 
required for somitogenesis and novel genes with roles in myogenesis and 
highlights in importance of in vivo study of complex transcriptional networks. 
Despite extensive cell culture study into the regulation of myogenesis by MyoD, 
novel targets that are only identified in vivo may therefore still be unknown. Recent 
advances in targeting technologies now also calls for the defence of morpholino 
studies due to the availability of genome targeting agents which are both cheap 
and simple to use in externally developing embryos like Xenopus and Zebrafish. 
 
This chapter presents the results from a PhD enhancement award that was 
granted for me to reassess the targets of MyoD at this same early stage using 
CRISPR/Cas9 for gene targeting and an RNA-Seq analysis. Therefore, it sits as a 
stand-alone chapter and it was published in Mechanisms of Development in 2017 
(McQueen and Pownall, 2017). 
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3.1.3. CRISPR/Cas9 as a gene-targeting tool in Xenopus 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are used 
by bacteria in archaea as an adaptive immune method against invading viruses. In 
particular, the bacteria Streptococcus pyogenes protect themselves from foreign 
nucleic acids (i.e. from viruses) through the induction of CRISPR RNAs (crRNAs). 
These are produced from incorporation of foreign DNA into the genome through 
exposure to an invading virus and they are located in proximity to CRISPR. This 
invading “protospacer DNA” is transcribed producing crRNAs specific to the 
invading viral DNA sequence. crRNAs form a complex with another RNA known as 
the trans-activating RNA (tracrRNA) and Cas9 endonuclease and through base 
pairing with invading DNA, effectively recruit Cas9 to targets DNA. When target 
sequences are adjacent to Proto- spacer Adjacent Motifs (PAMs), Cas9 induces a 
double-strand break in the invading DNA by cleavage, thus inactivating the viral 
DNA (Sander and Joung, 2014). Since the understanding that Cas9 gains 
specificity for recruitment to a target sequence through the interaction with two 
dual RNAs, and that this in fact can be replaced by a single programmed RNA 
designed to incorporate elements of both crRNA:tracrRNA (Jinek et al., 2012) 
known now as the guideRNA, there has been a great potential for CRISPR based 
techniques in gene targeting and genome-therapies.   
Recent developments in exploiting this gene targeting technology have now made 
directed targeting at the DNA level an easy and efficient option in a variety of 
model systems. Including the potential to create stable founder population mutants 
in Xenopus (Guo et al., 2014; Nakayama et al., 2013).  
Genome editing by CRISPR/Cas9 requires minimally the guide RNA (gRNA) 
sequence and Cas9 mRNA/Protein. In Xenopus, Cas9 protein may be co-injected 
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with gRNA to induce more rapid cleavage of the target site and higher efficiency 
targeting rates (Guo et al., 2014; Hwang et al., 2013; Nakayama et al., 2013). The 
availability of CRISPR/Cas9 as a targeting method offers many advantages over 
use of Morpholinos, especially the limited side-effects and higher specificity of 
gene targeting strategies compared with the effects of Morpholinos (Gentsch et al., 
2018). Moreover, as differences in phenotype are now being observed when 
repeats of Morpholino studies are carried out with CRISPR/Cas9, the validity of 
results from some Morpholino based studies is being questioned (Kok et al., 2014; 
Rossi et al., 2015; Schulte-Merker and Stainier, 2014). The injection of gRNA and 
Cas9 results in a population of mosaic founder individuals (F0s) and it is yet to be 
assessed whether the level of targeting and resulting mutations are sufficient to 
cause effects both at the level of the phenotype and at the molecular level. 
 
 
Figure 3.1: Schematic of Cas9 guide RNA base pairing with endogenous MyoD target sequence and 
recruitment of Cas9. The PAM NGG site is indicated in red. 
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3.1.4. Aims of this chapter 
Previous in vivo analysis of MyoD transcriptional activity in Xenopus used MOs to 
knock-down MyoD and Affymetrix gene-chip to identify targets (Maguire et al., 
2012). However, recent studies using other gene-targeting methods attempting to 
replicate results of antisense morpholinos in genetic mutants have shown 
discrepancies, presumed to be due to off-target effects means that targets 
identified using morpholino targeting require validation (El-Brolosy et al., 2018; 
Gentsch et al., 2018; Rossi et al., 2015).  
 
The aim of this chapter is to determine novel targets of MyoD during early 
myogenesis, which will be achieved through the targeting of MyoD by 
CRISPR/Cas9- now readily available and economical to use in Xenopus. This 
chapter will also assess whether the use of CRISPR/Cas9 in F0 embryos is 
effective method of gene targeting and advantageous over Morpholino studies 
when paired with global transcriptomic analyses (i.e. can new targets be 
indentified from mutation methods that are not found in MO studies). The analysis 
is carried out at the earliest NF stage that MyoD protein is found localised to the 
nucleus and therefore active (Hopwood et al., 1989), as was also used in Maguire 
et al., 2012. Comparison of previously identified target genes will be used to 
validate the previous Morpholino study and additional target genes will be 
identified by RNA-Seq. 
 
 To assess the effectiveness of CRISPR/Cas9 activity in Xenopus founder 
populations using tyrosinase as a target. 
 To disrupt expression MyoD in Xenopus embryos using CRISPR/Cas9. 
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 To evaluate at the individual sequence level, the extent and types of mutations in 
F0 embryos 
 To use CRISPR/Cas9 targeting with RNA-Seq to identify novel targets of MyoD 
during the earliest stages of myogenic differentiation. 
 
 
3.2. Results 
 
3.2.1. Validation of Cas9 effectiveness through F0 targeting of tyrosinase 
control. 
Previous studies investigating the effectiveness of Cas9 targeting in mosaic F0 
embryos, both in Xenopus and Zebrafish, have used genes with observable 
mutant phenotypes (Blitz et al., 2013; Hwang et al., 2013; Irion et al., 2014; 
Nakayama et al., 2014). The pigmentation gene tyrosinase has been commonly 
utilised in Xenopus CRISPR studies due to its distinctive albino phenotype (Guo et 
al., 2014; Nakayama et al., 2013).The tyrosinase gRNA sequence as designed in 
(Nakayama et al., 2014) with high efficiency 5’ primer was synthesised in vitro by 
PCR reaction followed by a transcription reaction with T7. 
To determine the effectiveness of Cas9 protein produced in house, 300pg of 
tyrosinase gRNA was injected alongside 1ng of Cas9 protein in solution. gRNA 
injected embryos cultured to NF Stage 40 (n=67) revealed effective targeting, 90% 
mutant phenotype observed. However, tyrosinase targeting also highlighted the 
mosaicism present between targeted individuals of the F0 population as a series 
of phenotypes were observed (Figure 3.2. A) from mild targeting [some 
pigmentation loss observed in the eye], to complete targeting [full loss of 
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pigmentation in both eye and skin resulting in an albino individual]. The largest 
percentage of individuals however showed high targeting by which most 
pigmentation in the eye is lost (Figure 3.2. B).  
As targeting of tyrosinase resulted in clear phenotypic changes, this was then 
injected to a small number of individuals additionally to each round of Cas9/MyoD 
gRNA injections to ensure successful targeting. 
 
Figure 3.2. Assessment of Cas9 targeting efficiency using tyrosinase as a visual marker. (A) NF stage 
40 embryos were assessed for loss of pigment and graded as per the severity scale. (B) Phenotypic 
proportions of individuals (n=67) categorised within the four classes were calculated and compared with 
individuals (n=30) injected with Cas9 only. 
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3.2.2. Gene targeting X. tropicalis MyoD using CRISPR/Cas9 
3.2.2.1. Detecting genetic disruption of MyoD in embryos 
 
Xenopus tropicalis is a diploid frog and, as such, genetic methods are simplified 
using this model. X. tropicalis MyoD was targeted using CRISPR/Cas9 in order to 
identify genes that require MyoD for their expression in the early mesoderm, prior 
to myogenic differentiation.  A synthetic guide RNA (gRNA) was designed against 
a sequence in exon 1 coding for the amino terminal part of the bHLH domain such 
that any disruptive mutation would result in truncation before the DNA binding 
domain. The gRNA was co-injected with Cas9 into 1- to 4-cell embryos.  
 
In order to measure mutagenesis, single embryos were collected for sequencing 
analysis. Non-homologous end-joining (NHEJ) that repairs DNA after cleavage by 
Cas9 results in random insertions or deletions (INDELs), therefore genomic DNA 
was extracted from individual embryos and the targeted region of the MyoD gene 
was amplified by PCR and cloned such that different mutations in a single embryo 
could be identified. A total of 35 embryos were collected and 3-15 clones were 
sequenced from each individual. Of these 35 embryos, 31 contained at least one 
mutated sequence (targeting of 88.6%; Figure 3.3. A), indicating a high efficiency 
of gene targeting. As expected, each embryo differed in the proportion of mutant 
sequences, some returning all mutated sequences, and others showing only 50% 
mutant sequences.  
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3.2.2.2. Characterising alleles 
 
Each sequence was further characterised to determine whether an insertion, a 
deletion or a point mutation had occurred. The average targeting efficiency 
throughout sequenced embryos shows that 78% of returned sequences were 
mutated (Figure 3.3. B), of which the majority were deletions (77%) rather than 
insertions or point mutations (Figure 3.3. C). The level of mosaicism within a single 
embryo was high with several different mutations identified in a single F0 embryo.  
10 sequences from a single embryo were aligned to the predicted wild type MyoD 
sequence (Figure 3.3. D). As predicted, all mutation events occur and the near the 
protospacer-adjacent motif (PAM) where NHEJ results in many different alleles.   
Figure 3.3.E shows the proportion of the alleles that code for frameshift mutations 
as a result of either a deletion or an insertion. Only a small proportion of 
sequences (2.3%) represent in-frame insertions. Frameshift mutations represent 
the majority of mutated sequences identified, however, this equates to less than 
half of all sequences returned (43.7%). This highlights a caveat when using F0 
embryos for genetic analyses; although CRISPR/Cas9 targeting results in a very 
high proportion of mutated alleles in an individual embryo, in this case, less than 
half of these mutations will result in a truncated protein or a genetic null.  
Mutations causing indels in multiples of 3 were categorised as in-frame 
deletions/insertions. 25.9% sequences returned were confirmed wild type, 35.1% 
showed frame shift deletions, 8.6% showed frame shift insertions, 24.1% showed 
in frame deletions, 2.3% showed in frame insertions and 4% showed missense 
mutations. 
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Figure 3.3. Assessment of CRISPR/Cas9 targeting efficiency of MyoD1 through genotyping. At NF 
stage 25, genomic DNA was extracted and a 432bp region including the predicted CRISPR target site was 
amplified by PCR and cloned into pGEM T-Easy. 3-15 clones per embryo were sequenced (a total of 153 
sequences were analysed). (A) Proportions of mutated vs wild type sequences within 35 individual embryos. 
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(B) Overall proportion of wild type and mutated sequences in confirmed Cas9 mutated embryos. (C) 
Characterisation of mutation types in confirmed Cas9 mutated embryos. (D) 10 sequences from a single Cas9 
targeted embryo indicates the level of mosaicism in F0 individuals. Cas9 PAM sequence is indicated in red 
underline. (E) Characterising the sequence categories present in sequenced F0 embryos. (Blue indicates 
mutation or disruption; orange indicates wild type sequence or silent mutation). 
 
 
3.2.2.3. Determining the presence of off-target effects. 
In other systems using CRISPR/Cas9 to generate mutations, the embryos are 
raised to maturity and out-crossed at least twice. This significantly reduces the 
likelihood of off-target mutations being carried forward. This study uses F0, so any 
potential off-target effects need to be considered. The MyoD target sequence 
identified in the application ChopChop (http://chopchop.cbu.uib.no) was selected 
due to its location within the functional domain of MyoD and also the prediction of 
zero mismatch off-targets elsewhere in the X.tropicalis genome. 
However, MRFs have a highly conserved functional domain, defining them as 
regulators of myogenesis, and Myf5 and MyoD have partially redundant roles 
within very similar time-points of development. At the NF stage analysed, the only 
other MRF active is Myf5. Therefore, to ensure that any effects of targeting are 
due to MyoD mutation and not due to off-target effects, the amino terminal of the 
Myf5 bHLH domain was also sequenced to ensure no mutations occur as a result 
of Cas9 targeting (Figure 3.4).  
Of the 14 sequences returned, no targeting was observed. Cas9 targeting of MyoD 
has been highly efficient and therefore it was concluded that off-target mutation of 
other MRFs would not be the cause of any changes in gene expression. 
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Figure 3.4. Analysis of potential off-target mutagenesis in the bHLH domain of Myf5. Genomic DNA 
from 5 embryos targeted for MyoD was also amplified using primers designed against the amino terminal of 
the bHLH domain of Myf5 and sequenced. Sequence reads were aligned to the wild type Myf5 sequence and 
analysed for mutations. 
 
3.2.3. Analysis of transcripts in MyoD-targeted embryos 
3.2.3.1. Disruption of MyoD gene transcription and MyoD activity 
To further characterise embryos targeted by CRISPR/Cas9 and to allow 
comparison of targets with those identified from previous studies (Maguire et al., 
2012), mRNA was extracted from groups of ten embryos at the same stage as 
before (NF Stage 11.5) and qRT-PCR was used to analyse the expression of 
MyoD and its known target gene identified in the previous screen Rbm24 (Seb4) 
(Li et al., 2010, Maguire et al., 2012). There was a significant decrease in MyoD 
expression (P< 0.01), (presumably from non-sense mediated decay) and Rbm24 
(P<0.05) when embryos injected with MyoD gRNA + Cas9 protein are compared 
to those injected with embryos injected with the same amount of Cas9 protein 
alone.  The results were calculated as relative proportions of expression and 
repeated for three biological replicates and relative expression of MyoD in targeted 
embryos compared with controls was reduced to 0.57 and Rbm24 is reduced to 
0.77 (Figure 3.5. A). In addition, RNA sequences were sequenced to determine 
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the mutation rate and 6 distinct mutations were identified from one sample set 
(Figure 3.5. B).  The total proportions for each of the mutations shown are as 
follows: -1= 175 (15%), -2= 14 (1%) -3= 219 (18%), -4= 70 (6%), -6= 70 (6%), -8= 
40 (3%). 49% total RNA-Seq reads for MyoD show mutation, however, almost half 
of the mutated sequences result in no frameshift of coding sequence and are 
therefore unlikely to result in non-functional protein. 
 
 
Figure 3.5. Validating samples sent for RNA-Seq. To determine the mRNA levels of MyoD in gRNA 
injected embryos, qRT-PCR analysis was carried out for MyoD and the known MyoD target Rbm24. Pair-
wise t-tests were carried out comparing relative expression for Cas9 only and gRNA injected sets. Error bars 
represent SEM, * = p<0.05, ** = p<0.01. (B) MyoD RNA sequences returned from mapping raw RNA-Seq 
reads to the Xenopus tropicalis MyoD1 gene. A total of 1200 sequences were extrapolated across the three 
biological replicates sent for RNA-Seq and proportions of reads showing each mutation type were calculated 
from. Sequences were aligned against the sequence for wild type MyoD.  
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3.2.3.2. Identifying genes that require MyoD using RNA-Seq analysis 
Three biological repeats for X.tropicalis experimental embryos (targeted for MyoD) 
and sibling controls (Cas9-only injected) were collected at NF Stage 11.5 and 
mRNA was extracted for RNA-seq. cDNA libraries were prepared and Illumina 
deep sequencing resulted in 440 million reads across the 6 samples. RNA-Seq 
reads were mapped using the Xenopus tropicalis genome version 9.0 
(Xenbase.org) and FPKM values were established for all genes.  Transcripts that 
align to MyoD were analysed for INDELs, and Figure 3.6.B shows that a significant 
proportion of the reads have deletions in the expected target site adjacent to the 
PAM. Insertions are less likely to be detected, as they would fail to align with 
reference genome. 
To produce an overview of the significance of fold changes observed in CRISPR 
targeted samples, a volcano plot for (log2) fold change vs (–log10) paired t-test P-
value was constructed using Python script (Figure 3.6). Each individual point 
represents a gene and the dotted line represents a p-value of <0.05. Points in red 
indicate genes with a fold change of less than 1; that is, where the average FPKM 
value of experimental samples have not doubled or halved compared to that of the 
control. Blue points represent genes with a fold change greater than 1 but a P-
value of >0.05, so not statistically significant. Yellow points represent genes with a 
fold change greater than 1 and a P-value of <0.05.  The majority of points show a 
fold change of less than 1 and P-values of >0.05, indicating no significant change 
in gene expression at NF Stage 11.5 in response to CRISPR/Cas9 targeting of 
MyoD. However, 1165 genes mapped to the X.tropicalis genome display 
significant change and are further analysed in sections 3.2.4 and 3.2.5.  
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Figure 3.6. Initial analysis of RNA-Seq data fold changes and t-test significance. RNA-Seq reads were 
mapped using the Xenopus tropicalis genome version 9.0 (Xenbase). FPKM (fragments per kilobase of 
transcript per million mapped reads) values were calculated in order to avoid bias towards longer fragments by 
normalising the number of reads per fragment to the length of the fragment. FPKM values for three biological 
replicates were analysed by pairwise t-tests comparing expression in control and MyoD CRISPR-targeted 
samples. A volcano plot showing t test significance value (-log10 p-value) vs fold change (log2) was 
constructed in Python. Genes in blue indicate a fold change of greater than 1, genes in yellow indicate a fold 
change greater than 1 and a p value of <0.05. 
 
 
3.2.4. Computational analysis of early genetic targets of MyoD 
Of the 1165 genes found to be significantly altered in the absence of MyoD, some 
showed very low expression levels. Therefore, a minimum expression threshold of 
5.0 FPKM average for the control samples was applied. In addition, as MyoD 
expression in targeted samples showed a fold change of 0.71, therefore genes 
with fold changes in this same range (between 0.68 and 0.91) were selected for 
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further analysis. During manual curation, two genes that fell just outside the criteria 
cut-off: FoxC1 (0.84; P<.058) and Pbx2 (0.93; P<.02) were also included. This 
resulted in a short list of 100 potential target genes (See Appendix, Table 1). 
Notably, previously identified target genes of MyoD, ESR1 and Esr2, Delta and 
Tbx6 were not identified in this screen, however, targets FoxC1, FoxC2 and 
Rbm24 were identified as in Maguire et al., 2012. 
 
3.2.4.1. Temporal expression analysis of potential target genes 
To further investigate whether the identified genes are expressed at a time 
consistent with activation by MyoD, temporal expression profiles were analysed. 
As MyoD protein is first detected in the mesoderm at NF Stage 11, candidate 
genes with expression prior to these stages are less likely to be bonafide target 
genes of MyoD. Furthermore, as the analysis was carried out at Stage 11.5, genes 
coding for contractile proteins or other differentiation specific genes are not 
expected to be identified by this study, however, the expression profile of Actc1 
was included as a reference for this class of genes. RNA-Seq data from a 
development time course of Xenopus tropicalis is available (Tan et al., 2013) and 
these expression profiles were used for hierarchical cluster analysis of target 
genes. To do this, expression data was extracted for the 100 short-listed genes 
(Appendix Table1) and used to create a heat map of expression levels over a 
developmental time course (Appendix Figure 1).  
33 genes aligning with reference profiles for determination (MyoD1) and 
differentiation (Actc1) were selected for further heat mapping and cluster analyses 
(shown in Table 3.1 and Figures 3.7. and 3.8.). Euclidean distance was used as 
the metric of linkage for complete samples and a selected cutting point for the 
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clustered dendrogram resulted in the formation of 5 clusters of distinct expression 
profiles; this is shown in the heat map where orange boxes represent highest 
expression levels (Figure 3.8.). To determine the expression patterns observed 
within the 5 clusters, profiles of relative expression for each stage were 
constructed from the expression data used in the heat map and clustering.  
 
Gene symbol ENSEMBL ID Average FPKM 
Control 
Average 
FPKM 
Experimental 
Experimental 
Relative 
expression 
p-value 
bmpr1b ENSXETG00000019220 8.01 5.45 0.68 0.02 
pgp ENSXETG00000016097 6.12 4.52 0.74 0.03 
gbx2.2 ENSXETG00000003293 42.10 31.57 0.75 0.01 
sp8 ENSXETG00000030115 12.27 9.28 0.76 0.05 
nkx6-2 ENSXETG00000023614 20.42 15.51 0.76 0.02 
tsfm ENSXETG00000009653 5.08 3.96 0.78 0.05 
decr2-like ENSXETG00000010329 12.93 10.08 0.78 0.04 
rbm20 ENSXETG00000025245 7.04 5.51 0.78 0.04 
zeb2 ENSXETG00000000237 18.67 14.88 0.80 0.01 
foxc2 ENSXETG00000016387 80.68 65.42 0.81 0.03 
babam1 ENSXETG00000025571 9.14 7.47 0.82 0.02 
gli2 ENSXETG00000011189 12.23 10.04 0.82 0.01 
sp5 ENSXETG00000025407 64.04 53.11 0.83 0.03 
pmm2 ENSXETG00000004549 45.85 38.21 0.83 0.04 
pygm ENSXETG00000034136 123.57 103.71 0.84 0.04 
foxc1 ENSXETG00000000594 73.17 61.58 0.84 0.06 
fstl1 ENSXETG00000018009 25.29 21.31 0.84 0.02 
pex16 ENSXETG00000001027 8.44 7.15 0.85 0.05 
slc13a4 ENSXETG00000008163 18.80 15.99 0.85 0.03 
ak6 ENSXETG00000018174 14.39 12.24 0.85 0.03 
pgk1 ENSXETG00000007447 19.96 17.15 0.86 0.02 
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mrps30 ENSXETG00000017716 11.89 10.23 0.86 0.04 
flvcr2 ENSXETG00000027282 8.63 7.47 0.87 0.04 
cdx1 ENSXETG00000010282 77.18 66.87 0.87 0.03 
pdlim7 ENSXETG00000007240 13.77 11.97 0.87 0.01 
msi1 ENSXETG00000012216 55.14 47.91 0.87 0.00 
rnf7 ENSXETG00000014753 99.16 86.80 0.88 0.04 
pcdh8.2 ENSXETG00000008792 73.31 64.29 0.88 0.01 
herpud2 ENSXETG00000013111 5.58 4.91 0.88 0.04 
rnf157 ENSXETG00000019548 5.75 5.16 0.90 0.05 
epn1 ENSXETG00000022662 42.43 38.19 0.90 0.04 
dnajc24 ENSXETG00000008179 14.14 12.76 0.90 0.03 
pbx2 ENSXETG00000005223 169.56 158.17 0.93 0.02 
Table 3.1. Shortlisted target genes identified from RNA-Seq analysis. After initial heatmapping and cluster 
analysis, only genes located within clusters showing developmentally relevant expression profiles were 
shortlisted as early MyoD targets. The list was manually curated using existing spatial expression profiles and 
literature to result in 33 shortlisted early target genes of MyoD1. 
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Figure 3.7. Hierarchical clustering of shortlisted early MyoD target genes. Expression 
data from (Tan et al., 2013) was transformed to relative expression data and uploaded to 
https://software.broadinstitute.org/morpheus/ for heat map conversion. Relative expression is shown as a 
scale of low (blue) to high (orange). Euclidean distance was used as the metric for hierarchical clustering of 
complete samples, which resulted in 5 clusters showing distinct expression profiles. (*) indicates genes which 
have known or predicted roles in muscle development, or interaction with MyoD. MyoD and Actc1 were 
included in the analysis in order to highlight relevant clusters of interest. 
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Each individual cluster was further analysed by time-course profiling (Figure 3.8.). 
Clusters 1 and 2 show similar overall expression profiles: genes within these 
clusters have very low or no maternal expression with earliest notable expression 
at stage 10 (Figure 3.8. A and Figure 3.8. B). Expression in both clusters 
increases during gastrula and neurula stages, however, in Cluster 1 expression 
increase is more rapid, as highest expression is observed at Stages 13-14, whilst 
genes in Cluster 2 show peak expression at Stages 16-18. Both clusters then 
show decreases in gene expression in later stages. Notably, MyoD itself is 
allocated to Cluster 2. Genes located in Cluster 3 also show low or no expression 
prior to mid-blastula transition (MBT) and the overall expression trend shows 
increasing expression until early tailbud Stages 20-22 (Figure 3.8. C.). Expression 
then decreases in later stages. Individual gene expression within this cluster 
however, is more varied than in other clusters. Cluster 4 is a much smaller cluster 
containing the known MyoD target alpha-cardiac actin (Actc1). Gene expression 
for this cluster shows delayed gene activation with increases occurring from Stage 
14 onwards, this increasing expression is maintained through tailbud stages and 
only decreases slightly in the later tadpole stages (Figure 3.8.D). Cluster 4 
contains the muscle glycogen phosphorylase pygm. Cluster 5 is distinct from all 
other clusters in that the genes located within this cluster show maternal 
expression (Figure 3.8.E.). Expression decreases rapidly after MBT and is at 
lowest levels during neurula stages, then increases again during tailbud Stages 
(20-28) through to later tadpole Stages (31-45). 
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Figure 3.8. MyoD target gene cluster analysis. Expression data from (Tan et al., 2013) was used in a time course analysis of whole embryonic development. Target 
genes with developmentally relevant expression profiles were identified from the initial heatmap. After hierarchical clustering, profiles of gene relative expression over 
time for each cluster reveals distinct expression profiles between clusters. Mean relative expression is shown for each cluster along with expression profiles for each 
gene. (A-E) represent clusters 1-5 respectively.
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3.2.5. Validation of identified target genes 
Hierarchical cluster analysis was used to highlight genes that show 
developmentally relevant expression profiles, and strengthen their status as 
candidates for early genetic targets of MyoD; clusters 1 and 2 include genes 
identified in other studies as myogenic or pre-myogenic genes.  In order to validate 
whether any of these genes require MyoD for their expression during gastrula 
stages, gRNA targeting MyoD together with Cas9 protein was injected and the 
expression of several candidate genes in these embryos at Stage 11.5 was 
assayed as compared to Cas9 only injected embryos using qRT-PCR (Figure 3.9). 
qRT-PCR analysis confirms Rbm20, Rbm24, Gli2, FoxC1, and Zeb2 (aka XSip1), 
as well as MyoD itself, are all significantly down-regulated in targeted embryos. 
This validation supports the notion that gene targeting and transcriptomic analysis 
of founder embryos has provided a robust list of candidates genes regulated by 
MyoD prior to the onset of skeletal muscle differentiation. 
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Figure 3.9. qRT-PCR analysis of identified early targets of MyoD at NF Stage 11.5. Analysis shows the 
expression of MyoD and the known MyoD target gene Rbm24 alongside predicted target genes Rbm20, Gli2, 
Foxc1 and Zeb2. Pair-wise t-tests were carried out for the mean relative expression of three biological 
replicates for Cas9 only and Cas9 plus gRNA injected sets for each gene. Error bars represent SEM, * = 
p<0.05, ** = p<0.01. 
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3.3. Discussion 
 
MyoD is known to direct several different sub-programmes of gene expression 
during myogenesis (Bergstrom et al., 2002; Blais et al., 2005; Soleimani et al., 
2012) consistent with its role as an essential determination gene for the 
proliferative myoblast (Rudnicki et al., 1993). However, MyoD is also a robust 
initiator of transcriptional targets during myogenic differentiation, distinguishing 
itself in this way from Myf5 (Conerly et al., 2016). It is an interesting proposition 
that one transcription factor can activate distinct panels of genes at two different 
stages of cell lineage specification. Indeed, this notion of promoter swapping is 
supported by MyoD binding analysis using chromatin immunoprecipitation (ChIP-
seq) protocols that have shown that MyoD functions as a transcriptional regulator 
during both myogenic determination and differentiation by binding and activating 
distinct sets of genes (Soleimani et al., 2012). This chapter successfully utilised 
CRISPR/Cas9 techniques to identify both known and novel MyoD target genes at 
the earliest stages of myogenesis- currently, no known RNA-Seq analysis has 
been carried out using F0 populations of embryos and therefore this chapter is of 
importance when deciding on future techniques in both this thesis and in the wider 
Xenopus community. 
 
3.3.1. Using F0 CRISPR/Cas9 targeted embryos 
CRISPR/Cas9 gene editing very effectively targeted the MyoD gene in embryos, 
however not all INDELs result in alleles that would generate a disrupted protein. 
Approximately 80% of injected embryos are successfully targeted and the 
penetrance of mutation in each individual is also very high. However, because 
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Cas9 can act on one or both (or neither) alleles in cells as the early embryo 
divides, and the nature of NHEJ is that it leads to random INDELs, the resulting F0 
embryos are inherently genetically mosaic. This leads to a population of F0s with 
ill-defined genotypes, with less than half of alleles analysed carrying a disruptive 
mutation. In zebrafish, it is standard practice to outcross founder fish and breed to 
a known mutant genotype (Li et al., 2016); however this technique is not feasible 
for Xenopus as outcrossing frogs requires more space and time.  
Nevertheless, it has been established that using founder embryos from gene 
editing protocols in transcriptional analyses is both feasible and valuable. 
CRISPR/Cas9 targeting of MyoD results in a significant reduction of MyoD 
transcripts overall and a high percentage of these with INDELs (Figure 3.3.); 
moreover, the known target gene Rmb24 (Seb4) is significantly down regulated in 
these samples. RNA-Seq analysis has provided a shortlist of genes that require 
MyoD, in vivo, prior to myogenic differentiation (Table 3.1.). 
Analysis of putative MyoD targets in the context of a published time course of 
gene expression during Xenopus tropicalis development (Tan et al., 2013) 
provided a way of curating genes on the basis of temporal expression, however 
spatial restriction of expression is also an important factor to consider.  
 
 
3.3.2. Rbm24 
Rbm24 has a single N-terminal RNA Recognition Motif (RRM) which is conserved 
throughout both invertebrates (C.elegans) and vertebrates. MyoD and Rbm24 (aka 
Seb4) share a very close expression pattern, both temporally and spatially, with 
the notable exception that Rbm24 is expressed in the cardiac as well as the 
113 
 
skeletal muscle cell lineage (Fetka et al., 2000; Li et al., 2010a; Maguire et al., 
2012). It was found that Rbm24 expression is at low levels in myoblasts 
expressing MyoD, then accumulates over time and is expressed in all skeletal 
muscle lineages (Grifone et al., 2014). Rbm24 (Seb4) is an RNA binding protein 
essential for cardiac and skeletal muscle specific alternative splicing (Cardinali et 
al., 2016; Yang et al., 2014). In mice, inducible Rbm24 mutants show defects in 
skeletal muscle M-band formation (Yang et al., 2014) and in C2C12 cells, Rbm24 
promotes myogenic differentiation through upregulation of Myogenin. This is 
achieved through interaction of Rbm24 with the 3’ UTR of Myogenin, promoting its 
stability within the cells. Knock-down of Rbm24 in C2C12 cells results in reduced 
levels of Myogenin and inhibited differentiation (Jin et al., 2010). Supporting this, 
downregulation of Rbm24 by the micro-RNA miR-222 causes defects in muscle 
differentiation which can be rescued through Rbm24 overexpression (Cardinali et 
al., 2016), whilst it has also been shown previously to be a direct target of MyoD 
(Li et al., 2010a). Recently, it has been found that Rbm24 is also essential for 
normal somitogenesis in fish (Maragh et al., 2014) consistent with the findings in 
Xenopus. 
 
3.3.3. Rbm20 
Rbm20, a related gene with similar functions specifically in driving cardiac 
development by directing cell specific alternative splicing (Li et al., 2013; Paquette 
et al., 2014), was also identified as a target in the analyses. Mutated rbm20 has 
been previously identified as a causative factor of Cardiomyopathy, and regulates 
genes related to cardiac development through repression of alternative splicing (Li 
et al., 2010b). A notable gene regulated by Rbm20 is the sarcomeric protein Titin 
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(Guo et al., 2012; Li et al., 2013). The spatial expression pattern of Rbm20 has not 
been examined in Xenopus, however, in chick embryos it shows very early (yet 
transient) expression in somites with persistent expression the heart 
(Geisha.arizona.edu). 
 
3.3.4. Zeb2 
Zeb2 codes for an E-box binding repressor, which could act like Snail repressors 
in modulating ‘enhancer swapping’, where MyoD binds to regulatory sequences in 
different genes in myoblasts as compared with myotubes (Soleimani et al., 2012). 
Moreover, during gastrulation Zeb2 is expressed in the dorsal marginal zone with 
some more lateral mesodermal expression overlapping with MyoD. 
 
3.3.5. Gli2 
Gli2 is a downstream effector of the Shh signalling pathway which has roles in 
many developmental programs, including myogenesis in amniotes (Pan et al., 
2006; Sasaki et al., 1999). In amniotes it has been shown previously that Gli2 and 
Gli3 effectors of Shh signalling promote skeletal muscle determination through 
regulation of MRFs. Whilst both Gli2 and Gli3 are sufficient to induce expression of 
Myf5 in somites (Borycki et al., 1999; McDermott et al., 2005), Gli2 has also been 
indicated as an essential factor for MyoD expression and promotes MyoD activity 
through direct interaction with MyoD and Mef2C at target gene promoters 
(Voronova et al., 2013). 
 In Xenopus, Gli2, along with Zeb2 (aka XSip1) is expressed in the neuroectoderm 
just after gastrulation (Aguero et al., 2012; Papin et al., 2002). The mesoderm, 
where MyoD is active as a transcriptional regulator, provides signals that instruct 
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the overlying ectoderm to become neural tissue, so it is possible that there is an 
indirect regulation of these genes by MyoD. There is however, no in situ 
hybridization data for gastrula specific expression of Gli2.   
This reflects one limitation of this type of study where the genes identified are not 
necessarily direct targets, particularly when a transcriptional network such as that 
downstream of MyoD, is so wide. Further investigation into the expression pattern 
of Gli2 at this stage might reveal in more detail, the potential that MyoD regulated 
effectors of Shh signalling. This is of particular interest as, in amniotes, Shh 
signalling from the floorplate activates expression of MyoD. In Xenopus, as MyoD 
is expressed much earlier than the formation of the floorplate, this regulatory 
pathway may be more complex, and result in downstream effects on MyoD 
expression at later stages. 
 
3.3.6. FoxC1 and FoxC2 
FoxC1 shows both early mesodermal and later somitic expression in Xenopus, 
and like Rbm24, FoxC1 was also identified as a direct target of MyoD in a previous 
analysis using morpholino oligos (Maguire et al., 2012). And chromatin 
immunoprecipitation (ChIP) of upstream promoter elements showed direct binding 
of MyoD at identified E-boxes.  
FoxC1 and FoxC2 are significant targets in the analyses and are known to be 
expressed in the paraxial mesoderm amniotes (Kume et al., 1998), as well as fish 
and frogs (Köster et al., 1998; Maguire et al., 2012; Topczewska et al., 2001). 
FoxC1/C2 are essential for somitogenesis (Kume et al., 2001; Topczewska et al., 
2001), and identified as transcriptional targets of MyoD in previous studies 
(Gianakopoulos et al., 2011; Maguire et al., 2012). In the early paraxial mesoderm, 
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FoxC1/C2 are co-expressed with the early muscle regulator Pax3, however later in 
somitogenesis FoxC1/2 regulate the endothelial lineage (Lagha et al., 2009; 
Mayeuf-Louchart et al., 2014) but their expression is nonetheless essential for the 
normal migration of muscle precursor cells to the limb (Mayeuf-Louchart et al., 
2016). Interestingly, Gli2 has been found to act upstream of FoxC1/2 in the 
induction of myogenesis in P19 cells (Savage et al., 2010). 
 
3.3.7. Pbx2 
Pbx2 is also an interesting target as this family of TALE-class homeodomain 
proteins are associated with myogenesis (Berkes et al., 2004; Maves et al., 2007) 
and binding sites for Pbx transcription factors are found in regions of the genome 
associated with MyoD binding (Fong et al., 2015); it is thought that Pbx proteins 
help ‘pioneer’ or establish the myogenic programme (Yao et al., 2013a). This 
model fits well with Pbx genes being early targets of MyoD in vivo.  
 
3.3.8. Sp8 and Sp5 
Genes coding for the zinc finger transcription factors Sp8 and Sp5 were also 
identified as targets in a screen for early targets of Wnt signalling (Nakamura et 
al., 2016) and as downstream regulators promoting FGF signalling (Branney et al., 
2009; Kasberg et al., 2013). Identifying the genes coding for Sp5/8 as early MyoD 
targets is consistent with the important role for FGF (Fisher et al., 2002) and Wnt 
(Hoppler et al., 1996) signalling in activating MyoD in Xenopus. The fact that some 
regulators are identified that are known to act with MyoD (such as Pbx and Sp5/8) 
as downstream targets of MyoD is not surprising as the analyses focus on a 
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window of time very early during the specification of the myogenic lineage when 
transcriptional feed-forward pathways are being established.  
More surprising is that later targets of MyoD are detected at such an early 
developmental stage: the skeletal muscle specific protocadherins (pcdh8) and 
kinases (pgk1 and pygm), and follistatin (fstl1) are expressed in somites (Berti et 
al., 2015) and are notable as they are identified as MyoD targets at such an early 
time-point. Of particular interest is that previous study had identified fstl1 as being 
negatively regulated by MyoD through the induction of miR-206 expression 
(Rosenberg et al., 2006), yet in CRISPR/Cas9 targeted embryos it appears 
downregulated. To determine whether this is due to differential regulation by MyoD 
in different model systems or at different stages of myogenic differentiation, further 
investigation is needed. 
 
3.4. Conclusions 
 
Overall, this chapter illustrates the ease of genetically modifying Xenopus embryos 
using CRISPR/Cas9 techniques. Cas9 specifically disrupts at the target sequence 
with no off-targeting of other related MRFs present at the time of the analysis. F0 
embryos show high targeting rates, as determined by T-cloning and sequencing, 
and there is significantly downregulated expression is detected of MyoD and its 
target genes. However, despite high targeting rates, less than half of the mutated 
sequences produced resulted in a frame-shift in the coding sequence of MyoD. 
Therefore while there is a significant loss of MyoD expression, it is not likely to be 
as complete as seen by targeting using MOs (Maguire Figure 1).  
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Due to the mosaicism of F0 embryos, achieving a high level of protein reduction 
would require out-crossing of mutants selected for specific mutations to produce 
MyoD+/- heterozygous and MyoD-/- homozygous populations of frogs. Even so, this 
chapter has identified novel transcriptional targets of MyoD in the frog gastrula and 
future adaptation of the CRISPR/Cas9 protocol such as injection of 2 gRNAs 
simultaneously to induce a larger deletion, or by targeting promoter elements to 
prevent transcriptional activation would make CRISPR a powerful tool in F0 
embryos. Nevertheless, this study provided an insight into the early transcriptional 
activity of MyoD, in vivo, prior to myogenic differentiation and has supported some 
of the findings of previous Morpholino experiments. 
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4. Characterising the expression of Polr3G and 
Polr3gL in vivo 
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4.1. Introduction 
Unlike RNA Polymerase I and RNA Polymerase II, RNA Polymerase III exists as 
two distinct forms depending on the alternate presence of the small subunit Polr3G 
or Polr3gL (RPC32ɑ or RPC32β) (Haurie et al., 2010). 
Polr3G has been associated with the proliferative state; transformed cells and 
pluripotent human stem cells have been shown to express higher levels of Polr3G 
than Polr3gL with expression of Polr3G, with its expression being downregulated 
during induced differentiation programmes such as exposure to Retinoic Acid 
(Wong et al., 2011). Polr3G overexpression has been shown to render ES cells 
more resistant to differentiation programmes of all three germ layers making it a 
novel factor of pluripotency during development. Polr3gL has been less studied in 
the literature, but is knockdown in stem cells leads to loss of cell survival, and its 
expression is maintained during differentiation (Haurie et al., 2010). These data 
suggest very different potential roles for these factors in vivo.  
This chapter presents the cloning and expression analysis of these two isoforms in 
Xenopus tropicalis. 
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4.1.1. Aims of this chapter: 
1. To identify Polr3G and Polr3gL in Xenopus. 
2. To characterise the temporal and spatial expression profiles of Polr3G and 
Polr3gL in vivo. 
3. To determine whether the expression of Polr3G and/or Polr3gL is regulated 
by the myogenic factor MyoD. 
 
4.2. Results  
 
4.2.1. Identification of Polr3G and Polr3gL genes in Xenopus tropicalis. 
In order to identify predicted Polr3G and Polr3gL genes in X.tropicalis, protein and 
mRNA sequences were identified from NCBI databases. Nucleotide and Protein 
BLAST analysis was carried out for the identified sequences in order to identify 
similar sequences in other organisms. Nucleotide BLAST analysis was also 
carried out for the published X.tropicalis version 8.0 genome to ensure the 
sequences were present. To determine that the annotated sequences were 
correctly identified and either Polr3G or Polr3gL in Xenopus, Polr3G and Polr3gL 
protein sequences for multiple vertebrate model organisms were identified in NCBI 
and a phylogenetic tree was constructed in MegAlign (Figure 4.1). The protein 
sequence for X.tropicalis Polr3G clustered closely with X.laevis Polr3G and was 
also more closely related to mammalian Polr3G than amphibian Polr3gL. All 
predicted Polr3gL sequences were also more closely related to each other than 
Polr3G sequences. Therefore, the annotated predicted genes were confirmed as 
Polr3G and Polr3gL. 
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Figure 4.1. The molecular phylogenetic analysis of Polr3G and Polr3gL proteins across 
vertebrates. The phylogenetic reconstruction was produced using the Jotun-Hein Method using 
DNAStar MegAlign software.  The scale bar represents a genetic distance of 100 nucleotide 
substitutions. 
 
Polr3G (and possibly Polr3gL) interacts with another RNA Polymerase III subunit, 
RPC62, via a core domain predicted to include amino acid residues 50 to 100 
(Boissier et al., 2015). Transcription initiation by RNA Polymerase III is dependent 
on the interaction of these subunits, along with one other to form a tertiary 
complex which is then incorporated into the RNA Polymerase III complex, 
suggesting that this domain may be important for protein function. Alignment of 
X.tropicalis Polr3G and Polr3gL protein sequences revealed that the paralogues 
shown only 48.4% identity (Figure 4.2. Unshaded indicates sequence difference). 
Low conservation was observed for much of the protein structure including both 
the core domain implicated in RPC62 interaction (Figure 4.2. Blue underline) and 
the peptide recognition sequence for a Xenopus tropicalis specific Polr3G antibody 
located at sites 91-103 (Figure 4.2. orange box).  
 
123 
 
 
Figure 4.2. Alignment of X.tropicalis Polr3G and Polr3gL protein sequences. Protein sequences 
were aligned in MegAlign using the Clustal W method. Divergence from Polr3G sequence is indicated 
in white. Peptide recognition sequence for custom-produced antibody against Polr3G is indicated by 
the orange box. The core domain implicated in interaction with RPC62 is indicated by blue underline 
(amino acids 50-100).  
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4.2.2. Cloning of regions of Xenopus tropicalis Polr3G and Polr3gL coding 
sequence for in situ probe synthesis 
Sequence differences at the nucleotide level allow the design of specific RT-PCR 
primers and allow distinct probes for in situ hybridisation analysis of both subunits. 
Figure 4.3 shows the nucleotide sequence alignment of X.tropicalis Polr3G and 
Polr3gL coding sequences. Primers are indicated in red for Polr3G sequence and 
green for Polr3gL. Sequence divergence in the regions amplified by these primers 
is sufficient to distinguish between the two paralogues in X.tropicalis, enabling RT-
PCR and in situ hybridisation to be carried out to compare expression profiles of 
the subunits. 
 
Figure 4.3. Alignment of X.tropicalis Polr3G and Polr3gL coding sequences. Sequences were 
aligned in DNAStar MegAlign using the Clustal W method. Sequence differences from Polr3G 
sequence are indicated in white. Primers designed for use RT-PCR and subsequent amplification of 
coding sequence regions for in situ hybridisation probe synthesis are indicated by red (Polr3G) and 
green (Polr3gL) arrows. 
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In order to characterise expression profiles of Polr3G and Polr3gL in X.tropicalis 
during development, RT-PCR and in situ hybridisation (ISH) assays were used. To 
generate probes, 400bp-600bp sections of the Polr3G and Polr3gL coding 
sequences were amplified from unique regions of each cDNA to ensure specific 
recognition of the different mRNAs. These sections were also used for RT-PCR 
analysis (Figure 4.5.A). The amplified products (Figure 4.4. A) were subsequently 
T-cloned into the pGEM T-Easy vector system for in situ hybridisation probe 
synthesis (Figure 4.4. B). The plasmids were sequenced to determine the 
orientation of insertion and antisense cRNAs were transcribed incorporating DIG-
UTP. 
 
4.2.3. Cloning full length Polr3G and Polr3gL mRNA for in vivo 
overexpression. 
In order to investigate gene function in Xenopus, synthetic mRNA injection to 
overexpress a protein of interest is often used as an initial functional assay. The 
full length sequence of Polr3G and Polr3gL mRNAs, including 3’ UTR, were 
collected from the NCBI mRNA database. Full length transcripts were amplified 
from cDNA at NF Stage 4 (Polr3G) and NF Stage 25 (Polr3gL) and were 
engineered to have restriction sites at 5’ and 3’ ends to allow for directional cloning 
into CS2+ (Figure 4.4. C) in addition to a KOZAK translation initiation sequence. 
 PCR products were T-cloned and subsequently excised from pGEM vectors using 
the designed restriction sites. Excised fragments were ligated into CS2+ vectors 
(Figure 4.5. D) digested with BamHI and XbaI and EcoRI and XbaI for Polr3G and 
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Polr3gL respectively. Plasmids were transformed into competent E.coli. Purified 
plasmid preps were then digested using the same restriction enzymes to confirm 
successful ligation before sequencing to ensure the predicted full length transcripts 
were successfully inserted (Figure 4.4. C). 
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Figure 4.4. PCR amplification of Polr3G and Polr3gL coding sequence regions for in situ probe and 
SP6-based mRNA synthesis. (A) Regions of Polr3G and Polr3gL CDS amplified by PCR using cDNA 
from embryos at NF stage 4 and NF stage 25 respectively. (B) Plasmid map of pGEM-TEasy vector. PCR 
product were cloned into pGEM and sequenced to determine the necessary linearisation and transcription 
enzymes to synthesise antisense probes. (C) Schematic showing restriction sites used for cloning the full-
length Polr3G and Polr3gL CDS into the expression vector CS2+. (D) Plasmid map of the CS2+ vector. 
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4.2.4. Expression patterns of Polr3G and Polr3gL during Xenopus 
development. 
4.2.4.1. Temporal expression patterns of Polr3G and Polr3gL. 
To determine the RNA expression patterns of Polr3G and Polr3gL during Xenopus 
tropicalis development, a stage series RT-PCR was carried out on the paralogues 
across all major stages of early embryogenesis (Figure 4.5. A). Polr3G expression 
is highest maternally, early in development, prior to Midblastula Transition (MBT) 
at NF stage 8.5. After the activation of embryonic transcription, Polr3G expression 
decreases rapidly to undetectable levels by NF stage 11. Polr3gL is not expressed 
maternally and is activated after MBT. It becomes detectable by NF stage 10 and 
is at highest expression levels at tailbud stages. This indicates that the two 
paralogues have different roles during development and that Polr3G is less active 
after MBT. RNA-Seq data supporting this was also published online (Figure 4.5. 
C). Polr3G protein expression as detected by western blot analysis is highest in 
embryos prior to MBT (Figure 4.5. B), however, protein is still detectable in later 
developmental stages indicating that Polr3G protein is relatively stable in vivo.  
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Figure 4.5. Temporal expression analysis of Polr3G and Polr3gL expression during Xenopus 
tropicalis development. (A) RT-PCR analysis of Polr3G and Polr3gL mRNA expression across a 
stage series of Xenopus tropicalis development. Total RNA was extracted from embryos at the 
desired NF stage using Tri-Reagent. 28S rRNA was used as an endogenous control. (B) Western 
blotting of temporal protein expression profile for Polr3G during development. GAPDH was used as a 
loading control. (C) RNA-Seq data for Polr3G and Polr3gL across Xenopus development carried out 
by Owens et al. 2016 and deposited online via Xenbase.org. 
 
4.2.4.2. Spatial expression profiles of Polr3G and Polr3gL. 
Spatial localisation of mRNAs can sometimes indicate the tissues or 
developmental pathways a protein is functional in. In situ hybridisation analysis 
was therefore carried out to determine whether Polr3G and Polr3gL are localised 
to specific regions within Xenopus tropicalis embryos during development (Figure 
4.6.A).  In situ specimens were left to develop for a longer period of time (24hours) 
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at 25°C to allow staining of Polr3G, expressed at low levels, to be detected. 
Polr3G is expressed maternally and is localised to animal hemispheres of cells 
during cleavage stages. At NF Stage 20, Polr3G expression is more localised and 
is detected within paraxial somitic mesoderm (Figure 4.6. B). By tailbud NF Stage 
23, Polr3G is detectable only at very low levels and is localised just to somites 
(Figure 4.6. C-D). This is supported by the RT-PCR analysis indicating high levels 
of Polr3G expression in early developmental stages which then decreases in later 
stages. At NF Stage 34, somitic expression of Polr3G is no longer detected and 
instead, expression is localised to the pronephros and structures of the eye 
(Figure 4.6. E). This indicates that somitic expression is transient and limited to 
early tailbud stages of development. 
In contrast, Polr3gL is not detectable by in situ hybridisation analysis until later 
stages. At NF Stage 20, Polr3gL expression is detected in the lateral plate 
mesoderm and is enriched in both anterior and posterior structures at NF Stage 20 
(Figure 4.7. B,), but overlaps with Polr3G as shown in dorsal views (Figure 4.7. 
B*). By NF Stage 23, Polr3gL is largely detectable only in anterior regions (Figure 
4.7. C), branchial arches and hindbrain although some expression is still 
detectable in the lateral plate mesoderm (Figure 4.7. C-D). Interestingly, whilst 
expression is detected in the mesoderm, no somitic expression of Polr3gL is 
detected (Figure 4.7. D). By NF Stage 30, anterior expression has resolved to 
expression in the branchial arches and hindbrain (Figure 4.7. E, arrows, ba). 
Expression is also detected in the blood and posterior mesoderm of the tail (Figure 
4.7. E, b and pm). 
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Figure 4.6. Spatial localisation of Polr3G mRNA 
expression during Xenopus development. (A-E) In 
situ hybridisation of Xenopus tropicalis stage series 
for Polr3G. Embryos were collected at cleavage (4-
cell) (A-A*), late neural (St20) (B-B*), tailbud (St23) 
(C-D) and tadpole (E) stages. In situ specimens were 
developed in BM purple substrate alongside a MyoD 
positive control. (D) Vibratome cross-section through 
St23 embryos probed for Polr3G expression. (s) 
somites, (n) notochord, (nt) neural tube, (psm) 
presomitic mesoderm, (pn) pronephros, (e) eye. (F) 
qRT-PCR for Polr3G (C) expression in tailbud (St23) 
sections. Head, Ventral and Dorsal sections were 
collected. Ct values were normalised to dicer. All 
expression values were calculated relative to somite 
expression. One-way ANOVA statistical analysis was 
carried out on relative expression of each section for 
each gene (*) represents the level of significance. 
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Figure 4.7. Spatial localisation of Polr3gL 
mRNA expression during Xenopus 
development. (A-E) In situ hybridisation of 
Xenopus tropicalis stage series for Polr3gL. (D) 
Vibratome cross-section through St23 embryos 
probed for Polr3gL expression. (s) somites, (lpm) 
lateral plate mesoderm, (n) notochord, (nt) neural 
tube, (ba) branchial arches, (pm) posterior 
mesoderm, (ov) otic vesicle, (b) blood. Arrows in 
B and B* indicate anterior structures and lateral 
plate mesoderm. Arrows in C, C* and E indicate 
hindbrain and branchial arches (C). (F) qRT-PCR 
for Polr3gL expression in tailbud sections. Head, 
Ventral and Dorsal sections were collected. All 
normalised expression values were calculated 
relative to somite expression. One-way ANOVA 
statistical analysis was carried out on relative 
expression of each section for each gene (*) 
represents the level of significance. 
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To confirm the overall spatial localisation patterns of Polr3G and Polr3gL in tailbud 
stages, embryo dissections were carried out at NF Stage 23. Anterior (head), 
dorsal (somite) and ventral sections were collected and quantitative RT-PCR 
analysis was carried out on sections to measure mRNA expression levels of 
Polr3G and Polr3gL relative to levels in the dorsal sections (Figure 4.6. And 4.7. 
F). Polr3G expression is highest in the somite sections as indicated by in situ 
hybridisation analysis with expression being significantly higher than both head 
and ventral sections (Figure 4.6.F). There is no significant difference in Polr3G 
expression between head and ventral sections. Polr3gL expression is significantly 
higher in somite sections than ventral sections, supporting in situ hybridisation 
data, however, there is no significant difference in expression between head and 
somite sections (Figure 4.7.F). Polr3gL expression is significantly higher in head 
sections compared with ventral sections. These results confirm expression 
localisation indicated from the in situ hybridisation analysis and suggest that 
Polr3G and Polr3gL have distinct temporal and spatial expression patterns during 
Xenopus development. 
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4.2.5. Regulation of somitic expression of Polr3G by myogenic 
factors. 
4.2.5.1. Locating predicted MyoD binding sites within the polr3g 
promoter region 
Polr3G expression at NF Stage 25 overlaps in the somites with 
expression of the myogenic regulatory factors MyoD and Mrf4. MyoD is 
known as the “Master Regulator” of myogenesis in Xenopus as it is the 
first myogenic gene to be induced in the mesoderm by Fgf signalling 
and MyoD expression alone is sufficient to induce expression of ɑ-actin 
(skeletal muscle) in animal caps. bHLH factors such as MyoD and Mrf4 
bind to DNA sequences with the consensus CANNTG known as E-
boxes. Therefore, to determine the possibility of MyoD regulating 
Polr3G directly, the genomic region surrounding the polr3g gene was 
scanned for sites matching this consensus. As the genome sequence 
surrounding Xenopus tropicalis was incomplete, Xenopus laevis polr3g 
was analysed. Xenopus laevis polr3g is similar in genomic structure, 
with 7 short coding exons and long introns. In the genomic region 
spanning 2Kb upstream of the 5’ UTR through to coding exon 2, a high 
number of E box sequences were located (Figure 4.8). This indicates 
that MyoD may be able to regulate Polr3G directly.  
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Figure 4.8. Overview of E-box locations within the Xenopus laevis polr3g genomic 
sequence. Green boxes represent exons 1-8. Red boxes indicate the presence of E box 
consensus sequence CANNTG. Arrows indicate regions of analysis in figure 4.9 and 4.10. (*) 
represents positive for MyoD binding. 
 
 
MyoD requires occupancy at two sites within close proximity in order to 
activate gene expression (Weintraub et al., 1990). Therefore, E-box 
sites located in the Xenopus laevis polr3g promoter region likely to be 
used for transcriptional regulation would be more likely to be situated in 
close proximity to another E-box site. The promoter region was 
therefore more closely analysed in order to identify any closely located 
E-box sites.  
Multiple E-box locations were identified with at least 2 sites in close 
proximity (Figure 4.9. A-E). Paired E-boxes are first located upstream 
of the 5’ UTR (Figure 4.9.A) whereby a pair of E boxes with the 
sequences CAGATG and CATTTG are identified. An additional E-Box 
sequence is located less than 100bp downstream, also with the 
sequence CATTTG. Four E-boxes are located 855-975bp downstream 
of non-coding exon 1 with sequences CAGCTG, CAGCTG, CAGGTG 
and CACCTG respectively (Figure 4.9.B). Any of these E-boxes might 
be paired with another within the region. Two potentially paired E-box 
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sequences were located 2156bp and 2176bp downstream of the exon 
1 and 704bp and 684bp upstream of the first coding exon and 
translational start site, both of the sequence CATTTG (Figure 4.9.C). 
Multiple E-boxes are located around and within the first coding exon 
with sequences CAGGTG, CACTTG, CATTTG, CAATTG (Figure 
4.9.D) and the final region observed was located in the intron between 
exons 1 and 2 (Figure 4.9.E). This region contained four E-box 
sequences CATTTG, CAGCTG, CAGGTG and CACATG. This 
evidence suggests that Polr3G regulatory regions contain DNA 
elements required for regulation by MyoD and therefore Polr3G could 
be a target gene activated by MyoD. 
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Figure 4.9. Genomic paired E-box locations within the polr3g genomic region.  
 
4.2.5.2. Analysis of MyoD binding at Polr3G regulatory sites. 
To determine whether MyoD might regulate Polr3G expression in the 
somites through binding at any of the identified consensus sequence 
regions, ChIP-PCR analysis was carried out on X.laevis NF Stage 25 
embryos overexpressing MyoD. In addition to the regions containing 
multiple E-box sites, with possible paired sites, three regions with 
single identified E-boxes were also included (Figure 4.8. Regions 6-8). 
These regions contained E-boxes with the either the sequence 
CAGCTG or CAGGTG, previously identified as the sequences more 
closely associated with activated transcription by MyoD in cell lines 
(Fong et al., 2012).  
Three regions of the rbm24 promoter were also included as a positive 
control for the ChIP assay. They were identified by a previous study in 
the Pownall lab in X.tropicalis and equating regions within X.laevis 
were located.  
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MyoD binding was identified in one region of the polr3g promoter 
containing multiple E-box sequences (Figure 4.10. A). Region 1 is 
located upstream of the first non-coding exon and contains three E-
boxes (Figure 4.9. A). No other region with multiple E-boxes showed 
the presence of MyoD above background levels. 
In addition, no region of the polr3g promoter with a single E-box 
sequence was positive for MyoD binding (Figure 4.10. B). MyoD 
binding was located at region 7, however this was not above 
background levels shown in the IgG control. 
Region 2 of the rbm24 promoter was shown to be positive for MyoD 
binding (Figure 4.10. C). Located upstream of the first coding exon, the 
region 2 paired E-box sequences were identified as CAGCTG and 
CAGCTG.  
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Figure 4.10. ChIP-PCR analysis of MyoD binding at Polr3G promoter sites. (A) Regions 
in which multiple E boxes were located in close proximity and potentially paired. Regions 
can be found in Figure 4.8. Above. (B) Regions where a single E-box sequence was located 
but with the consensus CAGCTG identified as associated with MyoD binding and 
transcriptional activation. (C) Regions identified within the known MyoD target gene Rbm24 
promoter as having multiple E-box sequences in close proximity. Note that nested PCR was 
used to visualise  MyoD binding. 
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4.2.6. Transcriptional regulation of Polr3G by MyoD 
4.2.6.1. Expression of Polr3G/Polr3gL in animal caps overexpressing 
MyoD protein 
The MRFs are responsible for the activation of many myogenic genes. 
To determine whether expression of Polr3G in the somites is regulated 
by the MRFs, animal caps from embryos overexpressing MyoD were 
collected at NF Stage 25 and qRT-PCR analysis was carried out for 
Polr3G and Polr3gL expression. The known MyoD target gene Actc1 
was also included. In caps overexpressing MyoD, Polr3G was 
significantly upregulated in comparison with control caps (Figure 4.11.). 
Polr3gL showed no change in expression. The known MyoD target 
gene Actc1 was also included. 
 
Figure 4.11. qRT-PCR analysis of Polr3G activation by MyoD in Xenopus tropicalis 
animal caps.  Analysis was carried out on total RNA for control animal cap and animal caps 
overexpressing 2ng MyoD for three biological replicates. Ct values were normalised to Dicer 
and expression values were calculated relative to control using the ΔΔCt method. t-tests 
were carried out to determine the statistical significance between the mean relative 
expression of control and MyoD overexpression (*) indicate level of significance.  
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4.2.6.2. Expression of Polr3G/Polr3gL in MyoD gRNA injected embryos 
To confirm regulation of Polr3G by MyoD at NF Stage 25, embryos 
targeted for MyoD expression by CRISPR/Cas9 were analysed for 
expression of Polr3G and Polr3gL by qRT-PCR (Figure 4.12.). Whilst 
MyoD and Rbm24 showed significant downregulation in targeted 
embryos, Polr3G and Polr3gL both showed modest changes in 
expression. Polr3G expression was downregulated to 0.91 control 
levels and Polr3gL was upregulated to 1.05 control expression levels. 
However, due to the mosaicism of F0 embryos, these smaller 
expression changes are more likely to be in line with the expected 
values from overexpression studies. 
 
Figure 4.12. qRT-PCR analysis of Polr3G and Polr3gL expression in F0 CRISPR/Cas9 
embryos targeted for MyoD. NF Stage 25 embryos targeted by CRISPR/Cas9 were 
collected and RNA extracted was analysed for expression of Porl3G and Polr3gL alongside 
MyoD and Rbm24 as control genes. Data was normalised to Dicer and relative expression 
values were calculated using the ΔΔCt method. Error bars represent SEM (n=2). 
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4.3. Discussion 
4.3.1. Polr3G and Polr3gL have distinct expression profiles during Xenopus 
development 
Peak expression of Polr3G in the earliest stages of Xenopus development (Figure 
4.5) indicate a role during the fast, synchronous cell divisions of cleavage stages. 
This supports previous data from cell line studies which identify Polr3G as a stem 
cell regulator. Polr3G is co-expressed with pluripotency factors such as Oct4 in 
ESCs and is downregulated during induced differentiation. Polr3G is also 
increasingly upregulated during staged oncogenic transformation of fibroblasts. 
In contrast with cell culture studies, Polr3gL is not expressed during early Xenopus 
development and is only activated after the onset of embryonic transcription at 
MBT (Figure 4.5). This is notable due to the fact that cell culture studies have 
shown that Polr3gL is essential for cell viability and survival. In human 
hepatocarcinoma cells, Polr3gL expression levels are maintained during 
differentiation and Polr3G is unable to compensate for loss of Polr3gL through 
siRNA targeting (Haurie et al. 2010) despite the maintenance of RNA Polymerase 
III activity by the Polr3G isoform. This suggests that, unlike cells, Polr3gL is not 
essential for cell growth and survival during early embryogenesis. It is possible 
that Polr3G is an essential factor for early developmental viability, however, as 
Polr3G mRNA and protein is expressed prior to MBT and likely to be maternally 
deposited into oocytes, depletion of Polr3G expression at this stage is not 
possible. 
After MBT, the expression profiles of Polr3G and Polr3gL remain strikingly 
different in Xenopus embryos. Expression of Polr3G, surprisingly, is isolated to the 
somites during late neural and early tailbud stages (Figure 4.6. C-D). In Danio 
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rerio, expression of Polr3G genes have also been characterised. The RNA 
Polymerase III gene polr3gla in D.rerio is also expressed in somites at the 20-25 
somite stage (Thisse et al., 2001) suggesting an evolutionarily conserved role in 
the muscle lineage for a subunit of the RNA Polymerase III complex during early 
myogenesis. However, the protein sequence of Polr3gla is distinct from Polr3G 
sequences of other species and through phylogenetic analysis is identified as 
Polr3gL (Figure 4.1). Therefore, muscle specific expression of Polr3G in 
X.tropicalis could be due to an acquired developmental role. As previous analysis 
of Polr3G and Polr3gL activity revealed that both subunits occupy the same target 
genes, but that the polr3g promoter but not the polr3gl promoter is occupied by 
Myc in P493-6 cells (Renaud et al., 2014), it is likely that these two subunits are 
regulated by different factors during development. 
 
4.3.2. Polr3G expression is regulated by myogenic factors 
Polr3G expression at tailbud stages overlaps with expression of key myogenic 
transcription factors MyoD and Mrf4. Previous analysis of early targets of MyoD 
revealed that MyoD binding was present at E box sequences in the promoter 
regions (Maguire et al., 2012). Multiple potential binding sites were located 
upstream of the polr3g coding sequence, and, as needed for MyoD activation, 
many sites were located in pairs. Unlike previous studies in cell lines, the site 
CAGGTG most associated with activation of transcription by MyoD (Fong et al., 
2012; Fong et al., 2015), were largely not located in the polr3g genetic region. This 
may mean that the predictions made in in vitro studies are not replicated in in vivo 
studies. ChIP analysis located a site in the Polr3G promoter region at which MyoD 
binding was positive. However, unlike other target genes, binding at only one 
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region was detected whereas MyoD binding at multiple sites was identified in 
previous studies. Notably, when the promoter region of Polr3gL was also 
examined, a number of E boxes were also identified (data not shown), yet MyoD 
overexpression did not lead to upregulated expression of Polr3gL in animal caps 
(Figure 4.11.). It is therefore possible that other bHLH factors including other 
MRFs, the neurogenic factor NeuroD2 and possible negative regulators may 
instead regulate Polr3gL expression via these E box sites. Additionally, as the 
MRF antagonist family of Id proteins are also bHLH factors, they may bind E box 
sites in the Polr3gL promoter to prevent MyoD binding (Benezra et al., 1990; 
Wang and Baker, 2015). 
MyoD overexpression in animal caps induces a conversion to a more myogenic 
state as indicated by the expression of skeletal muscle actin, Actc1. However, 
alone MyoD is not sufficient to drive full myogenic differentiation and expression of 
Myogenin and contractile protein genes (Hopwood and Gurdon, 1990). This 
indicates that MyoD animal cap cells expressing Actc1 are still in a progenitor-like 
state and, characteristic of early MyoD/Myf5 positive myoblasts, are still 
proliferative (Cossu and Butler-Browne, 1999). Polr3G expression was significantly 
upregulated in MyoD induced animal caps, and CRISPR/Cas9 targeting of MyoD 
resulted in downregulated expression of Polr3G indicating that the expression of 
Polr3G observed in the somites at tailbud regions is likely to be regulated, at least 
in part, by MyoD. As Polr3G is expressed at very low levels in post-MBT stages of 
development, and and RNA Polymerase III complex containing either Polr3G or 
Polr3gL is predicted to be required for the transcriptional initiation of target genes 
(Haurie et al., 2010), Polr3G may be an important limiting factor for the rate of 
transcription by RNA Polymerase III. As such, even modest increases in its 
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expression are likely to have a significant effect on the expression of its target 
genes. Interestingly, Polr3gL shows little change in expression in response to 
MyoD, suggesting that, these factors have different roles in both development and 
in myogenesis. It is a possibility that Polr3gL is regulated by later myogenic 
terminal differentiation factors such as Myogenin. However, this was not 
investigated in this thesis 
 
4.4. Conclusions 
 
This chapter has identified that Polr3G and Polr3gL have distinct temporal and 
spatial expression profiles during Xenopus tropicalis development. Polr3G is 
expressed at high levels pre-MBT and decreases during gastrulation as Polr3gL is 
activated. Polr3G expression during tailbud stages is enriched in early skeletal 
muscle structures and is co-localised with the myogenic factors MyoD and Mrf4 at 
this timepoint. This expression is transient, and later Polr3G is expressed in the 
pronephros indicating perhaps that Polr3G has different mechanism of regulation 
later in development. ChIP-PCR revealed that MyoD is able to bind regulatory 
regions of the polr3g gene similar to the observed binding in previous studies 
(Fong et al., 2012; Maguire et al., 2012) and increase its expression in animal 
caps alongside the myogenic marker gene Actc1. As MyoD acts as a myogenic 
determination factor, it is likely that the observed expression of Polr3G during 
myogenic differentiation is timed with commitment of cells to become proliferative 
myoblasts rather than terminal differentiation of skeletal muscle. Nevertheless, this 
chapter indicates that novel factors of RNA Polymerase III transcriptional 
regulation may have important developmental roles in Xenopus. 
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5. Regulation of tRNA transcription through the 
RNA Polymerase III subunit Polr3G 
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5.1. Introduction 
5.1.1. RNA Polymerase III studies in Xenopus 
Xenopus laevis were utilised as an important model for studying transcriptional 
regulation of all three RNA Polymerases and took prevalence in the 1970s. The 
vast numbers of synchronously developing Xenopus embryos accessible for 
biochemical and molecular studies enabled the study of transcriptional control of 
both RNA Polymerase II and RNA Polymerase III transcripts during oogenesis, the 
subsequent silencing of transcription during early development, and the 
reactivation of transcription at MBT (Newport and Kirschner, 1982a; Newport and 
Kirschner, 1982b; Wormington and Brown, 1983).  
It was found that during oogenesis, single oocytes accumulate around 90ng of 
tRNA over a number of months after which RNA Polymerase III activity, like RNA 
Polymerase II, is rapidly silenced (Gilbert, 2000). Studies of this kind led to 
identification of developmentally regulated tRNA and 5S rRNA genes. tRNATyr and 
5S rRNA have specific genes that are expressed in the oocytes prior to fertilisation 
and up to MBT, when transcription of zygotically expressed populations is 
activated (Stutz et al., 1989; Wolffe and Brown, 1988). At this point, the 
dissociation of transcription machinery from the oocyte-type genes causes the 
repression of these genes whilst stable interaction of transcription machinery and 
zygotic genes maintains their expression throughout development. These findings 
give early indications of the usefulness of Xenopus as a model for elucidating the 
complex mechanisms regulating initiation of transcription by Polymerase III. 
Xenopus laevis have also been used to analyse the genomic organisation of RNA 
Polymerase III targets identifying large clusters in which many tRNA genes are 
located, and revealing that these loci of >3kb are repeated hundreds of times in 
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the genome. Moreover, these clusters do not contain continuous tRNA sequences, 
but these sequences are separated by spacers of substantial size often much 
larger than the tRNA sequences themselves. This information better characterised 
possible regulatory regions of tRNAs, and suggested very early, the vast copy 
numbers of tRNA genes encoded by the Xenopus genome (Clarkson et al., 1973; 
Narayanswami et al., 1995; Rosenthal and Doering, 1983). 
The use of northern blot analysis has been common practice in molecular biology 
for measuring the expression of tRNAs in Xenopus and other model organisms 
and utilises the hybridisation of P32 labelled probes complementary to part of the 
tRNA sequence as a means of detecting expression both prior to and beyond 
onset of embryonic transcription (Stutz et al., 1989). However, the advent of 
reverse transcriptase-based methods such as quantitative PCR (qRT-PCR) 
provided easier and more quantitative methods for analysing transcription.  
An online genomic tRNA database predicts the number and genomic location of 
tRNA genes encoded within the genomes of many model organisms by predicting 
genome sequences that form cloverleaf structure through an adapted algorithm. 
This analysis has been carried out to include the Xenopus tropicalis genome 
(Chan and Lowe, 2016; Chan, P.P. & Lowe, 2009). Eukaryotic genomes contain 
multiple genes encoding the same anticodon and their high sequence homology 
within families, and synteny between species suggests that this is due to 
duplication events (Lloyd et al., 2012). It is predicted that in Xenopus tropicalis a 
total of 2638 genes encode tRNAs, this adds complication to looking at tRNA 
expression by methods such as RNA-Seq and ChIP-Seq whereby genomic 
mapping is key to the analysis. Multiple genes encode each anticodon and share 
very high sequence identity. For example, the AlaAGC anticodon is encoded for by 
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64 genes (Figure 5.1.) and much of the 73bp sequence is identical between all of 
the genes, making individual genes indistinguishable by transcriptomic methods. 
 
 
Figure 5.1 Alignment of tRNA AlaAGC genes predicted to be encoded by the Xenopus 
tropicalis genome by the GtRNAdb algorithm. FASTA sequences were aligned using Clustal 
Omega software. Colours indicate nucleotide identity. 
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5.1.2. tRNA assays 
tRNAs have often been considered to be ‘housekeeping’ RNAs with many 
publications using their expression as endogenous loading controls (Geslain and 
Pan, 2011). However, both ChIP-Seq and Microarray studies have indicated that 
tRNAs are tightly regulated with specific expression profiles amongst different 
tissue types and cell characteristics (Dittmar et al., 2006; Schmitt et al., 2014; 
Topisirovic and Sonenberg, 2014). This regulation has been shown to be 
important in the case of cancers with even small increases in tRNAiMet expression 
resulting in dysregulated cell division and changes in global tRNA expression 
patterns (Pavon-Eternod et al., 2013). Therefore, the developmental regulation of 
tRNA expression could be crucial to defining their potential role in differentiation 
and disease. 
Even now, techniques to effectively measure tRNA transcription at both the 
nascent and mature levels are not yet developed and tRNAs pose many problems 
for traditional high-throughput and quantitative methods. Problems with traditional 
sequencing methods come from tRNA molecules tight tertiary structure, making 
their sequence largely inaccessible for cDNA synthesis and adapter ligation for 
RNA-Seq methods. Extensive post-transcriptional modifications, particularly N1-
methyladenosine (m1A) and N1-methylguanosine (m1G) (Figure 5.2.), prevent 
primer extension by traditional Reverse Transcriptase enzymes. Recently, 
attempts to remove these modifications have been made to improve sequencing of 
tRNAs (Wilusz, 2015; Zheng et al., 2015), however this technique is not yet widely 
used with no standard protocols. 
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Figure 5.2. tRNA modifications known to be inhibitory for Reverse transcriptase first strand 
synthesis. m1A is a methyladenosine modification. m1G is a methylguanosine modification. 
 
Other high-throughput methods have been used to investigate tRNA expression. 
ChIP-Seq using an antibody for the catalytic subunit of RNA Polymerase III, 
Polr3A has been carried out to determine global localisation of Polymerase III at 
target sites. These studies argue that the presence of RNA Polymerase III binding 
represents transcriptional activation of target genes and that binding dynamics can 
show changes in expression. This technique has led to multiple publications 
investigating global tRNA transcriptional regulation (Kutter et al., 2011; Rudolph et 
al., 2016; Schmitt et al., 2014). However, ChIP-Seq requires extensive genome 
annotation as tRNAs are very repetitive in sequence. There are predicted to be 
over 2000 tRNA sequences in the Xenopus tropicalis genome, compared with 
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approximately 250 in the human genome (Chan & Lowe 2016). This adds 
complications to analysis as multiple copies of almost identical sequence are 
located in different genomic locations. In addition, published versions of the 
Xenopus genome, repetitive elements are masked and therefore it is likely that 
tRNA clusters are removed from genomic data. Moreover, it has been shown in 
cases of mRNA regulation that the presence of RNA Polymerase II and 
transcription factors at a site in the genome, is not always associated with 
activated transcription (Cao et al., 2010; Nakamura et al., 2016). Therefore, ChIP-
Seq may not accurately reflect transcription and expression levels of tRNAs. 
 
5.1.3. tRNA microarrays 
Another technique for tRNA expression analysis, the tRNA microarray, is based on 
hybridisation of labelled cRNA to 40-70mer probes which are immobilised onto a 
glass slide. RNA samples are labelled with the fluorescent dye Cy3 or, to compare 
two samples simultaneously, Cy3 and Cy5 and hybridised to the slide overnight at 
a temperature ranging between 42°c and 70°c. Slides are then scanned to 
produce a high resolution TIF image for which fluorescent intensity can be used as 
a measure of gene expression.  Previous studies have used microarrays designed 
for human tRNAs in order to look at expression differences between different 
tissue and cell types (Dittmar et al., 2006; Gingold et al., 2014; Topisirovic and 
Sonenberg, 2014). Due to the high conservation of tRNA sequences, individual 
genes are unable to be measured, however isoacceptor families can be 
distinguished from one-another.  
Dittmar et al. used a microarray designed for 49 anticodon families encoding all 
amino acids in humans plus an initiator methionine sequence (Dittmar et al., 
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2006). This study then compared expression of tRNA families between human 
liver, vulva, testes, ovary, thymus, lymph node and spleen versus levels in the 
brain. This study showed that different tissues are enriched for distinct tRNA 
families carrying amino acids of a particular biochemical property. Moreover, by 
comparing this with mRNA codon usage, expression of tRNA isoacceptors was 
shown to correlate with abundance of corresponding codons. tRNA microarrays 
were also used more recently, coupled with RNA-Seq, in order to determine 
whether proliferative cancer cells contained distinct tRNA profiles from senescent 
cells (Gingold et al., 2014; Topisirovic and Sonenberg, 2014). This study found 
that proliferative cells show upregulation of distinct families of tRNAs and that 
biased mRNA codon usage in proliferation genes match to the specific 
upregulated tRNAs. 
 
5.1.4. Aims of this chapter 
1. To measure tRNA expression in vivo during Xenopus development. 
2. To identify tRNA families and mRNAs activated or repressed by Polr3G activity 
in vivo. 
3. To determine if Polr3G overexpression has wider transcriptional effects by 
analysing mRNA expression in embryos overexpressing Polr3G. 
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5.2. Results 
5.2.1. Overexpression of Polr3G in vivo. 
In order to investigate gene function in Xenopus, synthetic mRNA injection to 
overexpress a protein of interest is often used as an initial functional assay. A 
cDNA coding for full length Polr3G mRNA was cloned into the CS2+ expression 
vector and mRNA was synthesised in vitro. Embryos were injected at the 1 or 2-
cell stage and allowed to develop to NF Stage 25 when endogenous Polr3G 
protein levels are downregulated. To show that injection of synthetic mRNA from 
constructs resulted in increased protein expression, a western blot was carried out 
for endogenous Polr3G protein and confirmed that protein expression in embryos 
injected with Polr3G mRNA was significantly upregulated in comparison to 
uninjected control embryos at NF Stage 25 (Figure 5.3). 
 
Figure 5.3. Overexpression of Polr3G in Xenopus tropicalis. Western blot analysis of endogenous Polr3G 
protein at NF Stage 25 in control uninjected samples versus embryos injected with 2ng synthetic Polr3G 
mRNA. A GAPDH loading control was also included. 
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5.2.2. Regulation of transcription by Polr3G at the onset of transcription 
To determine whether Polr3G overexpression has an effect on tRNA expression 
during development, 2ng of synthetic mRNA was injected into X.tropicalis embryos 
at the 1 or 2-cell stage and these were left to develop until Midblastula Transition 
(MBT) and the activation of transcription. MBT occurs at NF Stage 8.5 in Xenopus, 
so NF Stages 7, 8 and 9 were collected for analysis.  
RT-PCR analysis was carried out for selected tRNA families to determine their 
expression levels across a timecourse of stages.  At the earliest stages of 
development in control embryos, expression of tRNAs was not detected. In 
comparison with control uninjected embryos, embryos injected with Polr3G 
showed increased transcription of four tRNA families with tRNALeu transcripts 
detectable at NF Stage 7, and both tRNATyr and tRNAiMet detected at NF Stage 8 
(Figure 5.4. B). tRNA transcripts are undetectable at NF Stage 7 in control 
embryos (Figure 5.4. A) and both tRNATyr and tRNAiMet are undetectable until NF 
Stage 9. However, U6 RNA expression levels appears unchanged in embryos 
overexpressing Polr3G suggesting that Polr3G selectively regulates a subset of 
RNA Polymerase III target genes. As mature processed tRNAs are not detectable 
by cDNA/PCR methods, only nascent transcripts from active transcription prior to 
modification are detected in these analyses. This enables the identification of early 
changes to tRNA transcription dynamics. 
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Figure 5.4. RT-PCR analysis of tRNA transcription dynamics in response to overexpression of Polr3G 
at MBT. X.tropicalis embryos were injected at the 1-2 cell stage with 2ng Polr3G mRNA and left to develop 
until desired stages. RT-PCR for selected families of tRNAs was carried out against control uninjected 
embryos at the same NF Stages. tRNA families Tyr (GTA), Leu (CAA), iMet and eMet (CAT) were included in 
the analyses. The RNA polymerase III target U6 RNA was also included as a measure of altered wider 
Polymerase III transcription and the control gene Dicer was also included. (A) RT-PCR analysis of uninjected 
control embryos. (B) RT-PCR analysis of embryos overexpressing Polr3G. 
 
5.2.3. Detection of tRNA transcripts across development by Northern Blot 
The failure to detect tRNAs before the onset of transcription at MBT by RT-PCR 
was surprising and as early embryos are utilised to make protein in 
overexpression studies, it was predicted that this observation was the result of a 
PCR artefact. In order to test this, northern blot analysis was to measure 
expression of both tRNALeu and tRNATyr across development. Urea Acrylamide 
gels denature the tertiary structure of tRNAs and allow hybridisation of P32 labelled 
probes. Mature, processed tRNALeu and tRNATyr transcripts can be detected by 3’ 
probes by bands at 84nt and 73nt respectively, at all stages of development 
(Figure 5.5. A bottom and middle panel). An additional probe was designed to 
include the intron sequence of tRNATyr genes to allow measurement of nascent 
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tRNA transcripts and pre-tRNA. Intron probe hybridisation was only detectable in 
stages post-MBT when tRNA transcription by RNA Polymerase III is activated 
(Figure 5.5. A top panel). Two bands are detected, one at 103nt representing 
nascent tRNA transcripts including 5’ and 3’ sequences and an additional band at 
86nt representing pre-tRNA including intron only (Figure 5.5. B). The intron-
containing intermediate tRNA transcript is also detected using 3’ probes (Figure 
5.5. A middle panel- note band of higher molecular weight). Taking into account 
the correlation of RT-PCR products and the detection of nascent tRNA transcripts 
at post-MBT stages using Northern Blotting, these results indicate that while RT-
based methods such as PCR, RNA-Seq and microarray analyses do not detect 
mature tRNAs, they can be used to quantify nascent tRNA transcripts in Xenopus. 
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Figure 5.5. Northern blot analysis of both nascent and mature tRNA transcripts and processing of 
nascent tRNA Tyrosine transcripts. (A) Total RNA was extracted from 10 Xenopus tropicalis embryos at the 
desired developmental stage. RNA was run on an Acrylamide/Urea gel. Probes were labelled with P32. (B) 
Processing of tRNATyr transcripts indicating the bands identified from Northern Blot analysis. Note: This 
experiment was carried out with my supervisor Dr ME Pownall who has a license to use P32. 
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5.2.4. Microarray analysis of Polr3G regulation of tRNA expression dynamics 
at NF Stage 9 
5.2.4.1. Microarray design 
As active transcription of tRNAs can be detected using cDNA-based methods, in 
order to look more globally at tRNA expression dynamics in Xenopus, I designed a 
custom microarray by manually compiling tRNA sequences for Xenopus, Human 
and CHO genomes, to include probes for all tRNA isoacceptor families. Selected 
mRNAs for myogenic and contractile protein genes, as well as other bHLH factors, 
mesodermal genes and known targets of FGF signalling were also included. 
Briefly- 5 60mer probes were designed for each tRNA isoacceptor family passing 
quality checks using Agilent eArray software. Additional manual probes were 
designed for 5’, 3’ and middle sections of isoacceptor family sequences not 
included in the Agilent design. To determine probe specificity, sequences for CHO 
and Human tRNA isoacceptor families were also manually designed (see methods 
in Chapter 2 for full design details). Embryos were collected at NF stage 9, timed 
just after activation of embryonic tRNA transcription as detected by RT-PCR, for 
control and Polr3G overexpression samples. After quality control was carried out 
using the Agilent Bioanalyzer 2000 to determine RNA Integrity Numbers (RINs) 
(Figure 5.6), RNA samples were used to synthesise cDNA and subsequently 
labelled with Cy3. cRNA samples were hybridised for 17 hours at 65°c and 
resulting slides were scanned to create a high resolution TIFF file for processing of 
expression data (see methods 2.4.4).  
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Figure. 5.6. Bioanalyzer results for microarray RNA sample quality control. Samples 1, 3 and 
5 refer to control embryo samples at NF Stage 9. Samples 2, 4 and 6 are stage-matched embryos 
overexpressing Polr3G. 
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5.2.4.2. Analysing Fold Changes 
Analysis of both mean fold change and differences between the means of control 
and experimental samples were carried out for tRNAs by isoacceptor and by 
amino acid and summarised in Figure 5.7. Replicate probes gave highly 
coordinated fold changes and mean normalised expression for each anticodon 
family and additionally, t-testing of mean expression for Polr3G injected samples 
versus controls showed that tRNA expression levels were statistically different for 
many isoacceptor families.  
To ensure that changes in expression were sizably different whilst accounting for 
strong predicted regulation of tRNA genes, fold change thresholds of 0.8 and 1.2 
were used to define families as downregulated or upregulated respectively. 
Interestingly, more isoacceptor families appear upregulated than downregulated 
(Figure 5.7.A). When isoacceptor families are combined by amino acid isotype, 
fewer families show changes in levels exceeding the expression change 
thresholds (Figure 5.7.B).  
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Figure 5.7. Overall tRNA expression changes in response to Polr3G overexpression. Expression fold 
change summary of tRNA isoacceptor families in X.tropicalis NF Stage 9 whole embryos injected with 2ng 
Polr3G mRNA versus control uninjected across 3 biological replicates. Signal data was processed using 
GeneSpring to determine normalised signal values for each probe within each array, and a normalised 
intensity reading by comparing probes across the arrays. Normalised values were used to determine 
expression fold changes for each biological replicate to give an average fold change for each probe across the 
three replicates. Control and Polr3G injected mean expressions for each of the 5 probes designed per family 
were then analysed using t-tests to determine statistical significance of the change in expression for each 
anticodon isoacceptor family and amino acid isotype. To account for multiple comparisons, Bonferroni 
Correction was applied. (A) Summary chart of fold changes for isoacceptor families with raw signals of >10. 
Orange indicates up-regulated transcription, blue indicates down-regulated transcription, and pink indicates no 
change in expression. SEM is presented as error bars and * indicates the level of statistical significance. (B) 
Summary chart of fold changes for all isoacceptor family probes per amino acid family. Orange indicates up-
regulated transcription, blue indicates down-regulated transcription. 
 
164 
 
Particular subsets of amino acid isotype families show distinct regulation patterns 
between the isoacceptor families as a result of Polr3G overexpression. tRNAGln 
has two isoacceptor families detected at Stage 9 and whilst GlnCTG is significantly 
upregulated by overexpression of Polr3G, expression of GlnTTG is decreased to 
0.64 relative to control expression levels (Figure 5.8. A). A similar pattern of 
expression changes occurs in tRNAThr families (Figure 5.8. C).  tRNAIle shows 
upregulated expression of their isoacceptors which is conserved through to the 
amino acid level (Figure 5.7. B, Figure 5.8. B). tRNASer isoacceptor families show 
variable regulation by Polr3G; SerAGA and SerGCA families show no change in 
expression, SerGCT is significantly upregulated and SerTGA is significantly down-
regulated in embryos overexpressing Polr3G (Figure 5.8. D). Polr3G therefore 
specifically regulates a subset of tRNA isoacceptor families during early 
development and selectively activates or represses transcription. Despite 
significantly altered expression of tRNAGln, tRNASer, and tRNAThr isoacceptor 
families, at the amino acid family level, these changes equilibrate so that 
Glutamine, Serine and Threonine show no significant changes in level. This 
suggests that tRNA isoacceptor families equilibrate overall expression changes so 
that the relative levels of their amino acid remain constant, as suggested in a 
previous study (Schmitt et al., 2014).  
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Figure 5.8. Analysis of tRNA expression changes in response to Polr3G overexpression by amino 
acid. (A) Isoacceptors encoding families belonging to tRNAGln (B) tRNAile (C) tRNAMet (D) tRNASer . Orange 
indicates expression is significantly up-regulated. Blue indicates expression is significantly down-regulated. 
 
5.2.5. Validation of Microarray analysis 
The results from microarray analysis show some discrepancies from the initial 
analysis carried out by RT-PCR in Figure 5.4. Therefore, to determine possible 
reasons for these differences, and to validate the use of microarrays as a tool for 
measuring tRNA expression, variation analysis and an additional qRT-PCR 
analysis for tRNAiMet, tRNAeMet, tRNATyr, and tRNALeu  were carried out on NF 
Stage 9 control and Polr3G samples. Figure 5.9 shows that even within 
experimental sample groups, gene expression is largely variable. This may 
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account for the difference in expression change in the initial RT-PCR experiment 
versus later microarray experiments. 
 
Figure 5.9. Variation of gene expression within NF Stage 9 microarray samples. X1-3 represent control 
samples. X4-6 represent samples overexpressing Polr3G. Samples are paired such that sibling embryos are 
present in samples X1 and X4, X2 and X5 and X3 and X6 respectively. 
 
qRT-PCR analysis was carried out to quantify gene expression changes observed 
between additional control and Polr3G overexpression samples at NF Stage 9 in 
order to validate microarray results for the initially analysed tRNA families (Figure 
5.10.). Some variation can be observed in tRNALeu expression changes as in the 
microarray this was significantly upregulated whilst qRT-PCR analysis indicates in 
embryos overexpressing Polr3G, tRNALeu expression is moderately (but not 
statistically significantly) downregulated. tRNATyr is downregulated in both 
microarray and qRT-PCR samples, but is not statistically different from controls in 
qRT-PCR results. tRNAiMet again shows no change in expression compared with 
control embryos in response to Polr3G overexpression and tRNAemet also shows a 
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similar response. tRNAeMet was only detected at very low levels in the microarray 
samples and was included only as a comparison with tRNAiMet. This data suggests 
that the initial RT-PCR results were possibly outliers in the analysis as qRT-PCR 
and microarray data show similar results. 
 
 
Figure 5.10. Validation of microarray analysis by qRT-PCR of selected tRNA families. Total 
RNA was extracted from control embryos and embryos overexpressing Polr3G protein at NF Stage 
9 and rigorously DNase I treated using Zymo Clean and Concentrator-5 columns. qRT-PCR was 
carried out for tRNAiMet, tRNAeMet, tRNATyr and tRNALeu using primers previously used in RT-PCR 
in Figure 5.2. Relative expression values were calculated using the ΔΔCt method with Dicer used 
as an endogenous control. 
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5.2.6. Analysis of RNA Polymerase III targets and mRNAs 
To detect wider transcriptional changes as a response to Polr3G overexpression, 
probes for additional RNA polymerase III targets and selected mRNAs of interest 
were also analysed for changes in expression. Interestingly, RNA polymerase III 
targets somatic and oocyte 5S rRNAs were significantly downregulated (fold 
changes of 0.64 and 0.63 respectively) in samples overexpressing Polr3G 
compared with control embryos. 7SK RNA showed a fold change down to 0.81 
expression levels and 7SL RNA also was downregulated to 0.8 expression levels. 
Whilst U6 RNA appeared to show some level of upregulation (fold change 1.15), 
no RNA Polymerase III target was shown to be upregulated above the threshold 
cut-off (Figure 5.11.A). 
Several mRNAs selected for analyses were also shown to have significant 
changes in expression levels compared with controls. Many mRNAs showing 
significant changes beyond thresholds however (See Appendix. Table 2), were 
excluded due to low expression levels including all mRNAs down-regulated below 
threshold. mRNAs shown to be significantly upregulated include a number of key 
regulators of early embryonic patterning (Figure 5.11.B); the BMP antagonist and 
dorsalising factor chordin (chrd), the forkhead box transcriptional repressor foxd5; 
the bHLH transcriptional repressor id3; wnt8a, a ligand involved in ventral 
mesoderm patterning; the Spemann Organiser patterning gene (gsc); a regulator 
of mesoderm differentiation during gastrulation, eomesodermin (eomes); the 
mesendodermal patterning gene nodal (xnr4); and the left-right determination 
factor lefty. 
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Figure 5.11. Wider transcriptional effects of Polr3G overexpression. Expression fold change summary of 
RNA Polymerase III target genes and upregulated mRNAs in X.tropicalis NF Stage 9 whole embryos injected 
with 2ng Polr3G mRNA versus control uninjected across 3 biological replicates. Normalised values were used 
to determine expression fold changes for each biological replicate and combined to give an average fold 
change for each individual probe across the three replicates. Control and Polr3G injected mean normalised 
expression for each of the 5 probes designed per gene were then analysed using t-tests to determine 
statistical significance after Bonferroni Correction of the change in expression. (A) Summary chart of fold 
changes for RNA Polymerase III target genes with raw signals of >10. Orange indicates upregulated 
transcription, blue indicates down-regulated transcription, pink indicates no change in expression. SEM is 
presented as error bars and * indicates the level of statistical significance. (B) Summary chart of fold changes 
for genes upregulated in Polr3G overexpression samples. 
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5.2.7. Correlating tRNA anticodon family expression levels to tRNA 
anticodon family gene copy number. 
Previous studies in C.elegans have indicated that tRNA gene copy number (the 
number of genes encoded for within a genome) has a direct effect on the 
expression levels of particular tRNAs. The study showed that tRNA isoacceptor 
families with higher numbers of encoding genes were expressed at higher levels 
than tRNA isoacceptor families with lower gene copy numbers (Duret, 2000). With 
the microarray and GtRNAdb data, it is possible to test this hypothesis in Xenopus. 
Therefore, in order to determine whether gene copy number also has an effect in 
Xenopus, the correlation tRNA expression values from control NF Stage 9 
samples and gene copy numbers predicted from the GtRNAdb database 
(http://gtrnadb.ucsc.edu/) was analysed using Pearson’s correlation coefficient for 
linear relationships (Figure 5.12). The plot shows average tRNA isoacceptor 
expression values from the microarray against the corresponding gene copy 
number predicted for Xenopus tropicalis. A positive correlation is indicated by R2 
values close to the value of 1. No correlation between the factors was identified 
from the analysis (R2= 0.0081, p = 0.52). This indicates that in Xenopus, gene 
copy number does not affect expression levels of tRNA isoacceptor families. 
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Figure 5.12.  Linear correlation of tRNA expression levels to tRNA isoacceptor gene copy 
number. tRNA expression was calculated using average intensity values from NF Stage 9 control 
embryos. Linear correlation was determined using Pearson’s correlation coefficient R2= 0.0081. The 
x-axis values indicate tRNA anticodon gene copy number as predicted from http://gtrnadb.ucsc.edu, 
the y-axis values indicate log tRNA expression values. 
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5.3. Discussion 
5.3.1. Upregulation of Polr3G results in global changes in tRNA expression 
Polr3G overexpression at blastula stages, just after the onset of zygotic 
transcription, results in dynamic alterations in the expression of tRNA anticodon 
families, with many families showing significantly altered expression, both 
upregulated and downregulated. Interestingly, no previously identified tRNA 
families possibly regulated by Polr3G were shown to be significantly upregulated 
at NF Stage 9. Most notably, tRNAiMet showed no significant change in expression 
in Xenopus embryos in response to overexpression of Polr3G (Figure 5.7.), whilst 
in cell culture studies is significantly upregulated (Haurie et al., 2010). In cell 
studies, positive regulation of tRNAiMet by Polr3G also fits with the observations 
that both enhanced levels Polr3G expression, and upregulation of tRNAiMet 
expression are associated with increased proliferation and oncogenic 
transformation (Haurie et al., 2010; Pavon-Eternod et al., 2013). Therefore, in 
Xenopus early development, it is possible that Polr3G acts on different tRNA 
target genes to those in ESCs. 
One problem of looking at only nascent transcripts is that the total tRNA pools can 
not be measured and so overall tRNA expression may be quite different to the 
changes measured by microarray and differences in tRNA expression may be 
more significant than detected. One way to measure mature tRNA transcripts is by 
northern blot. The denaturing gel opens the cloverleaf structure of mature tRNAs 
allowing hybridisation. However, this method is not as quantitative as microarray 
analysis. Recently, modifying enzymes have been used to remove methylation 
marks on tRNAs which prevent elongation by reverse transcriptase, allowing total 
tRNA expression to be measured by reverse-transcriptase techniques such as 
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qPCR and high-throughput sequencing (Wilusz, 2015; Zheng et al., 2015). Whilst 
this method proves promising for the study of tRNAs in future, as yet no standard 
protocol has been developed for this treatment and therefore the use of modifying 
enzymes would not have been feasible in the scope of this thesis. 
 
5.3.2. A possible mechanism for the upregulation of RNA Polymerase II 
targets in embryos overexpressing Polr3G. 
It is surprising that overexpression of Polr3G results in the selected upregulation of 
a few RNA Polymerase II regulated genes with roles in early development (Figure 
5.11. B), as Polr3G is involved in the regulation of transcription by RNA 
Polymerase III. Moreover, these identified genes have not been previously 
identified in cell culture studies. Polr3G overexpression has been shown to 
upregulate RNA Polymerase II regulated factors involved in pluripotency, however 
this has only been shown to be indirect effect of Polr3G expression enhancing 
resistance to differentiation programmes in ESCs rather than direct regulation 
(Wong et al., 2011). Therefore, it is possible that Polr3G overexpression results in 
changes to RNA Polymerase II target genes through an indirect mechanism in 
Xenopus. 
One potential mechanism for the upregulation of these early patterning genes is 
the timing of MBT. All of the genes upregulated in embryos overexpressing Polr3G 
are activated rapidly at Stage 9 just after MBT and accumulate to maximum 
expression levels by gastrula stages (Figure 5. 13). In Xenopus, MBT is preceded 
by rapid synchronous cell divisions known as cleavage. During these stages, 
embryos do not increase in size, meaning that cells become smaller throughout 
consecutive divisions (Newport and Kirschner, 1982a). Previous studies in 
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Xenopus have shown that MBT is timed by the titration of four limiting replication 
factors (RecQ4, Treslin, Cut5 and Drf1) through the rapid cell divisions of cleavage 
stages, and the increase in Nuclear:Cytoplasmic (N:C) ratio (Collart et al., 2013; 
Newport and Kirschner, 1982b). Therefore, it may be possible that MBT and 
activation of transcription could be brought forward by more rapid cell division, 
increasing the N:C ratio more rapidly. 
Cell culture studies have indicated that Polr3G increases cell proliferation rates in 
cancer cell lines and increased tumour growth (Khattar et al., 2016). Furthermore, 
overexpression of Polr3G in ESCs results in the upregulation of positive cell cycle 
regulators such as CyclinE and Aurora Kinase A (Haurie et al., 2010). Therefore, it 
is possible that overexpression of Polr3G in Xenopus results in increased rates of 
cell division- this might result in premature activation of transcription of zygotic 
transcripts such as the patterning genes identified by the microarray as timing of 
MBT is brought forward. 
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Figure 5.13. RNA-Seq expression values across Xenopus tropicalis development of early 
patterning genes identified as upregulated in embryos overexpressing Polr3G. Genes 
identified by microarray analysis are included with the exclusion of Id3 due to scaling differences 
(Owens et al., 2016). Transcripts per embryo are displayed as unit of measure. 
 
5.3.3. Upregulation of Polr3G results in upregulation of key early 
developmental regulators 
Overexpression of Polr3G at NF Stage 9 results in the upregulation of a number of 
key early developmental and patterning genes. In cell studies, upregulation of 
Polr3G results in ectopic expression of cell cycle regulators Aurora Kinase A and 
Cyclin E and maintained expression of pluripotency factors in response to 
triggered differentiation (Haurie et al., 2010; Wong et al., 2011). Aurora Kinase A is 
a cell cycle serine threonine kinase with implications in oncogenesis (Fu et al., 
2007; Goldenson and Crispino, 2015), it is maternally expressed in Xenopus and 
is rapidly degraded post-MBT (Bischoff et al., 1998). Interestingly, in NF Stage 9 
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embryos overexpressing Polr3G, no upregulation of either Aurora Kinase A or 
Cyclin E was detected suggesting that Polr3G may have a different role during 
early development to stem cells. 
 
5.3.3.1. Chordin 
Chordin (Chrd) is a known BMP antagonist with roles in dorso-ventral patterning 
and neural induction in the early embryo (François and Bier, 1995). Chrd, in 
collaboration with noggin, act as potent dorsalising factors during early 
embryogenesis (Smith, 1995). Chrd is activated by organiser homeobox genes 
such as goosecoid (Gsc) (Sasai et al., 1994) and its overexpression in ventral cells 
results in induction of a second dorsal axis (Oelgeschläger et al., 2003). During 
neural induction, chordin inhibits the action of a member of the Bone 
Morphogenetic Protein family, BMP4 through direct interaction resulting in 
inhibition of ventral signals and dorsalised mesodermal fate (Piccolo et al., 1996; 
Sasai et al., 1995). Its upregulation in embryos overexpressing Polr3G may 
indicate that Polr3G has an early role in mesoderm induction in the early embryo. 
However, because Polr3G regulates tRNAs rather than mRNAs, this effect is likely 
to be indirect, possibly due to the mechanism described above. 
 
5.3.3.2. Wnt8a 
Wnt8 (wnt8a) is a secreted ligand that acts as a mesoderm patterning factor in 
Xenopus. Wnt8a is expressed ventrally in Xenopus gastrula mesoderm, excluded 
from the organiser region. Wnt8a is able to cooperate with the mesoderm inducing 
factor activin, and with mesodermal genes such as Xbra to promote a dorsal 
mesoderm (notochord and neural) fate (Cunliffe and Smith, 1994; Otte and Moon, 
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1992; Smith and Harland, 1991; Sokol and Melton, 1992). Co-expression of Wnt8a 
with both Xbra and Fgf4 enhances formation of muscle in ectodermal explant 
assays but is not sufficient alone to cause dorsal mesoderm differentiation 
(Christian et al., 1992; Sokol, 1993). There is also evidence that Wnt8a works with 
dorsalising signals from the Spemann Organiser acting on lateral mesoderm, 
resulting in a gradient response in dorso-ventral axis formation (Christian and 
Moon, 1993). Polr3G based upregulation supports the potential that RNA 
Polymerase III based transcription is able to indirectly regulate mesoderm 
induction during early development. Later expression of Polr3G in the somites may 
therefore be a downstream effect of early activity acting as a positive feedback 
loop. 
 
5.3.3.3. Id3 
Id3 acts as a transcriptional repressor of bHLH factor activity. Id proteins regulate 
the activation of networks by both the MRFs and NeuroD2 by prevention of 
dimerization of bHLH factors with their co-factors such as E proteins. Id3 acts 
downstream of Myc to promote cellular proliferation and survival in neural 
precursors (Kee and Bronner-Fraser, 2005; Light et al., 2005). Id proteins are also 
inhibitors of muscle differentiation and have been implicated in cancer (Jen et al., 
1992; Lasorella et al., 2014). This may indicate a conserved role for Polr3G in 
maintaining a proliferative and undifferentiated cell state in Xenopus development 
and in cells. 
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5.3.3.4. Foxd5 
Foxd5a (FoxD5) is a member of the forkhead box family of transcription factors 
and acts as a transcriptional repressor in neural fate specification (Fetka et al., 
2000; Sölter et al., 1999). Foxd5 is expressed maternally and zygotically in the 
neural ectoderm and paraxial mesoderm at gastrula stages and regulates a 
transcriptional network to promote expression of neural Sox and Zic genes (Yan et 
al., 2009a). Foxd5 expression in animal caps results in promotion of both 
mesodermal and neural fate. In whole embryos, dorsal injection of Foxd5 results in 
an expanded neural plate whilst ventral expression of Foxd5 results in a partial 
duplicated axis without secondary neural tissue. Foxd5, via notch signalling, 
maintains an undifferentiated cell fate within the neural plate regions by repression 
of differentiation genes and upregulation of early proneural genes NeuroD2 and 
Xnrgn1 (Sullivan et al., 2001; Yan et al., 2009b). Foxd5 is also thought to regulate 
convergent extension during gastrula stages (Fetka et al., 2000). Upregulation of 
Foxd5 by Polr3G may infer a role for Polr3G in maintaining an undifferentiated cell 
state during early Xenopus development supporting the evidence from cell studies 
(Wong et al. 2011). 
 
5.3.3.6. Eomes 
Eomesodermin (Eomes) is another transcription factor with roles in early 
determination of mesoderm (Russ et al., 2000; Ryan et al., 1996). Part of the T-
box family of transcription factors, Eomes expressed in response to Activin 
signalling (Ryan et al., 1996; Ryan et al., 2000) from MBT and is highest at 
gastrula stages before decreasing during neural stages of development. 
Expression of Eomes is localised to mesoderm at gastrula stages, is present in a 
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concentration gradient from dorsal-ventral regions and overlaps with factors such 
as Gsc but prior to Chrd and Wnt8. Moreover, expression of Eomes in in animal 
caps is sufficient to induce the expression of mesodermal genes Chrd, Xbra, Wnt8 
and Mix1 and in D.rerio has a role in regulating formation of the Spemann 
Organiser (Bruce et al., 2003; Ryan et al., 1996). This supports the evidence from 
Chrd and Wnt8 that Polr3G may have an indirect role in early mesoderm 
determination through upregulation of key mesoderm inducing factors. However, 
interestingly in ESC culture studies Eomes expression was downregulated when 
Polr3G was overexpressed (Wong et al., 2011). This may therefore infer that 
Polr3G has different roles in vivo and in vitro. 
 
5.3.4. Discrepancies between initial tRNA RT-PCR and Microarray analysis. 
One potential problem with the data analysis is that the microarray samples 
appear to show different results to Polr3G overexpression at early stages of 
development compared with initial RT-PCR data carried out for tRNAs iMethionine 
(CAT), eMethionine (CAT), Leucine (CAA) and Tyrosine (GTA) (Figure 5.4.). In 
particular, tRNATyr was downregulated in response to Polr3G overexpression in 
microarray samples whereas in the PCR data it appears to be upregulated and 
promiscuously activated at NF Stage 8.  
One possibility for this difference is that samples collected at NF Stage 9 have just 
undergone MBT and the activation of transcription of many mRNAs (Newport and 
Kirschner, 1982a; Newport and Kirschner, 1982b). Variation analysis revealed that 
samples collected for microarray show high levels of variability in expression such 
that expression values in one sample is less likely to representative of another.  
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Another possible reason for the differences seen is that embryos remain at NF 
Stage 9 for a long period of time. Whilst embryos are collected at roughly the 
same time post fertilisation each day of sample collections, embryos collected that 
look the same morphologically could be much further along in NF Stage 9 
development. Therefore, samples collected for PCR analysis may be collected 
earlier in NF Stage 9 where transcriptional regulation is altered to downregulate an 
initial burst of tRNA transcription than microarray samples, which were all collected 
at the same time post-fertilisation when incubated at the exact same temperature. 
A third possible reason for discrepancies is that there may be DNA contamination 
artefacts in PCR data. PCR methods involve the exponential amplification of DNA 
fragments, usually cDNA collected from RNA samples. mRNA PCR can be 
adapted to amplify RNA only by designing primers that either span exons with 
large introns between and using an extension temperature only suitable for the 
desired small product, or by designing primers across exon junctions again 
ensuring no intron sequence from DNA molecules is amplified. tRNAs are small in 
size ranging from just 70-100 base pairs, and their introns, included in just a small 
number of tRNA families, are very short usually consisting of around 10-15bp. This 
therefore means that PCR primers cannot be designed to exclude DNA. Moreover, 
in Xenopus tropicalis there are predicted to be over 2600 genes encoding tRNAs, 
therefore any DNA contamination is much more of a problem for tRNAs compared 
with mRNAs. Microarray analysis, whilst based on cDNA synthesis too, uses 
hybridisation as opposed to amplification to measure results. Therefore DNA 
contamination is much more likely to alter results of tRNA PCR analysis than 
microarray.  Moreover, whilst initial PCR analyses were crried out after a single 
DNase treatment, microarray samples were treated twice with DNase, meaning 
181 
 
these samples are much less likely to contain significant amounts of DNA. Whilst 
no band is detected in the No-RT sample, this represents only NF Stage 7 RNA 
and does not exclude the possibility of contamination in later stage samples. 
Finally,  microarray analyses were carried out in triplicate with quantitative 
readouts as a measure. Thhis therefore makes the results from the microarray 
analyses more robust than the gel-based RT-PCR analysis as statistical analysis 
could be carried out to ensure significant differences between samples. Therefore, 
the results from the microarray analysis can be considered the more accurate 
readout of Polr3G regulatory activity, though RT-PCR analysis can be improved to 
measure tRNAs more accurately by carrying out qPCR. 
 
5.4. Conclusions 
Overall, this chapter has shown that, whilst mature tRNAs can only be detected 
through Northern Blot analysis, it is possible to detect tRNA expression dynamics 
across development and between control and experimental samples by cDNA 
based RT-PCR and microarray based techniques. This chapter has shown that 
during early stages of development, Polr3G overexpression results in diverse 
changes to tRNA isoacceptor families, and possible activation of tRNA 
transcription prior to MBT. Polr3G overexpression may also resulted in the 
upregulation of crucial early transcriptional pathways involved in embryonic 
patterning. These results therefore suggest that Polr3G may act as an early 
developmental regulator in Xenopus and that dysregulated RNA Polymerase III 
activity has wider transcriptional effect in vivo. 
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6. Characterising a myogenic tRNA profile in 
Xenopus 
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6.1. Introduction 
 
6.1.1. Putative roles of Polr3G and Polr3gL in vivo. 
The incorporation of Polr3G or Polr3gL into the RNA Polymerase III complex forms 
two distinct isoforms of the enzyme. Polr3G and Polr3gL are thought to have 
diverged as the result of a gene duplication event with Polr3gL appearing to be the 
ancestral gene copy (Renaud et al., 2014). As these subunits were revealed by 
ChIP-Seq to have largely overlapping binding patterns in vitro but showed different 
regulation by the transcription factor c-Myc, it was determined that the isoforms 
adopted distinct functions through their interaction with regulators, rather than their 
capacity to activate specific subsets of target genes (Renaud et al., 2014). In cell 
lines, as discussed previously, Polr3G appears to associate more with proliferative 
capacity and stemness, whilst Polr3gL expression is maintained throughout 
induced differentiation leading to the hypothesis that this subunit has roles in later 
developmental commitment (Haurie et al., 2010; Wong et al., 2011). Chapter 4 
indicates that, as in cell studies Polr3G is downregulated during development and 
essentially replaced by Polr3gL expression (Figure 4.5). However transient 
expression of Polr3G is localised to the somites during early myogenesis and 
Polr3G is upregulated by the early MRF, MyoD (Figure 4.11). Therefore, it is 
possible that Polr3G and Polr3gL have different roles during early embryonic 
development through modified interaction with key transcriptional regulators and 
that Polr3G has a cooperative role with MRFs such as MyoD in the specification of 
early muscle lineages. 
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6.1.2. Early muscle lineages in Xenopus. 
In Xenopus, the early myogenic lineages are specified from mesoderm inducing 
signals in the dorsal marginal zone of blastula and gastrula stage embryos and the 
first expression of an MRF is detectable at gastrula stages. MyoD is expressed 
around the blastopore (excluding dorsal-most regions which will form the 
notochord) at gastrula stages and is localised to presomitic mesoderm during 
neurula stage development. Myf5, also induced by FGF signalling, shows more 
limited expression even within gastrula stages where it is expressed in the dorso-
lateral marginal zone of the blastopore (Hopwood et al., 1991; Maguire et al., 
2012). By late neurula and tailbud stages, expression of MyoD and Mrf4 are 
localised to segmenting somites along the dorsal axis of the embryo, (Della 
Gaspera et al., 2012; Hopwood et al., 1989). Somites contain precursor cells for all 
muscle lineages in the trunk and arise as paired epithelial condensations of 
paraxial mesoderm located either side of the neural tube, and arise from anterior 
to posterior positions (Emerson, 1993; Pownall et al., 2002). Proliferative 
myoblasts are localised to the somites, their fate maintained by axial signals and 
the eFGF-mediated community effect, and migrate out to the trunk of tadpoles 
during differentiation (Emerson, 1993; Standley et al., 2001). Therefore, during 
Xenopus development, muscle lineage specification and differentiation is localised 
to the dorsal axis of the embryo, marked by the expression of MRFs. 
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6.1.3. Aims of this chapter: 
1. To determine the effects of Polr3G or Polr3gL overexpression on the 
transcription of tRNAs in dorsal regions of Xenopus embryos. 
2. To identify any unique transcriptional targets of Polr3G and Polr3gL in the 
context of muscle differentiation. 
 
 
6.2 Results 
 
6.2.1. Regulation of expression of tRNAs in the dorsal region by Polr3G. 
To determine the effect of overexpression of Polr3G on the regulation of tRNAs 
within the muscle lineage, embryos were injected at the 1 and 2-cell stage with 
equal amounts of synthetic mRNA coding for either HA-tagged Polr3G or Polr3gL. 
Western blot analysis on Stage 25 embryos was used to measure protein 
expression as a result of injections by HA detection (Figure 6.1. A) and indicated 
that Polr3G and Polr3gL were expressed at equal amounts in all three biological 
replicates for the microarray. To ensure that the dorsal regions collected (Figure 
6.1. B) were correctly enriched for both Polr3G and MyoD as predicted by in situ 
hybridisation analysis, qRT-PCR analysis was carried out for expression of 
Polr3G, Polr3gL and MyoD in collected head, ventral and dorsal sections from 
microarray sibling embryo samples (Figure 6.1. C). Both Polr3G and MyoD show 
significantly upregulated expression in dorsal sections compared with head and 
ventral sections. Polr3gL expression in dorsal regions is significantly higher than 
ventral sections but no significant difference from expression in head sections. 
This high expression in dorsal regions reflects the expression of Polr3gL in the 
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lateral plate mesoderm detected in the in situ hybridisation analysis (Figure 4.7. C-
D). Polr3G expression is low post-MBT but is transiently enriched in the somites at 
tailbud stages, so overexpression analysis is used here to reveal transcript specific 
effects. 
 
Figure 6.1. NF Stage 25 overexpression of Polr3G and Polr3gL in Xenopus tropicalis embryos. (A) 2ng 
of HA-tagged Polr3G and Polr3gL mRNA was injected into Xenopus tropicalis embryos at the 1 to 2-cell stage 
of development and embryos were allowed to develop until NF Stage 25. Western blot analysis of 10 embryos 
alongside 10 control embryos was carried out for detection of HA-tag expression. A GAPDH loading control 
was also used. (B) Collection of dorsal regions was carried out to enrich for myogenic tissue at this stage of 
development. (C) qRT-PCR analysis was carried out for control sections for three biological to determine 
enrichment of MyoD and Polr3G as predicted by in situ hybridisation. Ct values were normalised to Dicer and 
expression values were calculated relative to Polr3G expression levels in ventral sections. One-way ANOVA 
statistical analysis of expression values was carried out for each gene between sections. (*) indicates level of 
significance * p<0.05, ** p<0.01, *** p<0.001. Note that scale on Y axis is logarithmic. 
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The same microarray approach that was used in Chapter 5 was used in this 
chapter to investigate tRNA expression changes in response to overexpression of 
either subunit. Total DNase treated mRNA was extracted from dorsal sections of 
control and experimental sibling embryos at the desired NF stage and labelled 
cRNA was synthesised for microarray hybridisation. Samples were collected such 
that control, Polr3G overexpression and Polr3gL overexpression samples were all 
collected from sibling embryos for 3 biological replicates. Computational analysis 
of the data was carried out as previously, with mean fold change versus control 
samples summarised in Figure 6.2. In comparison with NF Stage 9 data, relatively 
fewer tRNA isoacceptor families show significantly altered expression in response 
to overexpression of Polr3G. Only two isoacceptor families are significantly 
upregulated beyond the threshold of a 1.2 fold change. 6 families show 
significantly decreased expression and there appears to be fewer amino acid 
families showing different isoacceptor expression patterns. This may indicate a 
specific subset of tRNA families regulated within the muscle lineage by Polr3G. 
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Figure 6.2. Overexpression of Polr3G in NF Stage 25 dorsal regions results in limited changes to tRNA 
gene expression.  Expression fold change summary of tRNA isoacceptor families in X.tropicalis NF Stage 25 
dorsal sections injected with 2ng Polr3G mRNA versus control uninjected across 3 biological replicates. 
Isoacceptor families with raw signals of >10 were included in the analysis. Orange indicates up-regulated 
transcription, blue indicates down-regulated transcription, and pink indicates no change in expression. SEM is 
presented as error bars and * indicates the level of statistical significance between control and injected 
samples after Bonferroni Correction. 
 
Some amino acids do show differential regulation of their isoacceptor families in 
dorsal regions as summarised in Figure 6.2. tRNAAla isoacceptor families are all 
downregulated in response to overexpression of Polr3G in dorsal regions (Figure 
6.3. A, right-hand panel), contrasting with upregulation observed in NF Stage 9 
embryos overexpressing the subunit (Figure 6.3. A, left-hand panel). Similarly, 
tRNAArg and tRNALeu isoacceptors show altered expression changes in response 
to Polr3G overexpression at the two different stages. ArgCCG and ArgCCT 
expression does not change in response to overexpression of Polr3G at tailbud 
stages (Figure 6.3. C, right-hand panel), but ArgCCT is significantly upregulated in 
Stage 9 samples (Figure 6.3. B, left-hand panel). Interestingly, ArgTCG detected 
and upregulated at Stage 9 in Polr3G overexpression samples, is not detected at 
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stage 25. Instead ArgTCG is detectable and shows downregulated expression in 
Polr3G samples. LeuCAA is also shown to be upregulated in Polr3G overexpression 
samples at NF Stage 9 but downregulated in NF Stage 25 samples (Figure 6.3. 
C). These results indicate that Polr3G may have different roles in regulating tRNA 
expression throughout development. 
Contrastingly, tRNAVal isoacceptors appear to show very similar response to 
Polr3G overexpression at both stages analysed (Figure 6.3. D). Therefore, Polr3G 
may have a maintained role in the modulation of some tRNA isoacceptor families 
throughout embryonic development and tissue differentiation. 
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Figure 6.3. Highlighting tRNA isoacceptor family expression changes between NF Stage 9 embryos 
overexpressing Polr3G and NF Stage 25 dorsal sections overexpressing Polr3G. Relative fold change of 
amino acids by isoacceptor family in Polr3G injected samples versus controls. Left-hand panels show fold 
changes in NF Stage 9 samples, right-hand panels show fold changes in NF Stage 25 samples.  (A-D) 
Expressed isoacceptors encoding (A) tRNAAla (B) tRNAArg (C) tRNALeu and (D) tRNAVal. Orange indicates 
expression is significantly up-regulated. Blue indicates expression is significantly down-regulated. SEM is 
represented as error bars on the graphs and (*) indicates the level of statistical significance after Bonferroni 
Correction. 
 
 
6.2.2. Regulation of expression of tRNAs in the dorsal region by Polr3gL. 
To determine whether Polr3G and Polr3gL show different transcriptional activities 
within the early myogenic lineages, sibling samples from embryos overexpressing 
Polr3gL were also collected and analysed by microarray. Figure 6.4.A shows a 
summary for all isoacceptor families with expression values of above 10. Polr3gL 
overexpression, like Polr3G also results transcriptional changes to limited 
isoacceptor families in NF Stage 25 dorsal regions. However, Polr3gL appears to 
regulate similar families to Polr3G. All tRNAAla families, ArgTCG and LeuCAA all show 
significant downregulation in both microarrays (Figure 6.3, Figure 6.4. A). 
However, Pol3gL appears to downregulate a number of other families not 
significantly decreased in Polr3G samples for example IleAAT, LeuAAG and SerGCT. 
Moreover, whilst overexpression of Polr3gL results in significant upregulation of 
TyrGTA, and no significant changes to tRNAVal families, Polr3G overexpression 
results in no change in TyrGTA expression but significant upregulation of ValAAC and 
ValCAC at this stage. This indicates that Polr3G and Polr3gL may have distinct 
transcriptional activities within dorsal lineages. 
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To determine if Polr3G and Polr3gL differentially regulate tRNAs in dorsal 
sections, a comparison of normalised expression of tRNA isoacceptors in samples 
expressing each factor was carried out. Figure 6.4.B shows a scatterplot of 
expression data for each tRNA isoacceptor with detectable expression in both 
samples. The X-axis shows normalised expression in Polr3G samples and the Y-
axis shows normalised expression in Polr3gL samples. Points that fall outside of 
the dashed lines indicate that a tRNA is expressed by less than half in Polr3G or 
Polr3gL samples. In comparison to the expression levels in sibling embryos 
overexpressing Polr3G, tRNA gene expression is largely reduced in Polr3gL 
samples (Figure 6.4. B). The isoacceptors showing higher expression in embryos 
overexpressing Polr3gL (Figure 6.4. B, red circle) are AspGTC, TyrGTA and SerCGA, 
however, most data points show greater expression in Polr3G expressing 
samples. This indicates that at NF Stage 25, in dorsal regions, Polr3G expression 
activates or maintains higher levels of tRNA expression moreso than Polr3gL, but 
the two subunits may have different target genes. 
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Figure 6.4. Overexpression of Polr3gL in NF Stage 25 dorsal regions results in greater changes to 
tRNA gene expression than Polr3G.  Expression fold change summary of tRNA isoacceptor families in 
X.tropicalis NF Stage 25 dorsal sections injected with 2ng Polr3gL mRNA versus control uninjected across 3 
biological replicates. Isoacceptor families with raw signals of >10 were included in the analysis. Orange 
indicates up-regulated transcription, blue indicates down-regulated transcription, and pink indicates no change 
in expression. SEM is presented as error bars and * indicates the level of statistical significance between 
control and injected samples after Bonferroni Correction. (B) Scatterplot comparing normalised expression of 
tRNA isoacceptor families in embryos overexpressing Polr3G with Polr3gL. Solid line indicates no expression 
difference. Dashed lines indicate expression fold change of 2. Polr3G values are on the X-axis and Polr3gL 
values are on the Y-axis. 
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6.2.3. Validation of microarray results by qRT-PCR analysis. 
To confirm the results from the microarray, selected tRNA isoacceptor families 
were analysed by qRT-PCR in control and sibling matched embryos 
overexpressing either Polr3G or Polr3gL. All tRNAAla families were selected due to 
their conserved downregulation in both Polr3G and Polr3gL overexpression 
samples. In contrast, SerGCT was selected as it showed greater downregulation in 
samples overexpressing Polr3gL than Polr3G in the microarray analysis. All 
tRNAAla families show downregulated expression in Polr3gL samples (Figure 6.5.) 
In contrast to the microarray data, AlaAGC shows no downregulation in response to 
Polr3G overexpression but is significantly downregulated in Polr3gL. SerGCT is 
moderately downregulated in Polr3G samples, but is downregulated to a higher 
extent in response to Polr3gL overexpression. This data supports the findings from 
the microarray that overexpression of Polr3gL has a stronger downregulating 
effect on similar transcriptional targets as Polr3G. 
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Figure 6.5. Validation of microarray data by qRT-PCR analysis of selected tRNA isoacceptor families. 
Total RNA was extracted from control dorsal sections and sections overexpressing Polr3G or Polr3gL protein 
at NF Stage 25 and was rigorously DNase I treated using Zymo Clean and Concentrator-5 columns. qRT-PCR 
was carried out for tRNAs Ala and Ser, AlaAGC, AlaCGC and AlaTGC and SerGCT using primers designed to 
amplify the full tRNA sequence (between 70 and 100bp). Relative expression values were calculated using the 
ΔΔCt method with Dicer used as an endogenous control. 
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6.2.4. Correlation of tRNA abundance with mRNA codon usage during 
muscle differentiation (in collaboration with the Technology Facility at the 
University of York). 
Previous studies in humans have suggested that tRNA expression may be 
correlated with mRNA codon usage for specific tissues (Dittmar et al., 2006; 
Gingold et al., 2014). In order to assess this relationship in Xenopus, Codon 
Usage Estimate values were calculated by multiplying usage numbers for 
particular codons included in coding sequences of all mRNAs included on the 
arrays by the gene expression value of each mRNA (all three biological replicates 
included so replicate data points were expected to be located in close proximity to 
one-another). tRNA anticodon isoacceptor intensity values from the array were 
used as a measure of expression. Spearman’s correlation analysis was carried out 
on control samples used in the Stage 9 and Stage 25 microarrays for all mRNAs 
included on the array and then for a subset of mRNAs involved in muscle 
differentiation, not assuming a linear relationship. 
The scatterplots produced are shown in Figure 6.6 and indicate a weak correlation 
between tRNA expression and predicted codon usage at both stages , the 
correlation in NF Stage 25 dorsal samples is increased to 0.349 (Figure 6.6. B) 
from 0.175 at NF Stage 9 (Figure 6.6. A). This may indicate that throughout 
development, tRNA transcription is regulated increasingly to match mRNA codon 
usage. Very similar correlations are observed even if mRNA codon usage is 
calculated only for mRNAs encoding muscle specific (contractile protein) genes 
(Figure 6.6. C and D). Green data points to the far right of plots B and D, 
representing high tRNA expression values and high mRNA codon usage. This 
points were identified as tRNAs GluCTC and GluTTC (Note that these points also fall 
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to the right hand side of plots A and C alongside other isoacceptors) and red data 
points represent LeuCAG. A single data point is also located at the top left of plots B 
and D, representing high tRNA expression for low mRNA codon usage. This plot 
was identified as ThrCGT, however, only one biological replicate of the three 
included in the analysis was represented, therefore this is likely to be an 
anomalous result. 
In NF Stage 9 plots (Figure 6.6. A and C), grey data points representing low tRNA 
expression values but high mRNA codon counts were identified as LysCTT. LysTTT 
data points are located at similar mRNA codon counts, but higher tRNA 
expression (Figure 6.6. C, red circle). This result may indicate that LysTTT 
expression is favoured over LysCTT at these stages as it enables more efficient 
translation. 
 
198 
 
 
Figure 6.6. Correlation between mRNA codon usage and tRNA expression.  (A-B) correlation plots for 
tRNA expression versus codon usage using Spearman correlation coefficient for control embryos at NF Stage 
9 (A) and dorsal sections at Stage 25 (B) including all mRNAs on the microarray design. Each data point 
indicates a tRNA isoacceptor family expressed above threshold levels in the microarray. Isoacceptor families 
encoding the same amino acid are coloured the same. Data points were included for all three biological 
replicates rather than an average of the three in order to identify outliers in one of the sets. (C-D) correlation 
plots for samples included in charts A and B but including only mRNAs for contractile protein genes. 
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6.2.5. Targeting Polr3G expression in Xenopus tropicalis by Antisense 
Morpholino Oligo (AMO) knock-down. 
Gene targeting or knock-downs are a crucial method to determine a gene’s in vivo 
function. There is a high level of maternally stored Polr3G transcript, therefore in 
order to determine the function of Polr3G during development and myogenesis in 
more detail, post-transcriptional targeting by antisense morpholino knockdown 
appeared the most direct way-forward. CRISPR/Cas9 methods would not deplete 
the maternal store of Polr3G mRNAs. Antisense morpholinos can be effective to 
inhibit translation of mRNAs or to block correct splicing of a newly transcribed 
mRNA. Antisense Morpholinos (AMOs) targeting translation initiation through 
binding and blocking of the ATG start site were designed using the coding 
sequence and upstream sequences collected from EST data (Figure 6.7 A). 10ng 
of each AMO were injected alongside 10ng of a 5 base-pair mismatch control 
morpholino to ensure that any effects observed were not artefacts of AMO 
injection alone. Embryos were left to develop until NF Stage 25, the stage at which 
Polr3G mRNA expression is localised to the somites, and the efficiency of the 
translation blocking AMOs was assessed by western blot (Figure 6.7. B). Western 
blot analysis showed no decrease in protein levels of Polr3G at Stage 25 
compared with control embryos. 
 
An alternative AMO disrupting correct mRNA splicing of Polr3G was also designed 
to affect splicing of exons 2 and 3 within the coding sequence (Figure 6.7. C). The 
morpholino target site included the 3’ end of exon 2 and the intron 3’ to it. The 
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alternative splicing product would include an additional 748bp intron sequence 
between exons 2 and 3 and a premature stop codon 293bp downstream of exon 2 
(*) resulting in a truncated protein missing exons 3-7 of coding sequence. To 
determine whether mRNA splicing can be targeted by this morpholino, primers for 
RT-PCR were designed to amplify a control region within exon 2 and the 
alternatively spliced region using primers spanning exon 2 and exon 3. RT-PCR 
analysis was carried out on embryos injected with either control morpholino, or 
with increasing concentrations of splice-blocking morpholino (Figure 6.7. D). If 
splice-blocking had occurred, an additional PCR product of 847bp would be 
present in reactions using exon 2:3 spanning primers (Figure 6.7. D bottom panel, 
top arrow). No additional product was observed in any of the morpholino targeted 
embryo samples, therefore indicating that the splice-blocking morpholino is unable 
to target Polr3G mRNA in Xenopus tropicalis embryos. 
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Figure 6.7. Antisense Morpholino (AMO) targeting of Polr3G in Xenopus tropicalis. (A) Schematic 
diagram of Polr3G genomic sequence and coding exons. Green marks 5’ untranslated exon identified through 
EST analysis, Antisense Morpholino Oligo (AMO) target sequences are also identified in red. (B) Western blot 
for NF St25 embryos injected with 10ng Control Morpholino (CMO) or 10ng of translation blocking 
morpholinos. (C) Schematic diagram showing splice blocking morpholino targeting and primers designed for 
validation PCR. (D) RT-PCR analysis of Stage 25 embryos injected with CMO of a series of concentrations 
(20ng, 40ng, 60ng, 80ng) of splice-blocking MO. arrows mark the predicted control products. Lower panel 
upper arrow indicated predicted alternative splice product arrow. 
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6.3. Discussion 
 
6.3.1. Known roles of Polr3G and Polr3gL 
Polr3G overexpression has different results on tRNA expression at NF Stage 9 
and NF Stage 25. Targets such as tRNAAla and tRNAArg families upregulated at NF 
Stage 9 were shown to have reduced expression in response to Polr3G 
overexpression at NF Stage 25 (Figure 6.3. A and B). Moreover, targets with no 
change in expression at NF Stage 9 also had downregulated expression in NF 
Stage 25 samples. These results indicate the potential that Polr3G has different 
transcriptional activity throughout development and regulates different target 
genes at different stages and in different embryonic regions. tRNA expression in 
embryos overexpressing Polr3G are higher than embryos overexpressing Polr3gL. 
This may be due to the association of Polr3G expression with pluripotency and cell 
proliferation (Haurie et al., 2010). RNA Polymerase III targets are downregulated 
during differentiation programmes (White et al., 1989), and the downregulated 
expression of tRNAs in embryos overexpressing Polr3gL may be a result of 
increased RNA Polymerase III complexes incorporating Polr3gL to regulate 
transcription in a differentiated manner, whilst Polr3G maintains a more 
proliferative and pluripotent cell state with higher levels of RNA Polymerase III 
transcription. 
Changes in transcriptional activity can be a result of altered interactions with 
binding partners or co-factors or by different signalling environments. Polr3G is 
known to interact with another subunit of RNA Polymerase III, RPC62, which is 
involved in activation of transcription of target genes (Boissier et al., 2015; Wang 
and Roeder, 1997). It has not been established whether Polr3gL also interacts 
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with this subunit and therefore it is possible, due to low sequence identity with 
Polr3G, that Polr3gL interacts with other subunits of RNA Polymerase III to change 
overall binding activity. Moreover, as the negative regulator Maf1 binds to this sub-
complex in order to repress transcription by RNA Polymerase III (Vannini et al., 
2010), the differences in sequence may be sufficient to alter its regulation by Maf1 
in vivo.  
RNA Polymerase III is also regulated by a number of developmental signalling 
pathways (Erk, TOR) and cellular regulators (p53, Rb, Myc, Maf1) which alters its 
activity in vitro (Felton-Edkins et al., 2003a; Felton-Edkins et al., 2003b; Marshall 
et al., 2012). As signalling environments change during development with the 
activation of Fgf, Wnt, Bmp pathways as specification of germ layers and tissue 
differentiation occurs, it is likely that RNA Polymerase III activity will also change. 
This may therefore explain the change in transcriptional regulation observed 
between NF Stage 9 and NF Stage 25 samples across the microarrays. It does 
however, appear that changes in expression of particular tRNA families results in a 
weak correlative relationship with mRNA codon usage predicted at NF Stage 25 
(Figure 6.6. produced by Katherine Newling). The correlation between mRNA 
codon usage and tRNA expression has been previously described in human tissue 
and cell culture studies and is suggested to be due to altered translational 
pressure set between different cell types. Therefore RNA Polymerase III activity 
may be correlated with a drive fromtranslational pressure set by RNA Polymerase 
II as shown in previous studies (Dittmar et al., 2006; Gingold et al., 2014; Hentzen 
et al., 1981).  
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6.3.2. Gene-targeting of Polr3G 
Strategies to knockdown Polr3G using morpholinos were unsuccessful. A large 
maternal store of both mRNA and protein has prevented this important functional 
analysis of Polr3G in vivo. The only way to deplete maternal stores would be by 
CRISPR/Cas9 targeting of Polr3G and outcrossing of mosaic F0 individuals to 
produce populations of mutant individuals. However, this also has limitations which 
made the method unavailable within the scope of this thesis- the first being that 
Xenopus tropicalis require 6 months to reach sexual maturity and would require 
multiple rounds of offspring generation in order to produce heterozygous and 
homozygous mutant populations. The second limitation to the genetic targeting of 
Polr3G is that previous study has shown that depletion of Polr3gL in cell lines by 
siRNA targeting results in loss of cell survival and viability (Haurie et al., 2010). As, 
unlike in cell studies, Polr3G is the only paralogue expressed during early stages 
of Xenopus development until the activation of embryonic transcription at NF 
Stage 8, it is therefore possible that Polr3G would be essential for embryo survival 
before the expression of Polr3gL.  
As Polr3gL is only expressed after the activation of embryonic transcription, it 
would be possible to target its expression in Xenopus using morpholinos. This 
could also indicate whether Polr3G would be able to act to replace the loss of 
Polr3gL due to a level of redundancy between the two subunits which was not 
observed in cell studies (Haurie et al., 2010). However, as the focus of this thesis 
is to characterise the regulation of RNA Polymerase III transcription during 
myogenesis, and Polr3gL is not expressed in the somites at early stages of this 
differentiation programme, this analysis was beyond the scope of this thesis. 
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6.4. Conclusions 
 
Overall, the data in this chapter has revealed that overexpression of either Polr3G 
or Polr3gL in dorsal regions of tailbud Xenopus embryos results in similar changes 
to tRNA expression levels, but overexpression of Polr3gL appears to have a 
greater effect in downregulating expression. Data comparison for control 
embryos/sections of the two stages analysed by microarray revealed that a 
stronger correlation between tRNA expression and predicted mRNA codon usage 
is present in NF Stage 25 dorsal sections than NF Stage 9 embryos, possibly due 
to coordination of mRNA ‘demand’ and tRNA ‘supply’. However, as knockdown by 
morpholinos was unsuccessful, in order to fully characterise the role of Polr3G 
during myogenesis, disruption of protein function by gene targeting 
(CRISPR/Cas9) is required in future study. 
 
 
 
 
 
 
206 
 
 
 
 
 
 
 7. Determining the regulation of RNA 
Polymerase III activity during myogenic 
differentiation 
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7.1. Introduction 
 
7.1.1. MyoD is regulated by Wnt and FGF signalling pathways 
7.1.1.1. Wnt signalling 
Wnt ligands are a family of secreted glycoproteins that bind to Frizzled receptors 
on the surfaces of cell membranes to induce a downstream signal cascade. Wnt 
ligands have roles in regulating a multitude of cellular processes including cell 
polarity, cell fate specification, proliferation and the maintenance of stem cell 
populations. Wnts signal by distinct types of signalling, the canonical Wnt/β-
catenin pathway (Figure 7.1. A) and by non-canonical Planar Cell polarity (PCP) 
and Calcium dependent (PKC) pathways (Figure 7.1  B). 
In amniotes, Wnts are known as lateral signals that activate the myogenic genes 
MyoD and Myf5. Early experiments in chick identified that signals from the 
floorplate and neural tube were essential in establishing early myogenic lineages 
in unspecified somites (Münsterberg and Lassar, 1995). These signals were 
identified as a combination of Sonic Hedgehog (Shh) and Wnt ligands 1 and 3. 
The combination of Shh with one of these ligands was sufficient to induce 
expression of MyoD in dissected paraxial mesoderm in vitro (Münsterberg et al., 
1995). In mouse, Wnt signals from the neural tube and dorsal ectoderm activate 
both MyoD and Myf5, however with differential preference dependent on particular 
Wnt ligands. It was found that cultures of medial paraxial mesoderm, which in vivo 
gives rise to the epaxial somite,  expressed Myf5 initially in response to Shh and 
Wnt signals from the neural tube acting via Wnt1 (Borycki et al., 1999; Cossu et 
al., 1996; Tajbakhsh et al., 1998). Cells cultured from lateral paraxial mesoderm 
however were shown to express MyoD prior to Myf5 via Wnt7 signalling 
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(Tajbakhsh et al., 1998). This indicates that multiple Wnt ligands have a role in 
early specification of myogenic lineages in amniote development. 
In Xenopus, Wnt signalling also regulates MyoD expression. The inhibition of Wnt8 
through introduction of a dominant negative Wnt8 ligand inhibits expression of 
MyoD, whilst overexpression of Wnt8 results in ectopic MyoD expression (Hoppler 
et al., 1996). This regulation is via the β-catenin pathway as inhibition of GSK3β by 
introduction of LiCl resulted in expanded expression of MyoD around the 
blastopore at gastrula stages, whilst  inhibition through introduction of a truncated 
TCF3 protein (N-XTcf-3) results in reduction of MyoD expression at gastrula 
stages (Hamilton et al., 2001). Moreover, evidence exists to suggest that Wnt8 
enhances induction of dorsal mesoderm by FGF signalling resulting in increased 
MyoD expression in animal caps and greater muscle formation compared with 
similar overexpression levels of FGF4 alone (Burks et al., 2009; Slack et al., 
1988). 
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Figure 7.1. The Canonical and Non-Canonical Wnt signalling pathways. (A) The canonical Wnt/β-catenin 
pathway. Wnt ligands bind to either LRP5/6 and signal via the 7 transmembrane domain Frizzled which 
phosphorylates dishevelled (DVL). DVL disrupts the function of the GSK3β/PC/Axin complex which targets β-
catenin in the absence of Wnt signalling to the proteasome for degradation. β-catenin translocates to the 
nucleus and activates gene expression. (B) The non-canonical PCP and Ca2+ pathways. Wnt ligands again 
bind to Frz receptors on the cell surface to activate dishevelled, however in the PCP pathway, DVL activates a 
Rho GTPase based signalling cascade and in Ca2+ dependent signalling, DVL signals via CamKII and PKC to 
activate gene expression. 
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7.1.1.2. FGF signalling 
FGF is another known regulator of MyoD expression. There are 22 members of 
the Fgf family of secreted ligands, which all contain a 140 amino acid conserved 
“core” (Dorey et al., 2010; Pownall and Isaacs, 2010). Most members of the Fgf 
family, with the exception of intracellular ligands, signal through surface bound 
tyrosine kinase receptors (FGFRs 1-4) (Figure 7.2). Fgf ligands bind to FGFRs 
together with heparan sulfate (HS) in a 2:2:2 ratio. The dimerisation of FGFRs 
results in cross-phosphorylation of intracellular tyrosine residues and activates 
multiple signal transduction pathways including the PLCγ pathway which regulates 
cellular morphology and migration, the PI3K/PKB pathway regulating cell survival 
and the MAPK/Erk signalling pathway which has roles in proliferation and cell fate 
determination, including induction of mesoderm in the early embryo. 
Unlike amniotes, in Xenopus, both MyoD and Myf5, are activated prior to somite 
formation (Hopwood et al., 1989). MyoD protein is detectable by 
immunohistochemistry at Stage 11 (Hopwood et al., 1992), and lineage tracing of 
gastrula stage Xenopus embryos revealed that expression of MyoD was 
exclusively localised to mesodermal progenitor cells fated to the myotomal lineage 
and would give rise to skeletal muscle. Therefore, MyoD has been identified as a 
marker of muscle lineages in Xenopus development (Pownall et al., 2002). FGF4 
is expressed in the marginal zone as a response to mesoderm inducing signals, 
including Xnr1 and Xnr2 (Jones et al., 1995). Once expressed, FGF4 activates a 
wide variety of mesodermal genes including MyoD (Branney et al., 2009; Fisher et 
al., 2002; Isaacs et al., 1994). The ability of FGF4 to activate MyoD in the 
presence of the translation inhibitor cycloheximide shows that MyoD is in fact a 
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direct target of FGF4, rather than an indirect downstream target (Fisher et al., 
2002). 
During gastrula stages of Xenopus development, FGF4 mediates a phenomenon 
known as ‘the community effect’, whereby groups of muscle precursor cells in 
close proximity to one another are able to maintain myogenic specific gene 
expression (MyoD and Myf5), and are able to coordinate their differentiation 
(Standley et al., 2001). Therefore FGF4 is an important early mediator of 
myogenic specification, regulating the activity of MyoD and Myf5.  
As in tissue culture models, MyoD coordinates the activation of a wide network of 
target genes to direct full myogenic differentiation. In vivo studies have revealed a 
number of novel early target genes with roles in both myogenesis and 
somitogenesis that were significantly downregulated in Xenopus laevis gastrulae 
after Morpholino knockdown of MyoD. These targets had not been previously 
identified through studies in cell cultures and therefore, the network of direct MyoD 
target genes required for full myogenic differentiation may be far wider than 
previously thought (Maguire et al., 2012). However, MyoD alone is not always 
sufficient to drive full myogenic differentiation. Expression of MyoD mRNA in 
ectodermal explants (animal caps) results in expression of a-actin representing a 
change in fate to myogenic lineages, but no expression of Myogenin or contractile 
protein genes indicating full myogenic differentiation (Hopwood and Gurdon, 
1990). This was also shown in cell culture whereby ectopic expression of MyoD in 
hESCs alone was not sufficient to activate skeletal muscle differentiation and 
additionally required the chromatin remodelling factor BAF60C (Albini et al., 2013). 
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Figure 7.2. FGF signalling has diverse roles in regulating development. Binding of FGF ligands to surface 
FGFRs leads to dimerisation and autophosphorylation of the intracellular receptor domains. The 
phosphorylated domains are bound by signal transduction proteins and the activation of intracellular PLCγ, 
PI3K/PKB and Erk signalling cascades. 
 
 
7.1.2. The animal cap assay- a way to make muscle 
The Xenopus animal cap is a powerful tool for generating mesoderm from a naïve 
ectodermal tissue. As described above, Fgf and Wnt treated animal caps, make 
muscle. The technique makes use of pluripotent cells of the blastula stage embryo 
(NF Stage 8-9) and their competence to respond to factors both injected into the 
embryo, or diffusible factors in external culture media in order to change cell fate. 
Caps are grown to a desired stage and can then be used in morphological, RNA 
expression and protein expression analyses (Figure 7.3). 
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Figure 7.3. Schematic diagram of the animal cap explant assay. Control or injected embryos are left to 
develop until blastula Stages 8-9. They are removed of their membranes and the animal hemisphere cells 
dissected. Animal caps are grown in isolation in high salt media until the desired stage for collection. After 
which, caps are collected for RNA extraction or western blot analysis. 
 
The animal cap is so named due to the region of the embryo from which the 
explant is collected, the pigmented animal hemisphere. The term cap is used 
because these animal cells cover the blastocoel, a cavity formed during blastula 
stages of cell division. The cells of the Xenopus embryo contain sufficient yolk for 
survival so the caps are cultured in simple isotonic saline solution and no tissue 
culture type media supplement or growth factor serum is required as is the case in 
tissue culture studies. Isolated caps will differentiate into ectodermal tissue (skin 
and nervous system), forming atypical epidermis. However, animal caps are 
competent to form derivatives from all three germ layers in response to injected 
mRNAs, culture in soluble protein or grafting to other tissues, can be diverted to a 
new fate. 
Many cell fate changes also result in morphological changes such as cap 
elongation and many characterised growth factors in Xenopus development give 
recognisable phenotypic changes in the assay. It was found that overexpression of 
Fgf4 resulted in the formation of vesicles with differentiated mesodermal tissues 
muscle, blood and mesothelium (Slack et al., 1987). Fgf4 and activated Wnt 
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signalling (culture in LiCl or injection of Wnt8) in combination drives a more dorsal 
fate, muscle induction is increased compared with caps overexpressing equivalent 
levels of Fgf4 only and caps also show some induction of neural tissue, consistent 
with the role of the dorsal mesoderm as a neural inducer (Slack et al., 1988). 
To further investigate the expression of Polr3G in the myogenic lineage, an animal 
cap based protocol was used to generate skeletal muscle using Wnt8a (Wnt8) and 
Fgf4. This myogenic tissue could be directly compared to the untreated ectoderm 
from which it was derived. 
 
 
7.1.3. Aims of this chapter 
1. To determine whether combined FGF + Wnt signalling regulates Polr3G 
and Polr3gL expression. 
2. To determine whether induction of muscle differentiation by Fgf4 + Wnt8 in 
animal cap explants results in transcriptional changes to RNA Polymerase 
III targets. 
3. To determine whether Fgf4/Wnt8 are regulators of RNA Polymerase III 
transcription. 
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7.2. Results 
 
7.2.1. Characterising an induced myogenic tRNA profile 
7.2.1.1. Modelling myogenesis in vivo through the animal cap assay. 
To test the possibility that there is a muscle specific tRNA profile in Xenopus, the 
animal cap assay was used as a model of myogenic differentiation. 
Overexpression of Fgf4 alone in animal caps is sufficient to induce a change in 
fate to form primarily ventral mesoderm (Slack et al., 1987), and the induction of 
dorsal mesoderm (and muscle in particular) can be enhanced through the co-
injection of Fgf4 with Wnt8 as previously shown by enhanced expression of MyoD 
(Burks et al., 2009). In order to determine whether a myogenic-specific tRNA 
profile exists, and implicate any role for somitic Polr3G in this process, a model of 
myogenic differentiation in animal caps was analysed by microarray.  
 
Xenopus tropicalis animal cap explants were dissected at blastula stages (NF 
Stage 8/9) and cultured until tailbud stages (NF Stage 25) for analysis by custom 
microarray. To confirm the induction of muscle by the injection of Fgf4 and Wnt8, a 
set of animal caps were allowed to develop until NF Stage 40 and were processed 
for histological sectioning and staining with Borax-Carmine and Picro-
Blue/Naphthalene-Black. Figure 7.4. shows a fully differentiated control animal cap 
(Figure 7.4. A), while Figure 7.4. B and C are two examples of Fgf4/Wnt8 caps at 
Stage 40. A comparison of control and Fgf4/Wnt8 induced caps at NF Stage 40 
indicated that whilst control caps formed ciliated (Figure 7.4. A, arrow) atypical 
epidermis as predicted, caps overexpressing Fgf4 and Wnt8 were induced to form 
differentiated muscle (Figure 7.4. B) surrounded by a layer of mesothelium (mt). In 
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addition to muscle, some Fgf4/Wnt8 induced caps showed evidence of the 
differentiation of neural tissue (n) (Figure 7.4. C) and the organisation of tissue into 
neural tube-like structures (Figure 7.4. C, arrow). This is a result of the induction of 
dorsal mesoderm by Fgf4 and Wnt8 and its subsequent interaction with ectoderm 
also present in the caps mimicking the neural inductive signalling events that occur 
in whole embryos. Therefore, caps are sufficiently induced by Fgf/Wnt signalling to 
form differentiated muscle and can be used as a tool in microarray experiments to 
model myogenesis. 
 
Figure 7.4. Induction of myogenic differentiation in Xenopus tropicalis animal caps by co-injection of 
Fgf4 and Wnt8. Animal caps of control uninjected embryos and embryos overexpressing both fgf4 wnt8 were 
collected at NF Stage 8-9 and left to develop until the desired stage (NF Stage 40) after which they were fixed 
overnight in paraformaldehyde and processed for histological sectioning with borax carmine and picro-blue. (A) 
Control animal caps NF Stage 40 form ciliated outer layers with inner layers of atypical epithelium. (B) Animal 
caps overexpressing both Fgf4 and Wnt8 at NF Stage 40. Arrow marks formation of differentiated muscle, 
surrounded by (mt) mesothelium. C) Animal cap overexpressing both Fgf4 and Wnt8 at NF Stage 40. (mt) 
mesothelium, (m) differentiated muscle, (n) neural tissue, arrow marks formation of neural tube-like structures. 
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Whilst observation at NF Stage 40 indicates that differentiated muscle is formed as 
a result of co-injection of Fgf4 and Wnt8, the transcriptional changes driving this 
change in fate and morphology are initiated earlier in development. Therefore, 
animal caps collected at NF Stage 25 were also collected for imaging and 
processed for histology (Figure 7.5). Whilst differentiation of muscle is not yet 
obvious at this stage, movements of the dorsal mesodermal cells induced through 
injection of these factors is clear from the elongated morphology of caps in 
comparison with control caps (Figure 7.5. B). Sections also highlight this change in 
morphology with control cap sections being more uniformed and round (Figure 7.5. 
C) whilst caps induced by Fgf4/Wnt8 show elongation and empty spaces within 
the sections as a result of cell movements (Figure 7.5.D, arrow). Moreover, 
expression of MyoD and Actc1 as measure of myogenic induction at this stage 
were shown significantly increased in caps induced with both Fgf4 only and with 
both Fgf4 and Wnt8 (Figure 7.5. E) Therefore, the downstream transcriptional 
effects of mesoderm induction are likely to already be significant at NF Stage 25 
and therefore observing changes using microarray analysis should identify tRNAs 
and mRNAs transcribed during myogenesis. 
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Figure 7.5. Fgf4 + Wnt8 induces mesoderm formation in Xenopus tropicalis animal caps with 
morphological effects observable by NF Stage 25. (A) Xenopus tropicalis control animal caps collected at 
NF Stage 8-9 and allowed to develop until NF Stage 25. (B) Caps injected with 2pg Fgf4 and 20pg Wnt8 at the 
1- 2 cell stage. (C-D) Histological sections of control and Fgf4+Wnt8 injected animal caps at NF Stage 25 
stained with Borax Carmine and Picro-Blue. (C) Representative control cap (D) Fgf4 + Wnt8 injected cap. (E) 
RT-PCR of Actc1 and MyoD1 in control animal caps and caps induced with Fgf4 only or both Fgf4 and Wnt8. 
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 7.2.2. Microarray analysis of NF Stage 25 Fgf4 + Wnt8 induced animal caps 
 7.2.2.1. tRNA expression in control animal caps and animal caps induced by Fgf4 
+ Wnt8. 
To determine the regulation of tRNAs by FGF/Wnt signals, a custom Agilent 
microarray described in previous chapters (p80, p160) was used to analyse 
transcription in NF Stage 25 animal caps. Strikingly, when Fgf4/Wnt8 caps were 
analysed for expression in comparison to control caps, all tRNA isoacceptor 
families detected on the microarray showed significantly reduced expression in 
response to injection of Fgf4 + Wnt8 (Appendix. Table 3, Figure. 7.6. A). When 
other RNA Polymerase III targets were analysed, it was clear that they too were 
significantly downregulated in Fgf4 + Wnt8 samples, suggesting an overall 
repression of RNA Polymerase III transcription in response to these inductive 
signals. 
 
In contrast, and as expected, a number of contractile protein genes and the 
myogenic regulatory factor (MRF) genes were significantly upregulated in 
Fgf4/Wnt8 caps (Figure 7.6. B and C). Notably, the early myogenic marker gene 
Actc1 was highly upregulated, indicating that the muscle lineages induced were in 
the early stages of differentiation rather than terminally differentiated as expected 
at this stage. Of the myogenic factors, Myf5 was the most highly upregulated in 
response to Fgf4 + Wnt8 with a mean fold change of 69.6 (Figure 7.6. C), followed 
by MyoD (fold change- 23.9). Mrf4 and Myogenin, factors more associated with 
terminal differentiation, were less highly upregulated (fold change 12.4 and 6.4 
respectively).  
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Cell cycle regulators known for their role in proliferation (Ccne1, Ccne2, Mycl and 
Mycn) were upregulated in response to Fgf4 + Wnt8. Moreover, the cell cycle 
inhibitor p27kip1 was significantly downregulated (Figure 7.6. D). This indicates 
that induced animal caps at NF Stage 25 still proliferative. However, other markers 
of pluripotency such as Klf4, Klf6, Myc and Aurka show either unchanged or 
downregulated expression in Fgf4/Wnt8 caps, suggesting a loss of potency. 
Determined myoblasts expressing Myf5 and MyoD are still proliferative despite 
their commitment to a myogenic fate (Emerson, 1990; Pownall et al., 2002), 
therefore indicating that the cells in the Fgf4/Wnt8 induced animal caps are likely 
to be myoblasts, as shown in previous studies.  
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Figure 7.6. Overexpression of Fgf4 + Wnt8 in NF Stage 25 Xenopus tropicalis animal cap explants 
results in changes to altered RNA Polymerase III transcription and differentiation.  Expression fold 
change summary of X.tropicalis NF Stage 25 animal cap explants injected with 2pg Fgf4 and 20pg Wnt8 
mRNA versus control uninjected caps across 3 biological replicates. RNAs with raw signal intensities of >10 
were included in the analyses. (A) RNA Polymerase III target genes (significantly altered tRNA isoacceptor 
families are indicated in blue, other RNA Polymerase III targets are included in red). (B) Contractile protein 
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genes showing significant upregulation in Fgf4 + Wnt8 caps. Note that Y-axis scale is logarithmic (C) Myogenic 
Regulatory Factors. (D) Selected genes associated with pluripotency and cell cycle regulators. Pink in all 
panels indicates no significant change in expression. SEM is presented as error bars and * indicates the level 
of statistical significance between control and injected samples after Bonferroni Correction. 
 
7.2.2.2 Regulation of the Polymerase III transcription machinery by Fgf4 + Wnt8 
signalling. 
To determine possible reasons for the downregulation of RNA Polymerase III 
transcription, expression levels of known subunits of Polymerase III and its 
transcriptional machinery were also analysed. Significantly, many components of 
RNA Polymerase III machinery were significantly downregulated in response to 
Fgf4 + Wnt8 (Figure 7.7.)- notably, the components of the TFIIIB complex, Brf1 
and Bdp1 which are important for transcription initiation and have been implicated 
in F9 cell studies to be important for regulation of RNA Polymerase III transcription 
during differentiation (Athineos et al., 2010). The majority of RNA polymerase III 
subunits were also downregulated with the exception of Polr3A, Polr3C, Polr3K 
and Polr3gL (Figure 7.7.). These data indicate a downregulation of RNA 
Polymerase III activity at the transcriptional machinery level during myogenic 
differentiation.  
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Figure 7.7. Overexpression of Fgf4 + Wnt8 in NF Stage 25 animal cap explants results in 
downregulation of RNA Polymerase III core transcription machinery. Expression fold change summary 
of X.tropicalis NF Stage 25 animal cap explants injected with 2pg Fgf4 and 20pg Wnt8 mRNA versus control 
uninjected caps across 3 biological replicates. RNAs with raw signal intensities of >10 were included in the 
analyses. 
 
7.2.3. Validation of RNA Polymerase III downregulation by qPCR analysis 
To validate the global downregulation of RNA Polymerase III transcription in 
Fgf4/Wnt8 induced animal caps, selected tRNAs and the RNA Polymerase III 
target 5S rRNA were analysed for expression by qRT-PCR. In support of the 
microarray analyses, qPCR for selected RNA Polymerase III target genes showed 
decreased expression levels in induced caps compared with control levels (Figure 
7.8.). The confirmation that not only tRNA transcription is affected by the induction 
of a myogenic differentiation programme, but that wider RNA Polymerase III 
transcription is also downregulated. This is striking in comparison to the dramatic 
upregulation of a set of RNA Polymerase II genes. 
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Figure 7.8. Validation of RNA Polymerase III transcriptional changes in Fgf4 + Wnt8 induced animal 
caps by qRT-PCR. qRT-PCR analysis of expression of selected tRNAs and 5S rRNA in control and Fgf4 + 
Wnt8 induced animal caps was carried out at NF Stage 25. Relative expression levels compared with control 
cap expression was calculated using the ΔΔCt method using Dicer as an endogenous control for 3 biological 
replicates. Mean relative expression is presented on the chart with error bars representing SEM. 
 
7.2.4. Determining the regulation of Polr3G and Polr3gL by myogenic 
inducing growth factors 
When analysed separately, the three biological replicates included in the 
microarray showed different extents of induction of MRFs and contractile protein 
gene expression. Despite all being statistically significant, the extent of expression 
changes in experimental set 1 were much lower than in the other 2 sets. (Figure 
7.9. A- note logarithmic scale). This could be due to sample 1 being slightly 
younger than the other two, this is consistent with higher levels of Myf5 and lower 
levels of other contractile protein genes. Therefore, when analysing Polr3G and 
Polr3gL expression in Fgf4/Wnt8 induced caps by qRT-PCR, additional samples 
were collected to ensure staging of samples was representative. In caps induced 
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by Fgf4 + Wnt8, no significant change in Polr3G expression was identified, 
however Polr3gL was found to be significantly upregulated (Figure 7.9. B). Actc1 
was included as a control gene to ensure variation across the three samples was 
limited and did not affect statistical analyses. This data suggests that, unlike MyoD 
alone, Fgf4/Wnt8 induction of animal caps does not lead to upregulation of Polr3G 
but does result in increased expression of Polr3gL, the subunit included in the 
isoform of RNA Polymerase III more associated with differentiation. Despite 
sample 1 showing a less differentiated transcriptional profile, the qRT-PCR 
analysis validates the findings of the microarray where Polr3gL is upregulated 
along with the myogenic differentiation genes. 
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Figure 7.9. qRT-PCR analysis of Polr3G and Polr3gL expression levels in Fgf4 + Wnt8 induced animal 
caps at NF Stage 25. (A) Expression of contractile protein genes in the three biological replicates used for 
microarray analysis. Note the log scale for fold change. (B) qRT-PCR analysis was carried out for control 
animal caps and animal caps induced by Fgf4 and Wnt8 at NF Stage 25 for two biological replicates (2 and 3) 
included on the microarray analysis and an additional pair collected (set 4), but not analysed on the 
microarray, to account for lower values in experimental set 1. Ct values were normalised to the control gene 
Dicer and expression values were calculated relative to Polr3G expression levels in control caps. Paired t-tests 
were carried out for the data (*) indicates level of significance * p<0.05, ** p<0.01, *** p<0.001. Note that scale 
on Y axis is logarithmic. 
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7.2.5. Investigating Maf1 and Polr3G as regulators of RNA Polymerase III 
downregulation during myogenic differentiation 
Maf1 is a known negative regulator of RNA Polymerase III activity. Nuclear Maf1 
inhibits interaction of the transcription initiation complex of RNA Polymerase III to 
inhibit transcription (Vannini et al., 2010). As Maf1 was not included on the 
microarray, an additional animal cap experiment was designed and carried out on 
a single biological replicate to investigate (1) whether Maf1 is regulated during 
myogenic differentiation induced by Fgf4/Wnt8 and therefore if Maf1-based 
negative regulation could be a possible mechanism of the downregulation of RNA 
polymerase III activity observed in animal caps and (2) whether expression of 
Polr3G is sufficient to rescue the downregulation of RNA Polymerase III target 
genes in Fgf4/Wnt8 animal caps. 
Animal caps were injected either with combined 2pg Fgf4 + 20pg Wnt8 as per the 
microarray analysis or were injected with a combination 2pg Fgf4 + 20pg Wnt8 + 
1ng Polr3G mRNA and allowed to develop until NF Stage 25. qRT-PCR analysis 
was carried out on selected RNA Polymerase III target genes as well as Maf1 and 
Actc1 (to determine induction of myogenic differentiation). Table 7.1 shows the 
relative fold changes of expression of each gene analysed in both experimental 
sets of caps versus expression in uninjected control caps. Polr3G overexpression 
in animal caps induced with Fgf4/Wnt8 was not sufficient to rescue the 
downregulation of RNA Polymerase III target genes observed in the microarray 
and Fgf4/Wnt8 only caps. However, overexpression of Polr3G reduced the 
expression of Actc1 in Fgf4/Wnt8 caps. Previous study in ESCs showed that 
Polr3G overexpression results in a resistance of ESCs to induced differentiation by 
Retinoic Acid (Wong et al., 2011). This result therefore suggests that Polr3G may 
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be able to inhibit induction of myogenic differentiation in animal caps by Fgf4/Wnt8 
but is not sufficient to rescue the downregulation of Polymerase III activity. 
Maf1 expression is not significantly upregulated in animal caps induced by 
Fgf4/Wnt8 (Table 7.1, middle column). Moreover, Erk-based phosphorylation of 
Maf1 in Drosophila results in the inhibition of nuclear localisation of Maf1, and the 
upregulation of RNA Polymerase III activity (Sriskanthadevan-Pirahas et al., 
2018). Therefore, Maf1-based inhibition is unlikely to be the mechanism of 
downregulation observed during myogenic differentiation of animal caps. 
 
 Control Fgf4 + Wnt8 Fgf4 + Wnt8 + 
Polr3G 
iMet 1.000 0.153 0.184 
Tyr 1.000 0.224 0.266 
Ala 1.000 0.697 0.621 
5S 1.000 0.325 0.386 
Actc1 1.000 77.849 35.300 
Maf1 1.000 1.134 0.691 
Table 7.1. Investigation of Maf1 as a potential regulator of RNA Polymerase III activity in differentiating 
animal caps. Relative expression values of selected RNA Polymerase III target genes, the RNA Polymerase 
III regulator Maf1 and Actc1 as a marker of myogenic differentiation in control animal caps, animal caps 
induced with Fgf4 and Wnt8 and animal caps expressing Fgf4, Wnt8 and Polr3G. 
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7.3. Discussion 
7.3.1. Downregulation of Polymerase III activity 
The results from the microarray analysed in this chapter indicate that, whilst 
myogenic and contractile protein genes are significantly upregulated in response 
to induction of myogenesis in animal caps by Fgf4 and Wnt8 (Figure 7.6. B and C), 
a global downregulation of RNA Polymerase III transcription is evident (Figure 7.6. 
A and D). tRNAs and other RNA Polymerase III target genes show greater 
downregulation as a response to Fgf4 and Wnt8 than any other overexpression 
analysis carried out in this thesis with most tRNA expression levels downregulated 
to 0.6 or under compared with control cap levels. This was surprising due to the 
expectation that RNA Polymerase III activity may correlate to mRNA codon usage 
demand set by differentiated cells as observed in other studies in human tissue 
and the silkworm silk gland (Dittmar et al., 2006; Garel and Hentzen, 1974; 
Hentzen et al., 1981).  
However, downregulation of RNA Polymerase III activity in response to 
differentiation has also been observed in F9 Embryonal Carcinoma (EC) cell 
culture studies. An initial study using the cell line described revealed that when F9 
cells are induced to differentiate into endoderm by exposure to Retinoic Acid, 
transcription of tRNAs, alongside other RNA Polymerase III targets were 
dramatically downregulated. This study also showed that the downregulation effect 
was due to reduced activity of the TFIIIB complex (White et al., 1989). Subsequent 
studies confirmed this finding and determined that the loss of TFIIIB activity was 
due specifically to decreased levels of the Brf1 and Bdp1 subunits of TFIIIB 
accompanied with downregulated c-Myc expression and downregulation of Erk 
phosphorylation (Athineos et al., 2010; Dumay-Odelot et al., 2010). Surprisingly, in 
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this analysis, Fgf4/Wnt8 induced caps show no change in Myc (c-Myc) expression 
and indeed, upregulated Mycn and Mycl expression was observed. However, 
consistent with the previous studies in F9 cells, Brf1 and Bdp1 (along with most 
other subunits of the RNA Polymerase III transcriptional machinery) were 
downregulated in response to Fgf4/Wnt8 induced myogenic differentiation (Figure 
7.7). It is possible that in vivo differentiation programmes modulate RNA 
Polymerase III activity using these same mechanisms here and that induction of 
cell differentiation or loss of pluripotency drives downregulation of RNA 
Polymerase III activity. 
  
7.3.2. Regulation of Pluripotency and Proliferation during Fgf4/Wnt8 induced 
myogenesis 
7.3.2.1. Proliferation Markers 
The downregulation of RNA Polymerase III during F9 cell differentiation was found 
to be a response of reduced cellular proliferation identified by to the reduced levels 
of positive regulators of TFIIIB activity c-Myc and phosphorylated Erk (Athineos et 
al., 2010). These mechanisms are unlikely to be working in Fgf4/Wnt8 animal 
caps. In control animal caps, no activation of Erk signalling is induced. Fgf4 
signals through the MAPK/Erk signalling pathway during mesoderm induction, thus 
increasing levels of dpErk in animal caps (Branney et al., 2009). Therefore, a 
reduction in activated Erk levels compared with control animal caps would not be 
likely in this context. Moreover, while the regulatory phosphorylation state of Myc 
is unknown in this context (Macek et al., 2018; Welcker et al., 2004), 
transcriptional levels of Myc remain unchanged (Figure 7.6. D). Overall the 
conclusion is that the regulation of these factors is unlikely to be a conserved 
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mechanism for the downregulation of RNA Polymerase III targets observed in this 
analysis. As some other cell cycle genes were included on the microarray, these 
were analysed in order to try to determine proliferation levels. Surprisingly, despite 
activation of myogenesis, the cell cycle progression markers Ccne1 and Ccne2 
(Caldon and Musgrove, 2010) were upregulated in the growth factor induced caps 
(Figure 7.6. D). Moreover, the cell cycle inhibitor and known promoter of neuronal 
differentiation p27kip was significantly downregulated (Carruthers et al., 2003). 
These data suggest that cells in Fgf4/Wnt8 induced caps have increased 
proliferation rates despite activating both myogenic and neurogenic differentiation 
programmes. MyoD and Myf5 are expressed in determined proliferative myoblasts 
prior to full myogenic differentiation (Pownall and Emerson, 1992). Therefore, in 
myogenic lineages, differentiation programmes are activated and proceed in the 
presence of cell proliferation, before the myoblasts exit the cell cycle during 
terminal differentiation and formation of mature muscle. Therefore, it may be that 
in vivo regulation of RNA Polymerase III activity during myogenesis is independent 
of proliferation levels and that a more decisive signal dominates expression of 
Polymerase III products. The data in this chapter is suggestive of a mixed 
population of cells, some of which are still proliferative and expressing MyoD and 
Myf5, whilst others have exited the cell cycle and express differentiation genes 
such as Myogenin and Myhs. 
Much regulation of RNA Polymerase III activity is directed by protein-protein 
interactions and modifications (Felton-Edkins et al., 2003b; Sutcliffe et al., 2000; 
Vannini et al., 2010; Welcker et al., 2004). Therefore, investigation of the post-
transcriptional regulation of RNA Polymerase III basal transcriptional machinery 
and its regulators of activity such as Maf1 and c-Myc may elucidate in more detail 
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the mechanism of the downregulation observed in animal caps. This would give 
the model of downregulation constructed from cell culture studies an in vivo 
developmental context. Moreover, as cell growth rates appear to determine 
transcriptional activity of RNA Polymerase III in other model organisms (Dong et 
al., 1996; Dumay-Odelot et al., 2010; Sriskanthadevan-Pirahas et al., 2018; White, 
2005), a closer look at proliferation rates using PCNA as a marker of proliferative 
cells may help to explain the slightly contradictory cell cycle results from the 
microarray and whether all cells are dividing or whether only a  subset is 
responsible for this result. 
 
7.3.2.2. Pluripotency markers 
Some markers of pluripotency (Klf4 and Klf6) were significantly downregulated in 
Fgf4/Wnt8 induced animal caps (Figure 7.6. D) (Nandan and Yang, 2009). 
However, other factors indicative of a pluripotent state were upregulated. Oct4 and 
Sox2 are typically markers of pluripotent stem cells and are coexpressed with 
Polr3G in ESCs (Wong et al., 2011). Therefore it is surprising for them to be 
upregulated in Fgf4/Wnt8 caps. However, animal caps induced by these growth 
factors also differentiate into neural tissues in addition to myogenic lineages 
(Figure 7.4.). Sox2 is a marker of neuromesodermal progenitors, the neural crest 
and is expressed in the neural tube, a structure observed in differentiated 
Fgf4/Wnt8 induced animal caps (Chal and Pourquié1, 2017; Graham et al., 2003; 
Monsoro-Burq et al., 2005; Takemoto et al., 2011). Moreover, the homeobox gene 
Oct4 is known to interact with Sox family proteins during neurogenesis and its 
inhibition results in repression of neural induction (Archer et al., 2011). This 
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therefore may explain why an increase in expression of these factors is observed 
in the microarray, despite induction of differentiation. 
 
7.3.3. Regulation of Polr3G by Fgf4 and Wnt8 
Unlike MyoD expression alone, Fgf4 and Wnt8 combined overexpression in animal 
caps leads to no change in Polr3G expression but increased expression of 
Polr3gL (Figure 7.7. and Figure 7.9. B). The aim of this chapter was to capture 
early stages of the myogenic differentiation programme, in which proliferative 
mesodermal cells become specified to the skeletal muscle lineage and express 
the early myogenic regulatory factors MyoD and Myf5. The data collected 
indicates that MyoD and Myf5 were significantly upregulated in Fgf4/Wnt8 caps 
compared with control levels and that Myf5 was the most significantly upregulated. 
It is widely accepted that Myf5 is the earliest expressed MRF and a marker of 
undifferentiated myoblasts, while MyoD is activated just after Myf5 playing a role in 
terminal differentiation as well as specification of progenitor cells (Conerly et al., 
2016; Hopwood et al., 1991; Tajbakhsh et al., 1998). At first glance, this indicates 
that the Fgf4/Wnt8 caps collected were in the earliest stages of myogenesis. 
However, there was also upregulated expression of Mrf4 and Myogenin too (12.4 
and 6.4 fold change respectively) (Figure 7.6. C), but to a lesser extent. This 
observation, along with the downregulation of some genes associated with 
pluripotency (Klf4 and Klf6) and upregulation of some contractile protein genes, 
indicates that the Fgf4/Wnt8 caps were committed to terminal myogenic 
differentiation. This programme of full myogenic differentiation cannot be induced 
by MyoD alone in animal caps, or indeed not in ES cells or P19 cells (Albini et al., 
2013; Fong et al., 2012; Hopwood and Gurdon, 1990). The transient somitic 
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expression of Polr3G observed in tailbud stages of Xenopus development, and the 
ability of MyoD to activate Polr3G expression in animal caps (Figure 4.6, Figure 
4.11), suggests that there is a specific early timepoint at which myoblasts express 
Polr3G, possibly whilst still proliferative, before further differentiation. The 
experiment described in this chapter did not capture that timepoint.  
During differentiation of ES cells, Polr3G expression is downregulated and the 
expression of Polr3gL is maintained, indicating that the Polr3gL isoform of RNA 
Polymerase III is more associated with differentiated, mature cell types (Haurie et 
al., 2010).  This is consistent with the upregulation of Polr3gL observed in the 
microarray study. In this study the early specification of cells to the myogenic 
lineage has already occurred in the NF Stage 25 Fgf4/Wnt8 caps, and the now 
committed myoblasts are differentiating and activating the expression of 
differentiation factors such as Myogenin and contractile protein genes. This data 
may also explain the observation that overexpression of Polr3gL in embryos 
results in a greater downregulation of tRNAs compared with Polr3G (Figure 6.4). 
That Polr3gL, in response to differentiation factors, acts to promote myogenic 
differentiation in embryos, and the corresponding downregulation of RNA 
Polymerase III activity.  
The overexpression of Polr3G in ESCs resulted in reduced expression of many 
differentiation markers after induced differentiation by Retinoic Acid (Wong et al., 
2011), suggesting that Polr3G actively promotes pluripotency in the presence of 
driving signals of differentiation. Therefore, it was possible that relieving limitations 
to expression levels of Polr3G might be able to rescue the downregulation of 
tRNAs and other target genes during myogenic differentiation of animal caps. In 
this study, Polr3G alone was not sufficient to upregulate expression of tRNAs and 
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5S rRNA in animal caps compared with caps induced by Fgf4/Wnt8 only. It 
therefore may be that, at this stage during myogenic differentiation, Polr3gL, as its 
expression exceeds that of Polr3G and the two factors appear to regulate the 
same target genes, competes with and is able to overcome the activity of Polr3G 
in the regulation of RNA Polymerase III target genes. However, the reduced 
expression of Actc1 in the presence of Polr3G suggests that, as in ESCs, Polr3G 
can increase resistance of cells to fully differentiate and maintain a progenitor-like 
state even in the presence of inducing signals.  
 
7.4. Conclusions 
 
This chapter has shown that Fgf4 and Wnt8 induces a myogenic transcriptional 
profile in animal caps, characterised by upregulation in MRFs (primarily Myf5) and 
contractile protein genes (Myh). The overexpression of Fgf4 and Wnt8 in animal 
caps also results in a downregulation of many subunits of RNA Polymerase III 
transcriptional machinery, of particular interest Brf1 and Bdp1, and this 
downregulation is coupled with global downregulation of RNA Polymerase III 
transcriptional targets, consistent with early studies in F9 cells (Athineos et al., 
2010; White et al., 1989). Fgf4/Wnt8 induction of animal caps resulted in no 
change in expression of Polr3G at the stage analysed but showed upregulated 
expression of Polr3gL, the paralog expressed later in development and maintained 
during differentiation. This is possibly due to the activation of a terminal myogenic 
differentiation programme by Mrf4 and Myogenin that are also found to be 
upregulated in the Fgf4/Wnt8 animal caps. Together these results suggest that 
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Polr3G expression in the somites, regulated at least in part by MyoD (Figures 
4.10- 4.12) has transient activity and does not have a role in full myogenic 
differentiation. Polr3gL is the relevant isoform at the stage analysed here at the 
onset of full myogenic differentiation. 
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8. Discussion 
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8.1. Summary 
 
The aim of this PhD was to determine whether transcription by RNA Polymerase 
III is regulated during myogenic differentiation in Xenopus tropicalis, and whether 
the alternate subunit Polr3G or Polr3gL has a role in this regulation. The data 
presented in chapters 4-7 characterise the distinct expression profiles of these 
subunits during development and show that Polr3G is transiently expressed in the 
somites during early myogenic differentiation, identifying the subunit as a potential 
novel player in the regulation of myogenesis. I have shown that Polr3G is at least 
partly regulated by MyoD in vivo, but that an induced model of full myogenic 
differentiation in animal caps by expression of Fgf4 and Wnt8 results in 
upregulated levels of Polr3gL instead. I have also shown through custom-designed 
tRNA microarrays, that modulation of Polr3G expression leads to dynamic 
changes in expression of tRNAs during early development and in myogenic 
lineages, and that Polr3gL overexpression results in a greater downregulation of 
tRNAs compared with overexpression of Polr3G. This suggests that these RNA 
Polymerase III subunits have overlapping target genes, but different levels of 
activity when expressed in Xenopus. This thesis is the first study to characterise 
these subunits using a model organism.  
I have also shown in chapter 7 that wider effects on RNA Polymerase III activity 
are imposed during the induction of skeletal muscle differentiation in animal caps 
as a result of growth factor signalling. This chapter shows that Fgf4/Wnt8 induced 
differentiation results in dramatic downregulation of tRNAs and other RNA 
Polymerase III target genes, as well as subunits of RNA Polymerase III 
transcriptional machinery. This thesis is the first study to identify a conserved 
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effect of differentiation programmes on the activity of RNA Polymerase III in cell 
culture studies and in animal caps. 
 
 
8.2. The ever expanding network of transcriptional regulation by MyoD 
When MyoD was first discovered, its importance in regulating myogenesis was 
determined by a simple experiment whereby driving its expression was sufficient 
to convert a number of cell types to a myogenic fate (Choi et al., 1990; Davis et al., 
1987; Pinney et al., 1988). By the 1990s, MyoD had been coined a master 
regulator of myogenesis (Weintraub et al., 1991); its expression in fibroblasts 
sufficient to drive expression of myosin heavy chain and its expression was found 
localised to the somites of many model organisms (Davis et al., 1987; Pownall et 
al., 2002). In Xenopus, MyoD expression was shown localised early to myogenic 
lineages in both the early mesoderm and the somites (Hopwood et al., 1989; 
Pownall et al., 2002). However, shortly after it was determined that MyoD alone 
could not convert Xenopus ectodermal explants to a myogenic fate (Hopwood and 
Gurdon, 1990), suggesting and so a wider transcriptional network was required.  
The advances in transcriptomic analyses have enabled, in great detail, the 
characterisation of the MyoD transcriptional network. MyoD has been shown to 
interact with a number of cofactors such as E proteins, Mefs and Pbx2 (Berkes 
and Tapscott, 2005; Tapscott, 2005) that generate a feed-forward circuit for MyoD 
transcriptional activity. MyoD has also been shown to interact with different 
genomic regulatory elements in myoblasts compared with differentiated myofibers. 
This process, known as enhancer switching, is regulated by the presence or 
absence of the inhibitory complex Snai1-HDAC1/2 which, when bound to 
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enhancer sites, prevents MyoD binding (Soleimani et al., 2012). This prevents 
activation of late differentiation genes.  These experiments showed that 
transcriptional regulation by MyoD was regulated temporally (Penn et al., 2004). 
More recently, ChIP studies in P19 cells have shown MyoD is required not only for 
activation of myoblast genes during differentiation of stem cells to muscle, but 
initially regulates pre-myogenic mesoderm genes such as Meox1, Pax7 and Six1 
(Gianakopoulos et al., 2011).  
 
The enhancement of genome-wide analyses such as RNA-Seq and ChIP-Seq in 
the 2000s, resulted in the genome-wide mapping of specific DNA sequence 
elements which are more likely to be used by MyoD in order to activate gene 
expression, though MyoD was found to bind many intergenic regions associated 
with no gene activation (Cao et al., 2010). Studies have also shown that MyoD 
binding is associated with chromatin remodelling and epigenetic modifications in 
the absence of gene expression (Conerly et al., 2016; De La Serna et al., 2005; 
Oler et al., 2010). Together, these data indicate that MyoD not only directly 
activates gene expression of target genes through binding of enhancers in their 
regulatory regions, but may also have a facilitative role in enabling other factors to 
activate target genes, thus regulating in an independent manner too. High-
throughput, RNA-sequencing has also been useful in the identification of muscle-
specific non-coding RNAs in chick (Rathjen et al., 2009). This thesis describes a 
genome-wide analysis in Xenopus revealing novel targets of MyoD within the early 
myogenic lineage. 
 
Maguire et al. 2012, highlighted the importance of including in vivo studies when 
characterising gene networks through identification of many novel MyoD target 
241 
 
genes, with roles in somitogenesis in addition to genes involved in myogenic 
differentiation such as Myf5. This study on an Affymetrix microarray containing 
14,000 features identified over 300 genes differentially regulated in embryos 
targeted with MyoD antisense morpholinos. This study revealed a novel function of 
MyoD to drive two processes important for the formation of skeletal muscle 
simultaneously (Maguire et al., 2012).  Another important finding from this study 
was the evidence that Myf5 expression during gastrula stages of Xenopus 
development is dependent on MyoD. Previous studies in other vertebrates and in 
Xenopus identify Myf5 as the earliest MRF expressed (Hopwood et al., 1991; 
Pownall et al., 2002; Rudnicki et al., 1993), yet perhaps MyoD expression is 
required for establishment of Myf5 expression in mesoderm to establish a 
myogenic lineage much earlier than the formation of somites. 
 
A role for MyoD in the regulation of RNA Polymerase III activity during myogenesis 
in Xenopus. 
This thesis has revealed that transcription by RNA Polymerase III may also be an 
important node in the MyoD transcriptional network. Like microRNAs, tRNAs are 
small, non-coding RNAs important for post-transcriptional regulation of gene 
expression. As mediators of translation, their expression levels are highly 
coordinated with cell growth and proliferation rates (Dumay-Odelot et al., 2010; 
White, 2005) and evidence exists to suggest that their expression levels also 
correlate with demand from mRNA codon usage (Dittmar et al., 2006; Gingold and 
Pilpel, 2011). However, in vivo development is highly complex and it is likely that 
many factors influence activity of RNA Polymerase III. This thesis has shown that 
MyoD can regulate Polr3G, a developmentally regulated subunit in Xenopus, and 
that through induced myogenic differentiation, Fgf4/Wnt8 induction of animal caps 
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activates the related gene Polr3gL. This results in a strong downregulation of other 
RNA Polymerase III transcription factors and targets of RNA Polymerase III. In 
contrast to findings in cell culture studies, evidence in Chapter 7 however, 
suggests that, as indicated by the upregulation of key cell cycle genes, that RNA 
Polymerase III activity is downregulated independently of cell proliferation. 
 
It is not yet clear whether a conserved determinant of tRNA expression levels is 
present throughout eukaryotes. Studies in invertebrates suggest that tRNA 
expression is dependent on other controlling factors such as gene copy number 
(Duret, 2000). In this study, tRNA isoacceptors with greater number of encoding 
genes are more highly expressed than those with lower gene numbers. However, 
data from Chapter 5 suggests that this is not the case in Xenopus (Figure 5.12.). 
Data in this thesis instead suggests that the conversion of lineage and 
transcriptional changes in protein coding genes during myogenic differentiation 
may have a dominant regulatory effect on RNA Polymerase III activity in vivo. 
Chapter 6 indicates an increasing correlation between mRNA codon usage and 
tRNA isoacceptor expression from the microarray results in NF Stage 25 embryos 
compared with NF Stage 9 embryos but that during early stages of myogenic 
differentiation, a weak correlation still exists (Figure 6.6). It is not yet clear if the 
resulting levels of mature tRNA pools correlates at all to mRNA codon usage in 
muscle cells. Previous study in human tissues has shown correlation between 
codon usage bias and tRNA expression in human tissues, however only a small 
number of isoacceptor families showed a significant and strong correlation 
(Dittmar et al., 2006). It is possible therefore, that by inclusion of all isoacceptors 
expressed above threshold level may mask a subset of families with a stronger 
correlation to mRNA codon usage. It would therefore be useful to extend this 
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analysis to look at a more differentiated stage of myogenesis (i.e. NF Stage 40) 
and to analyse individual amino acids for correlation to determine if a subset show 
enhanced coordination to RNA Polymerase II activity as in human studies. 
Studies in bacteria support this finding by suggesting that the correlation of tRNA 
expression to corresponding mRNA codons enhances translational efficiency of a 
cell, this would be favourable in cells undergoing differentiation as enhanced 
translation would enable the cell to produce new proteins faster (Dittmar et al., 
2006; Gingold et al., 2014; Saikia et al., 2016). However, contrasting with this 
evidence, other mammalian studies suggest that during differentiation of muscle 
and liver, a dominant regulation mechanism exists to maintain stable levels of 
tRNAs throughout development, as upregulation of one gene of an isoacceptor 
family results in corresponding downregulation of a different gene within the same 
family (Rudolph et al., 2016; Schmitt et al., 2014). This evidence therefore 
suggests that tRNA levels are stable, despite changing translational needs. This 
thesis, whilst contrasting with invertebrate studies, does not yet clearly define a 
dominant determinant of tRNA expression in vivo. 
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8.3. Polr3G regulation by other myogenic factors 
This thesis investigates the role of MyoD in regulation the RNA Polymerase III 
subunits Polr3G and Polr3gL during myogenesis. However, in Xenopus Myf5 and 
Mrf4 are also important regulators of myogenesis with overlapping expression 
profiles. In amniotes, MyoD independent lineages within somites express Myf5, 
and the two appear to have partially redundant roles during myogenic 
determination (Haldar et al., 2008; Rudnicki et al., 1993). Myf5 and MyoD are also 
known markers of proliferative myoblasts (Emerson, 1990; Pownall and Emerson, 
1992), and Polr3G is known to be associated with proliferation in cell culture 
studies and cancer(Durrieu-Gaillard et al., 2017; Haurie et al., 2010). It is therefore 
possible that during early embryo development and myogenic specification, 
Polr3G is regulated by Myf5 in addition to MyoD. Additionally, in Xenopus, Mrf4 
has a very similar expression pattern to MyoD during tailbud stages and has been 
shown to have roles in both determination of myogenic lineage and in myogenic 
differentiation (Della Gaspera et al., 2012; Jennings, 1992; Kassar-Duchossoy et 
al., 2004). Therefore, transient expression of Polr3G in the somites at tailbud 
stages might be a result of combined regulation by MyoD and Mrf4.  
Muscle-specific miRs have been identified in vertebrates and shown to have 
important roles in the regulation of myogenesis. miR-1, miR-133 and miR-206 are 
all induced by MRFs in chick and expressed in the somites during myogenesis 
(Sweetman et al., 2006; Sweetman et al., 2008). miR-206 has been shown to 
promote differentiation of muscle cells by downregulation of inhibitory factors such 
as MyoR, an antagonist of MyoD activity; Id3, an HLH factor predicted to 
antagonise bHLH protein function through interaction with E proteins and other 
factors associated with precursor cells such as Utrn (Kim et al., 2006; Rosenberg 
et al., 2006). In cell culture studies, Polr3G downregulation during differentiation of 
245 
 
hESCs has been shown to be under the control of microRNAs. miR-1305 has 
been shown to promote differentiation of all three germ layers in ESCs. 
Overexpression of miR-1305 resulted in upregulation of markers of all germ layers 
including the mesoderm markers Gata4 and Foxa1, whilst downregulation resulted 
in upregulation of Oct4 and Nanog (Jin et al., 2016). miR-1305 promotes 
differentiation through its downregulation of Polr3G and restoration of pluripotency 
can be achieved through overexpression of Polr3G or knockdown of miR-1305 
indicating that interactions between small non-coding RNAs are important 
determinants of cell differentiation. As Polr3G downregulation by miR-1305 did not 
discriminately upregulate markers of any one particular germ layer, and miR-1305 
is not known to be expressed in the muscle lineage, it is possible that regulation of 
Polr3G by cell type-specific miRs may be a determinant in many differentiation 
programmes. As muscle miRs are known, their regulation of Polr3G may be an 
important missing link between MRF activity and transcriptional regulation RNA 
Polymerase III. This is unlikely to be the mechanism that regulates the transient 
expression of Polr3G in the somites, as MiR binding sites are very specific (only 
miR-203 binding sites identified by TargetScan)(Agarwal et al., 2015) . However 
any, role for somite specific MiRs in regulating Polr3G may be an interesting 
avenue of investigation. 
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8.4. Post-transcriptional regulation of RNA Polymerase III activity 
The central dogma of molecular biology is that the conversion of genetic 
information to protein output involves a two-step process: transcription and 
translation. Regulation of gene expression can occur at many stages during these 
processes and therefore, transcriptional output is by no means the full picture in 
studying gene expression. It is well established that RNA Polymerase III activity is 
regulated post-transcriptionally through disruption or promotion of protein-protein 
interactions between subunits and components of the transcriptional machinery, 
and through inactivation of factors through post-translational modifications such as 
phosphorylation.  
This thesis studies the transcriptional regulation of RNA Polymerase III during 
muscle differentiation, and the possibility that myogenic factors play a role in 
mediating this activity. It has been shown that the MRF MyoD at least in part 
regulates expression of Polr3G and that myogenic signalling pathways regulate 
expression of both targets and subunits of RNA Polymerase III, however further 
study is required to determine the full mechanism of this regulation. 
The proto-oncogene c-Myc is a bHLH transcription factor and a key regulator of 
RNA Polymerase III activity. c-Myc is an activator of RNA polymerase III activity 
and promotes transcription of tRNAs through recruitment of RNA Polymerase III, 
via interaction with TFIIIB, to target genes (Gomez-Roman et al., 2003). Previous 
studies have shown that downregulation of Polymerase III subunits Brf1 and Bdp1, 
and associated target genes during F9 cell differentiation are accompanied by 
downregulation of c-Myc protein expression (Athineos et al., 2010). Depletion of c-
Myc is sufficient to inhibit RNA Polymerase III activity thus providing an 
explanation for this result (Felton-Edkins et al., 2003b). Phosphorylation of c-Myc 
is known to regulate its activity through protein destabilisation (Welcker et al., 
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2004). More recently, P21 (RAC1)–activated kinase 2 (Pak2) mediated 
phosphorylation has also been shown to modulate c-Myc activity through its bHLH 
domain by phosphorylation of residue Ser-373 in the bHLH domain of c-Myc, 
inhibiting its interaction with its binding partner Max; this results in inhibition of Myc 
DNA binding at target genes (Macek et al., 2018). It may be that Fgf4 activity 
results in the phosphorylation of c-Myc in a residue crucial for its interaction with 
the TFIIIB complex which, whilst does not result in reduced expression of c-Myc, 
does result in reduced c-Myc activity and the downregulation of RNA Polymerase 
III target genes. 
Binding of Fgf ligands to target receptors results in an intracellular signalling 
cascade marked by phosphorylation of Erk. Erk signalling has been shown to 
phosphorylate and negatively regulate the activity of the RNA Polymerase III 
repressor Maf1. Maf1 inhibits RNA Polymerase III transcription through the 
disruption of the interaction between the Polr3G subcomplex and other initiation 
factors of the RNA Polymerase III transcriptional machinery Brf1 and TBP (Vannini 
et al., 2010).  Maf1 has recently been shown to promote differentiation of mouse 
embryonic stem cells to adipocytes (Chen et al., 2018). Inhibition of Maf1 in 
mESCs results in reduced differentiation of mesoderm and upregulated expression 
RNA Polymerase III target genes. In addition, targeting of Brf1 in mESCs resulted 
in enhanced adipogenesis, suggesting that downregulation of RNA Polymerase III 
mediated by Maf1 is important for differentiation. This downregulation of RNA 
Polymerase III target genes is consistent with the results in Chapter 7. In 
Drosophila, Ras/Erk signalling promotes cell proliferation rates by inhibiting 
nuclear localisation of Maf1 to enhance tRNA synthesis in both stem cells and 
epithelial lineages (Sriskanthadevan-Pirahas et al., 2018). However, as Erk 
signalling when activated through Fgf4, in the context of mesoderm induction, 
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promotes cells to differentiate into muscle, and this results in global 
downregulation of RNA Polymerase III transcriptional machinery and target genes. 
It is therefore more likely that induction of muscle differentiation in animal caps by 
Fgf4/Wnt8 resulted in the upregulation of Maf1 activity through an indirect 
mediator, or possibly through phosphorylation of Maf1 at a different position to 
enhance its repressor activity. Maf1 expression was shown to not be increased in 
animal caps induced by Fgf4/Wnt8, so transcriptional regulation of this factor in 
animal caps is unlikely to be the mechanism of repression of RNA Polymerase III 
activity in contrast with previous studies. However, post-transcriptional activity, 
particularly the nuclear localisation of Maf1, may still be an interesting avenue of 
investigation for future study. 
 
8.5. Can a potential role for Polr3G in muscle cell progenitors be translated 
to satellite cells? 
Polr3G is expressed in undifferentiated stem cells and, during Xenopus 
development, is present at highest levels in the earliest few stages prior to 
activation of transcription and induction of tissue differentiation programmes. 
However, a role for Polr3G and its expression in populations of adult stem cells 
has not yet been characterised. During development, mesodermal cells become 
determined to the myogenic lineage through embryonic signals such as Fgf and 
Wnt and differentiate into proliferative myoblasts expressing MyoD and Myf5 
(Emerson, 1990; Pownall and Emerson, 1992). Subsequently, through activation 
of a myogenic transcriptional programme directed by MRFs, myoblasts exit the cell 
cycle and differentiate to form myotubes and myofibers.  
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Muscle is stable throughout embryogenesis and into adulthood. It is maintained in 
response to natural cell turnover resulting from daily use but also has the capacity 
to regenerate in response to injury (i.e. from mechanical strain) due to the 
presence of satellite cells within the organisation of myofibers (Schmalbruch and 
Lewis, 2000; Yin et al., 2013). Satellite cells are so named because they are 
located at the periphery of myofibers. They are mononucleated and under normal 
conditions, non-dividing cells. However, they retain the capacity to rapidly re-enter 
the cell cycle after injury, forming proliferative myoblasts (Yin et al., 2013). 
Satellite cells can both self-renew through asymmetric cell division (and can divide 
symmetrically too) (Kuang et al., 2007), and can differentiate into functional 
myoblasts and myofibers. These characteristics define them as a population of 
muscle-specific adult stem cells. Pax7 is the conserved marker of satellite cell 
populations and is required for their specification (Seale et al., 2000) and most 
quiescent satellite cells also express Myf5 (Beauchamp et al., 2000). However, 
subsets of satellite cells do not express Myf5, and 25% of satellite cell populations 
are also positive for expression of MyoD. In addition, MyoD-/- cells show reduced 
differentiation capacity (Cornelison and Wold, 1997; Megeney et al., 1996; 
Sabourin et al., 1999; Wood et al., 2013) indicating that, as with embryonic 
myogenesis, MRFs have essential roles in regulation of adult muscle maintenance 
and induced myogenesis of muscle specific-stem cells. 
Day-to-day turnover of muscle cells can be repaired without cell death or 
inflammatory signalling responses. However, large injuries inflicted by trauma or 
as a result of genetic mutation result in necrosis of myofibers and inflammatory 
signalling, leading to activation, proliferation and subsequent differentiation of 
satellite cells. Satellite cells are essential for myogenic regeneration, as ablation of 
all Pax7+ cells results in total loss of regeneration in response to injury (Lepper et 
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al., 2011). Satellite cells have also been shown to have a role in regeneration of 
Xenopus tadpole tail muscle (Chen et al. 2006) and, as a side note, satellite cells 
were originally identified in frogs (Mauro, 1961). 
Importantly, adult tissues lose their regenerative capacity and ageing muscle is 
less able to repair after injury, either day-to-day or more traumatic. The ageing 
population is at increased risk of muscle atrophy and the degeneration of skeletal 
muscle (Sarcopenia) (Walston, 2012), which is correlated to a progressive loss in 
satellite cell function and reduced numbers of Pax7+ cells (Alway et al., 2014). 
Moreover, satellite cells are defective in some patients with muscular dystrophy, 
where these cells lose their proliferative capacity, and due to a lack of defined cell 
polarity, these cells lose their capacity to self-renew, thus depleting satellite cell 
populations (Blau et al., 1983; Chang et al., 2016) . Additionally, stem cell 
“exhaustion” of satellite cells in mice, caused by defective telomerase activity and 
resulting telomere shortening through successive rounds of degeneration and 
regeneration, resulted in Muscular Dystrophy phenotypes similar to that shown in 
human patients (Sacco et al., 2010). Thus far, effective treatment of these 
conditions has been evasive, but enhancement of satellite cell populations could 
be a promising therapeutic option. 
Knockdown of Polr3G in ESCs results in upregulation of many differentiation 
markers (Wong et al., 2011), including mesoderm marks Brachyury and Eomes. 
As this thesis has revealed that Polr3G is transiently expressed in myoblasts 
during early stages of myogenic differentiation, it is also possible that Polr3G is 
expressed in satellite cell populations along with Pax7 and either MyoD or 
Myf5.  In addition, Polr3G interacts with telomerase in transformed cells and 
enhances its recruitment to and activation of target genes (Khattar et al., 2016). 
Dysfunction of telomerase and shortened telomeres have been identified in 
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muscular dystrophy patients, resulting in non-functional satellite cell populations 
(Sacco et al., 2010; Tichy et al., 2017). The shortening of telomeres results in the 
inability of satellite cells to replenish damaged muscle fibres as they become less 
able to self-renew and replenish their population in ageing muscle. Another 
common problem with ageing satellite cells is the disruption of asymmetric cell 
division meaning that the daughter cells produced are then both committed, and 
can no longer act to replenish the reservoir of muscle stem cells (Blau et al., 
2015). The role of RNA Polymerase III in satellite cells has not been investigated, 
however, Polr3G overexpression in ESCs results in increased expression of 
pluripotency markers and decreased expression of lineage commitment marker 
genes in response to differentiation by Retinoic Acid (Wong et al., 2011). Polr3G, if 
overexpressed in ageing satellite cell populations, may result in resistance to 
lineage commitment of stem cell populations, meaning that reservoirs can 
replenish muscle fibres for longer than normal. Moreover, Polr3G and its 
interaction with TERT is implicated in the increased cell proliferation observed in 
cancers, and is predicted to be due to the enhanced activation of tRNAs and other 
RNA Polymerase III targets observed in resulting cell populations (Khattar et al., 
2016). As telomerase dysfunction is implicated in satellite cell “exhaustion”, and 
the inability to replenish populations of stem cells in muscle, it is possible therefore 
that expansion of satellite cell populations in patients with muscular dystrophy, or 
age-related muscle degeneration, may be achieved through overexpression of 
Polr3G and TERT in combination. These two factors would tackle both reduced 
population replenishment and reduced ‘stemness’ in satellite cells in combination. 
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8.6. Future Work 
 
8.6.1. Gene targeting of Polr3G/Polr3gL 
The targeting of Polr3G by antisense morpholinos was not possible in this thesis 
due to the high level of maternal RNA and protein stored in the embryo. 
Nevertheless, knockdown study is a crucial component of gene functional 
characterisation and future study would benefit from targeting using CRISPR/Cas9 
and out-crossing offspring to form heterozygous and homozygous populations. In 
ESCs, Polr3G was found to be non-essential for cell growth and viability, and was 
unable to compensate for the loss of Polr3gL in siRNA knockdown lines 
suggesting that Polr3gL is essential in ESCs for survival (Haurie et al., 2010). 
However, as Polr3G is expressed in oogenesis and cleavage stages, this may not 
be possible as this subunit may be essential for viability in the early embryo. 
Genetic compensation has been shown to be induced in CRISPR/Cas9 
mutagenesis studies (Rossi et al., 2015), whereby genes of similar function to the 
target gene are upregulated as a result of mutagenesis, and reduce the effects of 
the knockdown. It is not known exactly how this mechanism of compensation 
works, but it is thought to involve the detection of products formed from nonsense-
mediated decay of mutated mRNA transcripts. Nonsense-mediated decay is 
facilitated by mRNA surveillance genes which detect premature stop codons 
upstream of exon-exon junctions. A recent study has shown that mutating the 
decay factor Upf1 results in decreased genetic compensation in CRISPR/Cas9 
mutants (El-Brolosy et al., 2018). It is therefore possible that CRISPR/Cas9 based 
targeting of Polr3G would upregulate expression of Polr3gL in order to 
compensate; this kind of redundancy between related factors is seen in MyoD-/- 
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mutant mice where the increase in Myf5 expression allows skeletal muscle to 
develop despite the absence of MyoD (Rudnicki et al., 1992; Rudnicki et al., 
1993).  
El-Brolosy also showed that mutations resulting in the complete inhibition of 
transcription of the target gene results in reduced genetic compensation and 
enhancement of mutant phenotypes (El-Brolosy et al., 2018). Therefore, targeting 
the promoter regions of target genes could overcome this artefact. As analysis of 
tRNA modulation in response to Polr3gL overexpression at MBT stages was not 
carried out in this thesis, it is yet to be determined whether both subunits regulate 
the same target genes as seen in the NF Stage 25 analysis carried out in this 
thesis. 
In addition to full characterisation of Polr3G, which might not be possible, Polr3gL 
could be targeting using morpholinos due to its expression post-MBT. This would 
be a more immediate way to determine whether Polr3G and Polr3gL can 
compensate for each other in vivo during development as mRNA rescue 
experiments can be easily coupled with morpholinos targeting in Xenopus. As 
Polr3gL is induced by Fgf4 and Wnt8 in animal caps, it is also possible that 
Polr3gL has a role in differentiation of myoblasts. Therefore, if morpholino 
targeting resulted in loss of myogenic differentiation, it would reveal a subunit of 
RNA Polymerase III with a role in myogenesis with a unique repertoire of RNA 
polymerase III (and possibly RNA Polymerase II) target genes.  
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8.6.2. Analysis of Regulation of Polr3G/Polr3gL by other myogenic factors 
Extended analysis of regulation of Polr3G by other MRFs during the early stages 
of muscle differentiation may determine whether RNA Polymerase III is also 
regulated independently of MyoD (Myf5, Mrf4). Myf5, whilst the earliest expressed 
myogenic factor in Xenopus is expressed in a more limited number of cells even 
from gastrula stages. The localised expression to the dorsal-lateral marginal zone 
at gastrula stages is followed by expression in only the outer regions of somites at 
tailbud stages (Hopwood et al., 1991; Maguire et al., 2012). Whilst Polr3G is not 
expressed in a similar pattern to Myf5 at these stages, it is possible that MyoD and 
other MRFs co-regulate both Polr3G and Polr3gL and that this regulation occurs at 
earlier developmental stages. An existing model in cell culture studies predicts that 
Myf5 acts earlier in myogenesis to remodel chromatin through histone 
modifications, and that MyoD recruits RNA Polymerase II to target genes and 
activates transcription (Conerly et al., 2016). Therefore, co-expression of MyoD 
with Myf5 may result in greater activation of Polr3G than MyoD achieves alone. 
The role of Mrf4 is not as clearly defined as Myf5 and MyoD as it can act as both a 
specification factor, compensating for the loss of Myf5 (Kassar-Duchossoy et al., 
2004) and as a differentiation factor alongside Myogenin (Chanoine et al., 2004; 
Pownall et al., 2002). Its expression in the somites at tailbud stages of Xenopus 
development overlaps with MyoD (Della Gaspera et al., 2012) which could mean 
they act together in regulating the same target genes. Polr3G expression is 
located in the same regions as both MyoD and Mrf4. If the expression of Mrf4 acts 
as a molecular switch to convert determined myoblasts to differentiation, it may be 
that factors such as Mrf4 and Myogenin act as negative regulators of Polr3G, 
although MRFs are widely accepted to be transcriptional activators, so this 
regulation would most likely be indirect. 
255 
 
8.6.3. Post-transcriptional regulation of RNA Polymerase III subunits, 
cofactors, regulators 
Much regulation of RNA Polymerase III activity occurs post-transcriptionally. To 
fully characterise the regulation of RNA Polymerase III during Fgf4 and Wnt8 
induced myogenesis, protein based analyses should be carried out to determine 
the post-transcriptional effects in addition to the results observed in the microarray 
in Chapter 7. Protein levels of Brf1 and Bdp1 are reduced during F9 cell 
differentiation and transcriptional downregulation of these factors is also observed 
in Fgf and Wnt induced animal caps. Determining the result on protein expression 
would fully characterise this observation in caps to determine a conserved 
regulation of RNA Polymerase III during different differentiation programmes.  
Moreover, analysis of post-translational modifications may also determine the 
mechanism by which RNA Polymerase III activity is modulated during myogenic 
differentiation. As no transcriptional downregulation of the positive Polymerase III 
regulator c-Myc is observed, it may be that regulation of its expression or activity is 
due to protein targeting or through disruption of function (Macek et al., 2018; 
Salghetti et al., 1999). Phosphorylation of c-Myc as a result of Fgf4 and Wnt8 
signalling may determine the downregulation of RNA Polymerase III activity 
observed. 
In addition, as no clear negative regulator of RNA Polymerase III was identified by 
transcriptomic analyses to explain the downregulation of both RNA Polymerase III 
targets and transcription factors, it may be that expression of regulators such as 
Rb are higher in Fgf4/Wnt8 induced caps. This would be detectable by western 
blot analysis. 
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8.7. Conclusions 
 
This discussion presents evidence that the known MyoD transcriptional network is 
becoming more complex with the improvements to whole-genome sequencing and 
transcriptomic analyses, and that this network is not limited to protein coding 
mRNAs, but also includes epigenetic modifications and regulation of non-coding 
RNAs (MicroRNAs). Evidence of the regulation of Polr3G by MyoD in Xenopus 
also indicates that RNA Polymerase III transcriptional activity may also be a node 
in this network and the role of Polr3G in promotion of pluripotency may also have a 
role in regulation of adult stem cells. With a potential role in myogenic progenitors, 
overexpression of Polr3G and Telomerase in satellite cell populations may act as 
a novel therapeutic strategy for treatment of age-related muscle degeneration and 
muscular dystrophy. 
Furthermore, this thesis has suggested that the downregulation of RNA 
Polymerase III activity appears to be conserved between cell lines and in animal 
cap explants, with the induction of myogenic differentiation resulting in global 
downregulation of RNA Polymerase III target genes. This thesis also suggests 
that, in addition to the subunits Brf1 and Bdp1, most other transcription factors of 
RNA Polymerase III are also downregulated during myogenic differentiation of 
animal caps, with the exception of Polr3gL. In contrast to findings in cell culture, 
where this effect is attributed to reduced proliferation, the animal cap forms 3D 
tissues with multiple cell types, where induction of myogenic differentiation may 
first lead to the determination of proliferative myoblasts. Therefore the 
downregulation of RNA Polymerase III transcription may be an effect of post-
translational modifications to key RNA Polymerase III regulators, requiring further 
investigation. 
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Appendix 
 
Gene 
symbol 
ENSEMBL 
ID 
mean 
control 
mean 
experimental 
fold change p-value 
bmpr1b ENSXETG00000019220 8.01 5.45 0.68 0.02 
myod1 ENSXETG00000001320 90.10 64.29 0.71 0.02 
ndufaf3 ENSXETG00000024755 15.31 11.02 0.72 0.03 
tmem141 ENSXETG00000003949 8.53 6.25 0.73 0.04 
pgp ENSXETG00000016097 6.12 4.52 0.74 0.03 
trdmt1 ENSXETG00000027671 5.01 3.72 0.74 0.04 
rassf8 ENSXETG00000023490 11.13 8.34 0.75 0.04 
gbx2.2 ENSXETG00000003293 42.10 31.57 0.75 0.01 
nodal  6.12 4.62 0.76 0.03 
sp8 ENSXETG00000030115 12.27 9.28 0.76 0.05 
ndufb4  16.41 12.42 0.76 0.01 
nkx6-2 ENSXETG00000023614 20.42 15.51 0.76 0.02 
tsfm ENSXETG00000009653 5.08 3.96 0.78 0.05 
decr2-like ENSXETG00000010329 12.93 10.08 0.78 0.04 
rbm20 ENSXETG00000025245 7.04 5.51 0.78 0.04 
zeb2 ENSXETG00000000237 18.67 14.88 0.80 0.01 
mespa  9.87 7.87 0.80 0.05 
znf638 ENSXETG00000015780 6.74 5.38 0.80 0.02 
sod1 ENSXETG00000007350 28.27 22.64 0.80 0.05 
foxc2 ENSXETG00000016387 80.68 65.42 0.81 0.03 
babam1 ENSXETG00000025571 9.14 7.47 0.82 0.02 
gli2 ENSXETG00000011189 12.23 10.04 0.82 0.01 
arl10  9.70 7.98 0.82 0.01 
ccne2 ENSXETG00000006660 72.36 59.78 0.83 0.02 
mrpl15 ENSXETG00000008103 12.68 10.49 0.83 0.05 
sp5 ENSXETG00000025407 64.04 53.11 0.83 0.03 
lrrn1-
like.1 
 6.57 5.46 0.83 0.05 
mthfs ENSXETG00000024293 17.77 14.80 0.83 0.01 
pmm2 ENSXETG00000004549 45.85 38.21 0.83 0.04 
c4orf32  26.81 22.39 0.83 0.04 
endog ENSXETG00000025614 9.73 8.14 0.84 0.04 
pygm ENSXETG00000034136 123.57 103.71 0.84 0.04 
foxc1 ENSXETG00000000594 73.17 61.58 0.84 0.06 
sowahc  5.89 4.96 0.84 0.01 
fstl1 ENSXETG00000018009 25.29 21.31 0.84 0.02 
sema4c ENSXETG00000001251 22.06 18.66 0.85 0.04 
pex16 ENSXETG00000001027 8.44 7.15 0.85 0.05 
fahd1-like  8.00 6.79 0.85 0.05 
ephb1 ENSXETG00000013722 7.89 6.71 0.85 0.03 
slc13a4 ENSXETG00000008163 18.80 15.99 0.85 0.03 
AK6 ENSXETG00000018174 14.39 12.24 0.85 0.03 
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rbm24 ENSXETG00000024618 30.00 25.56 0.85 0.03 
tmem18 ENSXETG00000027985 42.69 36.39 0.85 0.01 
hunk ENSXETG00000007352 41.66 35.63 0.86 0.00 
cdr2 ENSXETG00000016662 6.64 5.69 0.86 0.01 
dctpp1 ENSXETG00000018900 12.09 10.36 0.86 0.03 
pgk1 ENSXETG00000007447 19.96 17.15 0.86 0.02 
mrps30 ENSXETG00000017716 11.89 10.23 0.86 0.04 
dgcr14 ENSXETG00000022387 6.43 5.54 0.86 0.02 
jam3  5.05 4.36 0.86 0.05 
stx18 ENSXETG00000016051 14.61 12.60 0.86 0.02 
cables2 ENSXETG00000002013 24.42 21.07 0.86 0.00 
zbtb8a.1  5.58 4.82 0.86 0.04 
cinp ENSXETG00000010255 7.06 6.10 0.86 0.03 
bicd2-
like.1 
 38.26 33.10 0.87 0.04 
flvcr2 ENSXETG00000027282 8.63 7.47 0.87 0.04 
cdx1 ENSXETG00000010282 77.18 66.87 0.87 0.03 
vps25 ENSXETG00000024599 15.21 13.19 0.87 0.05 
mib1 ENSXETG00000003146 14.11 12.25 0.87 0.03 
sept6-like  12.70 11.03 0.87 0.02 
pdlim7 ENSXETG00000007240 13.77 11.97 0.87 0.01 
msi1 ENSXETG00000012216 55.14 47.91 0.87 0.00 
znf219 ENSXETG00000016157 19.87 17.28 0.87 0.05 
rnf7 ENSXETG00000014753 99.16 86.80 0.88 0.04 
rint1 ENSXETG00000023226 9.88 8.66 0.88 0.02 
hmg20b ENSXETG00000022092 12.48 10.94 0.88 0.04 
pcdh8.2 ENSXETG00000008792 73.31 64.29 0.88 0.01 
lrpap1 ENSXETG00000005500 11.86 10.41 0.88 0.02 
ext1 ENSXETG00000019136 47.42 41.62 0.88 0.03 
wipf2-like  24.34 21.36 0.88 0.02 
nr6a1 ENSXETG00000008578 71.16 62.60 0.88 0.05 
herpud2 ENSXETG00000013111 5.58 4.91 0.88 0.04 
plekhg4  10.65 9.42 0.88 0.04 
cenpf ENSXETG00000023124 34.80 30.79 0.89 0.00 
rnf34 ENSXETG00000020965 7.57 6.71 0.89 0.04 
dhx32-like  17.74 15.73 0.89 0.05 
bri3bp ENSXETG00000001207 16.21 14.38 0.89 0.01 
ggnbp2  24.95 22.16 0.89 0.05 
ell2 ENSXETG00000013296 18.61 16.58 0.89 0.05 
vdac3  17.56 15.66 0.89 0.05 
ephb3 ENSXETG00000017293 42.52 37.95 0.89 0.02 
rhog-
like.1 
 14.00 12.52 0.89 0.05 
pttg1ip.2  5.42 4.86 0.90 0.05 
rfc2 ENSXETG00000018234 11.70 10.49 0.90 0.01 
rhoa.2 ENSXETG00000009241 445.54 399.57 0.90 0.02 
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rnf157 ENSXETG00000019548 5.75 5.16 0.90 0.05 
prr13-like  65.55 58.85 0.90 0.04 
mybl2 ENSXETG00000012125 51.14 45.92 0.90 0.01 
gigyf1 ENSXETG00000018415 23.73 21.32 0.90 0.03 
ilvbl  6.74 6.07 0.90 0.05 
epn1 ENSXETG00000022662 42.43 38.19 0.90 0.04 
nacc1 ENSXETG00000005594 44.47 40.05 0.90 0.03 
irf6.2 ENSXETG00000018661 13.55 12.22 0.90 0.02 
rhpn2 ENSXETG00000018271 9.65 8.71 0.90 0.02 
fmnl3-like  15.30 13.80 0.90 0.02 
slc30a1  26.69 24.09 0.90 0.04 
dnajc24 ENSXETG00000008179 14.14 12.76 0.90 0.03 
usp28 ENSXETG00000022958 10.14 9.16 0.90 0.03 
nsd1-like  7.39 6.68 0.90 0.02 
cdc42se2-
like.1 
 6.09 5.51 0.90 0.01 
pbx2 ENSXETG00000005223 169.56 158.17 0.93 0.02 
actc1 ENSXETG00000012911 - - - - 
Appendix Table 1. 100 shortlisted genes significantly downregulated in embryos targeted with MyoD 
gRNA. After paired t-test analysis, 1165 genes were identified as showing significant differences in expression 
in Cas9 only controls and MyoD gRNA targeted samples. Of these genes, 100 were shortlisted as potential 
target genes of MyoD showing a fold change of 0.68-0.91 and an average control FPKM of >5. In addition, 
foxc1 and pbx2 were manually added to the list despite not meeting criteria cutoffs due to their implicated 
roles as MyoD interactants/targets. As another reference gene for expression profiles, the MyoD target actc1 
was also included in further analysis. 
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Appendix Figure 1. Hierarchical clustering using Euclidean distance of developmental expression 
profiles of 73 target genes shortlisted from the initial RNA-Seq results filtering. Genes included are 
those which had ENSEMBL IDs and were included in the dataset from (Tan et al., 2013). Myod1 and actc1 
were also included as reference genes. Clusters were manually assessed to shortlist developmentally 
relevant clusters for further analysis (*). 
 
 
Gene 
name 
Control_1/ 
Polr3G_1 
Control_2 
/Polr3G_2 
Control_3/ 
Polr3G_3 
Average FC p-value 
bmp4 1.543689 1.416169 1.456241 1.472033 0.0026 
bmp7.2 1.165607 1.081415 1.140376 1.129133 0.0121 
chrd 1.771032 2.130559 2.786807 2.229466 0.0360 
eomes 1.481903 1.919614 1.780796 1.727438 0.0369 
foxd5 1.420048 2.049841 2.462223 1.977371 0.0058 
fzd1 1.127759 0.950777 1.234178 1.104238 0.1810 
gsc 1.484293 1.613645 1.644941 1.58096 0.0212 
id3 1.945837 1.761897 1.827762 1.845165 0.0098 
lefty 1.594944 1.344384 1.47802 1.472449 0.0090 
nodal 1.630057 1.813672 1.491113 1.644947 0.0063 
nodal 2a 
like 
1.316108 1.101156 1.122252 1.179839 0.0283 
nodal3a 1.293065 1.14928 1.359913 1.267419 0.0231 
nodal3c 1.322936 1.17073 1.333059 1.275575 0.0141 
nog 1.445232 1.286689 1.667153 1.466358 0.0334 
oct4 1.032665 1.211562 1.241664 1.235147 0.0898 
polr3G 777.7382 324.8658 373.2499 491.9513 0.0055 
sox17 1.271671 1.047167 1.498247 1.272362 0.1138 
sox17b.
1 
1.356134 1.126055 1.178551 1.220247 0.0044 
sox17b.
2 
1.376717 1.095506 1.164169 1.21213 0.0143 
wnt8a 1.628576 1.768179 1.823384 1.740046 0.0152 
Appendix Table 2. Curated genelist of mRNAs with significantly upregulated expression in embryos 
overexpressing Polr3G at NF stage 9. 
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GeneName Average Control Average Fgf4/Wnt8 Fold change 
AlaCGC 1.118668 0.649607 0.580501 
AlaTGC 1.030837 0.593304 0.571457 
ArgCCT 1.108241 0.659931 0.595372 
AsnGTT 1.135748 0.67515 0.591122 
CysACA 1.351646 0.715613 0.532681 
CysGCA 1.361717 0.768962 0.564647 
GlnCTG 1.309711 0.618362 0.474755 
GlnTTG 1.110973 0.681004 0.612963 
GlnTTG 1.30932 0.564803 0.431448 
GluCTC 1.110934 0.691623 0.623652 
GluTTC 1.309936 0.76054 0.580613 
GlyCCC 1.055806 0.717104 0.670402 
GlyGCC 1.109038 0.629752 0.567774 
GlyTCC 1.098989 0.631297 0.573973 
IleAAT 1.105668 0.692492 0.626242 
IleTAT 1.323536 0.643281 0.486073 
LeuAAG 1.253989 0.674589 0.537955 
LeuCAA 1.796093 0.950372 0.525164 
LeuTAA 1.437447 0.786479 0.552508 
LysTTT 1.067345 0.701763 0.654048 
PheAAA 1.309667 0.753875 0.576305 
PheGAA 1.322102 0.758373 0.57363 
SerAGA 1.054232 0.651607 0.616673 
SerCGA 1.095853 0.705067 0.643278 
SerGCT 1.080569 0.617578 0.577136 
SerTGA 1.076661 0.634404 0.589072 
SerTGA 1.036689 0.648076 0.62629 
ThrTGT 1.093908 0.704634 0.644398 
TrpCCA 1.251981 0.730306 0.579566 
TyrGTA 1.046715 0.764457 0.729131 
TyrGTA 1.175729 0.65707 0.559161 
ValAAC 1.229314 0.665965 0.541949 
ValCAC 1.271793 0.715918 0.563035 
ValTAC 0.91455 0.834654 0.912627 
Appendix Table 3. Fold changes induced by Fgf4/Wnt8 in animal caps for all tRNA isoacceptors with 
expression values of >10 included on the custom Agilent microarray. 
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Chal, J. J. and Pourquié1, O. P. (2017). Making muscle: skeletal myogenesis in 
vivo and in vitro. Development 15, 2104–2122. 
Chan, P. P. and Lowe, T. M. (2016). GtRNAdb 2.0: an expanded database of 
transfer RNA genes identified in complete and draft genomes. Nucleic Acids 
Res. 44, D184–D189. 
Chan, P.P. & Lowe, T. M. (2009). GtRNAdb: A database of transfer RNA genes 
detected in genomic sequence. Nucleic Acids Res. 37, 93–97. 
Chang, N. C., Chevalier, F. P. and Rudnicki, M. A. (2016). Satellite Cells in 
Muscular Dystrophy - Lost in Polarity. Trends Mol. Med. 22, 479–496. 
Chanoine, C., Della Gaspera, B. and Charbonnier, F. (2004). Myogenic 
regulatory factors: redundant or specific functions? Lessons from Xenopus. 
Dev. Dyn. 231, 662–70. 
Chen, J.-F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. 
M., Conlon, F. L. and Wang, D.-Z. (2006). The role of microRNA-1 and 
microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 
38, 228–233. 
Chen, C. Y., Lanz, R. B., Walkey, C. J., Chang, W. H., Lu, W. and Johnson, D. 
L. (2018). Maf1 and Repression of RNA Polymerase III-Mediated 
Transcription Drive Adipocyte Differentiation. Cell Rep. 24, 1852–1864. 
Choi, J., Costa, M. L., Mermelstein, C. S., Chagas, C., Holtzer, S. and Holtzer, 
H. (1990). MyoD converts primary dermal fibroblasts, chondroblasts, smooth 
muscle, and retinal pigmented epithelial cells into striated mononucleated 
myoblasts and multinucleated myotubes. Proc. Natl. Acad. Sci. U. S. A. 87, 
7988–7992. 
267 
 
Christian, J. L. and Moon, R. T. (1993). Interactions between Xwnt-8 and 
Spemann organizer signaling pathways generate dorsoventral pattern in the 
embryonic mesoderm of Xenopus. Genes Dev. 7, 13–28. 
Christian, J. L., Olson, D. J. and Moon, R. T. (1992). Xwnt-8 modifies the 
character of mesoderm induced by bFGF in isolated Xenopus ectoderm. 
EMBO J. 1, 33–41. 
Clarkson, S. G., Birnstiel, M. L. and Purdom, I. F. (1973). Clustering of transfer 
RNA genes of Xenopus laevis. J. Mol. Biol. 79, 411–29. 
Collart, C., Allen, G. E., Bradshaw, C. R., Smith, J. C. and Zegerman, P. 
(2013). Titration of Four Replication Factors is Essential for the Xenopus 
laevis Midblastula Transition. Science (80-. ). 341, 893–896. 
Conerly, M. L., Yao, Z., Zhong, J. W., Groudine, M. and Tapscott, S. J. (2016). 
Distinct Activities of Myf5 and MyoD Indicate Separate Roles in Skeletal 
Muscle Lineage Specification and Differentiation. Dev. Cell 36, 375–385. 
Cornelison, D. D. W. and Wold, B. J. (1997). Single-Cell Analysis of Regulatory 
Gene Expression in Quiescent and Activated Mouse Skeletal Muscle Satellite 
Cells. Dev. Biol. 191, 270–283. 
Cossu, G. and Butler-Browne, G. (1999). In vivo satellite cell activation via Myf5 
and MyoD in regenerating mouse skeletal muscle. J. Cell Sci. 112, 2895–
2901. 
Cossu, G., Kelly, R., Tajbakhsh, S., Di Donna, S., Vivarelli, E. and 
Buckingham, M. (1996). Activation of different myogenic pathways: myf-5 is 
induced by the neural tube and MyoD by the dorsal ectoderm in mouse 
paraxial mesoderm. Development 122, 429–37. 
Crighton, D., Woiwode, A., Zhang, C., Mandavia, N., Morton, J. P., Warnock, 
L. J., Milner, J., White, R. J. and Johnson, D. L. (2003). p53 represses RNA 
polymerase III transcription by targeting TBP and inhibiting promoter 
occupancy by TFIIIB. EMBO J. 22, 2810–20. 
Cunliffe, V. and Smith, J. C. (1994). Specification of mesodermal pattern in 
Xenopus laevis by interactions between Brachyury, noggin and Xwnt-8. 
EMBO J. 13, 349–59. 
268 
 
Dang, C. H. I. V (1999). c-Myc Target Genes Involved in Cell Growth , Apoptosis , 
and Metabolism. Mol. Cell. Biol. 19, 1–11. 
Davis, R. L., Weintraub, H. and Lassar, A. B. (1987). Expression of a single 
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000. 
De La Serna, I. L., Ohkawa, Y., Berkes, C. A., Bergstrom, D. A., Dacwag, C. S., 
Tapscott, S. J. and Imbalzano, A. N. (2005). MyoD targets chromatin 
remodeling complexes to the myogenin locus prior to forming a stable DNA-
bound complex. Mol. Cell. Biol. 25, 3997–4009. 
Della Gaspera, B., Armand, A.-S., Sequeira, I., Chesneau, A., Mazabraud, A., 
Lécolle, S., Charbonnier, F. and Chanoine, C. (2012). Myogenic waves and 
myogenic programs during Xenopus embryonic myogenesis. Dev. Dyn. 241, 
995–1007. 
Desai, N., Lee, J., Upadhya, R., Chu, Y., Moir, R. D. and Willis, I. M. (2005). 
Two steps in Maf1-dependent repression of transcription by RNA polymerase 
III. J. Biol. Chem. 280, 6455–62. 
Dittmar, K. A., Goodenbour, J. M. and Pan, T. (2006). Tissue-specific 
differences in human transfer RNA expression. PLoS Genet. 2, e221. 
Dodou, E., Xu, S.-M. and Black, B. L. (2003). mef2c is activated directly by 
myogenic basic helix-loop-helix proteins during skeletal muscle development 
in vivo. Mech. Dev. 120, 1021–1032. 
Dong, H., Nilsson, L. and Kurland, C. G. (1996). Co-variation of tRNA 
Abundance and Codon Usage in Escherichia coli at Different Growth Rates. J. 
Mol. Biol. 260, 649–663. 
Dorey, K., Amaya, E., Harpal, K., Yamaguchi, T. P., Rossant, J. and 
Papalopulu, N. (2010). FGF signalling: diverse roles during early vertebrate 
embryogenesis. Development 137, 3731–42. 
Draper, B. W., Morcos, P. A. and Kimmel, C. B. (2001). Inhibition of zebrafish 
fgf8 pre-mRNA splicing with morpholino oligos: A quantifiable method for 
gene knockdown. Genesis 30, 154–156. 
Dumay-Odelot, H., Durrieu-Gaillard, S., Da Silva, D., Roeder, R. G. and 
269 
 
Teichmann, M. (2010). Cell growth- and differentiation-dependent regulation 
of RNA polymerase III transcription. Cell Cycle 9, 3687–3699. 
Duret, L. (2000). tRNA gene number and codon usage in the C. elegans genome 
are co-adapted for optimal translation of highly expressed genes. Trends 
Genet. 16, 287–289. 
Durrieu-Gaillard, S., Dumay-Odelot, H., Boldina, G., Tourasse, N. J., Allard, 
D., André, F., Macari, F., Choquet, A., Lagarde, P., Drutel, G., et al. (2017). 
Regulation of RNA polymerase III transcription during transformation of 
human IMR90 fibroblasts with defined genetic elements. Cell Cycle 4101, 1–
34. 
Eisen, J. S. and Smith, J. C. (2008). Controlling morpholino experiments: don’t 
stop making antisense. Development 135, 1735–43. 
El-Brolosy, M., Rossi, A., Kontarakis, Z., Kuenne, C., Guenther, S., Fukuda, 
N., Takacs, C., Lai, S.-L., Fukuda, R., Gerri, C., et al. (2018). Genetic 
compensation is triggered by mutant mRNA degradation. bioRxiv 328153. 
Emerson, C. P. (1990). Myogenesis and developmental control genes. Curr. Opin. 
Cell Biol. 2, 1065–1075. 
Emerson, C. P. (1993). Embryonic signals for skeletal myogenesis: arriving at the 
beginning. Curr. Opin. Cell Biol. 5, 1057–1064. 
Felton-Edkins, Z. A., Fairley, J. A., Graham, E. L., Johnston, I. M., White, R. J. 
and Scott, P. H. (2003a). The mitogen-activated protein (MAP) kinase ERK 
induces tRNA synthesis by phosphorylating TFIIIB. EMBO J. 22, 2422–2432. 
Felton-Edkins, Z. A., Kenneth, N. S., Brown, T. R. P., Daly, N. L., Gomez-
Roman, N., Grandori, C., Eisenman, R. N. and White, R. J. (2003b). Direct 
regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell 
Cycle 2, 181–4. 
Fetka, I., Doederlein, G. and Bouwmeester, T. (2000). Neuroectodermal 
specification and regionalization of the Spemann organizer in Xenopus. Mech. 
Dev. 93, 49–58. 
Fisher, M., Isaacs, H. and Pownall, M. (2002). eFGF is required for activation of 
270 
 
XmyoD expression in the myogenic cell lineage of Xenopus laevis. 
Development 129, 1307–1315. 
Fong, A. P., Yao, Z., Zhong, J. W., Cao, Y., Ruzzo, W. L., Gentleman, R. C. and 
Tapscott, S. J. (2012). Genetic and epigenetic determinants of neurogenesis 
and myogenesis. Dev. Cell 22, 721–35. 
Fong, A. P., Yao, Z., Zhong, J. W., Johnson, N. M., Farr, G. H., Maves, L. and 
Tapscott, S. J. (2015). Conversion of MyoD to a neurogenic factor: binding 
site specificity determines lineage. Cell Rep. 10, 1937–46. 
François, V. and Bier, E. (1995). Xenopus chordin and Drosophila short 
gastrulation genes encode homologous proteins functioning in dorsal-ventral 
axis formation. Cell 80, 19–20. 
Fu, J., Bian, M., Jiang, Q. and Zhang, C. (2007). Roles of Aurora kinases in 
mitosis and tumorigenesis. Mol. Cancer Res. 5, 1–10. 
Garel, J. P. and Hentzen, D. (1974). Codon responses of tRNAAla , tRNAGly and 
tRNASer from the posterior part of the silkgland of Bombyx mori L. FEBS Lett. 
39, 359–363. 
Gentsch, G. E., Spruce, T., Monteiro, R. S., Owens, N. D. L., Martin, S. R. and 
Smith, J. C. (2018). Innate Immune Response and Off-Target Mis-splicing 
Are Common Morpholino-Induced Side Effects in Xenopus. Dev. Cell 44, 
597–610. 
Geslain, R. and Pan, T. (2011). tRNA: Vast reservoir of RNA molecules with 
unexpected regulatory function. Proc. Natl. Acad. Sci. U. S. A. 108, 16489–
90. 
Giacinti, C. and Giordano, A. (2006). RB and cell cycle progression. Oncogene 
25, 5220–7. 
Gianakopoulos, P. J., Mehta, V., Voronova, A., Cao, Y., Yao, Z., Coutu, J., 
Wang, X., Waddington, M. S., Tapscott, S. J. and Skerjanc, I. S. (2011). 
MyoD directly up-regulates premyogenic mesoderm factors during induction 
of skeletal myogenesis in stem cells. J. Biol. Chem. 286, 2517–2525. 
Gilbert, S. (2000). Developmental Biology. 6th Edition. 
271 
 
Gingold, H. and Pilpel, Y. (2011). Determinants of translation efficiency and 
accuracy. Mol. Syst. Biol. 7, 481. 
Gingold, H., Tehler, D., Christoffersen, N. R., Nielsen, M. M., Asmar, F., 
Kooistra, S. M., Christophersen, N. S., Christensen, L. L., Borre, M., 
Sørensen, K. D., et al. (2014). A Dual Program for Translation Regulation in 
Cellular Proliferation and Differentiation. Cell 158, 1281–1292. 
Goldenson, B. and Crispino, J. D. (2015). The aurora kinases in cell cycle and 
leukemia. Oncogene 34, 537–545. 
Goljanek-Whysall, K., Sweetman, D. and Münsterberg, A. E. (2012). 
microRNAs in skeletal muscle differentiation and disease. Clin. Sci. 123, 611–
25. 
Gomez-Roman, N., Grandori, C., Eisenman, R. N. and White, R. J. (2003). 
Direct activation of RNA polymerase III transcription by c-Myc. Nature 421, 
290–4. 
Goodarzi, H., Nguyen, H. C. B., Zhang, S., Dill, B. D., Molina, H. and Tavazoie, 
S. F. (2016). Modulated Expression of Specific tRNAs Drives Gene 
Expression and Cancer Progression. Cell 165, 1416–1427. 
Gossett, L. A., Kelvin, D. J., Sternberg, E. A. and Olson, E. N. (1989). A New 
Myocyte-Specific Enhancer-Binding Factor That Recognizes a Conserved 
Element Associated with Multiple Muscle-Specific Genes. Mol. Cell. Biol. 9, 
5022–5033. 
Graham, V., Khudyakov, J., Ellis, P. and Pevny, L. (2003). SOX2 Functions to 
Maintain Neural Progenitor Identity. Neuron 39, 749–765. 
Grewal, S. S. (2015). Why should cancer biologists care about tRNAs? tRNA 
synthesis, mRNA translation and the control of growth. Biochim. Biophys. 
Acta 1849, 898–907. 
Grifone, R., Xie, X., Bourgeois, A., Saquet, A., Duprez, D. and Shi, D. L. 
(2014). The RNA-binding protein Rbm24 is transiently expressed in myoblasts 
and is required for myogenic differentiation during vertebrate development. 
Mech. Dev. 134, 1–15. 
272 
 
Guo, W., Schafer, S., Greaser, M. L., Radke, M. H., Liss, M., Govindarajan, T., 
Maatz, H., Schulz, H., Li, S., Parrish, A. M., et al. (2012). RBM20, a gene for 
hereditary cardiomyopathy, regulates titin splicing. Nat. Med. 18, 766–773. 
Guo, X., Zhang, T., Hu, Z., Zhang, Y., Shi, Z., Wang, Q., Cui, Y., Wang, F., 
Zhao, H. and Chen, Y. (2014). Efficient RNA/Cas9-mediated genome editing 
in Xenopus tropicalis. Development 141, 707–14. 
Haldar, M., Karan, G., Tvrdik, P. and Capecchi, M. R. (2008). Two cell lineages, 
myf5 and myf5-independent, participate in mouse skeletal myogenesis. Dev. 
Cell 14, 437–45. 
Hamilton, F. S., Wheeler, G. N. and Hoppler, S. (2001). Difference in XTcf-3 
dependency accounts for change in response to beta-catenin-mediated Wnt 
signalling in Xenopus blastula. Development 128, 2063–2073. 
Hanahan, D. and Weinberg, R. A. (2000). The Hallmarks of Cancer. Cell 100, 
57–70. 
Hasty, P., Bradley,  a, Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, 
E. N. and Klein, W. H. (1993). Muscle deficiency and neonatal death in mice 
with a targeted mutation in the myogenin gene. Nature 364, 501–506. 
Haurie, V., Durrieu-Gaillard, S., Dumay-Odelot, H., Da Silva, D., Rey, C., 
Prochazkova, M., Roeder, R. G., Besser, D. and Teichmann, M. (2010). 
Two isoforms of human RNA polymerase III with specific functions in cell 
growth and transformation. Proc. Natl. Acad. Sci. U. S. A. 107, 4176–81. 
Heasman, J. (2002). Morpholino Oligos: Making Sense of Antisense? Dev. Biol. 
243, 209–214. 
Heasman, J., Kofron, M. and Wylie, C. (2000). βCatenin Signaling Activity 
Dissected in the Early Xenopus Embryo: A Novel Antisense Approach. Dev. 
Biol. 222, 124–134. 
Hentzen, D., Chevallier, A. and Garel, J.-P. (1981). Differential usage of iso-
accepting tRNASer species in silk glands of Bombyx mori. Nature 290, 267–
269. 
Hoppler, S., Brown, J. D. and Randall, T. M. (1996). Expression of a dominant-
273 
 
negative Wnt blocks induction of MyoD in Xenopus embryos. Genes Dev. 10, 
2805–2817. 
Hopwood, N. D. and Gurdon, J. B. (1990). Activation of muscle genes without 
myogenesis by ectopic expression of MyoD in frog embryo cells. Nature 347, 
197–200. 
Hopwood, N. D., Pluck, A. and Gurdon, J. B. (1989). MyoD expression in the 
forming somites is an early response to mesoderm induction in Xenopus 
embryos. EMBO J. 8, 3409–17. 
Hopwood, N. D., Pluck, A. and Gurdon, J. B. (1991). Xenopus Myf-5 Marks 
Early Muscle-Cells and Can Activate Muscle Genes Ectopically in Early 
Embryos. Development 111, 551–560. 
Hopwood, N. D., Pluck, A., Gurdon, J. D. and Dilworth, S. M. (1992). 
Expression of XMyoD protein in early Xenopus laevis embryos. Development 
114, 31–38. 
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., 
Peterson, R. T., Yeh, J.-R. J. and Joung, J. K. (2013). Efficient genome 
editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227–9. 
Irion, U., Krauss, J., Nüsslein-Volhard, C., Auer, T. O., Bene, F. Del, Auer, T. 
O., Duroure, K., Cian, A. De, Concordet, J.-P., Bene, F. Del, et al. (2014). 
Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 
system. Development 141, 4827–30. 
Isaacs, H. V, Pownall, M. E. and Slack, J. M. (1994). eFGF regulates Xbra 
expression during Xenopus gastrulation. EMBO J. 13, 4469–4481. 
Jen, Y., Weintraub, H. and Benezra, R. (1992). Overexpression of Id protein 
inhibits the muscle differentiation program: In vivo association of Id with E2A 
proteins. Genes Dev. 6, 1466–1479. 
Jennings, C. G. (1992). Expression of the myogenic gene MRF4 during Xenopus 
development. Dev. Biol. 151, 319–32. 
Jin, D., Hidaka, K., Shirai, M. and Morisaki, T. (2010). RNA-binding motif protein 
24 regulates myogenin expression and promotes myogenic differentiation. 
274 
 
Genes to Cells 15, 1158–1167. 
Jin, S., Collin, J., Zhu, L., Montaner, D., Armstrong, L., Neganova, I. and 
Lako, M. (2016). A Novel Role for miR-1305 in Regulation of Pluripotency-
Differentiation Balance, Cell Cycle, and Apoptosis in Human Pluripotent Stem 
Cells. Stem Cells 34, 2306–2317. 
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A. and Charpentier, 
E. (2012). A Programmable Dual-RNA–Guided DNA Endonuclease in 
Adaptive Bacterial Immunity. Science (80-. ). 337, 816–822. 
Jones, C. M., Kuehn, M. R., Hogan, B. L., Smith, J. C. and Wright, C. V (1995). 
Nodal-related signals induce axial mesoderm and dorsalize mesoderm during 
gastrulation. Development 121, 3651–3662. 
Kanaya, S., Yamada, Y., Kudo, Y. and Ikemura, T. (1999). Studies of codon 
usage and tRNA genes of 18 unicellular organisms and quantification of 
Bacillus subtilis tRNAs: gene expression level and species-specific diversity of 
codon usage based on multivariate analysis. Gene 238, 143–155. 
Kantidakis, T., Ramsbottom, B. A., Birch, J. L., Dowding, S. N. and White, R. 
J. (2010). mTOR associates with TFIIIC, is found at tRNA and 5S rRNA 
genes, and targets their repressor Maf1. Proc. Natl. Acad. Sci. U. S. A. 107, 
11823–8. 
Kasberg, A. D., Brunskill, E. W. and Potter, S. S. (2013). SP8 regulates 
signaling centers during craniofacial development Abigail. Dev. Biol. 381, 
312–323. 
Kassar-Duchossoy, L., Gayraud-Morel, B., Gomès, D., Rocancourt, D., 
Buckingham, M., Shinin, V. and Tajbakhsh, S. (2004). Mrf4 determines 
skeletal muscle identity in Myf5:Myod double-mutant mice. Nature 431, 466–
71. 
Kee, Y. and Bronner-Fraser, M. (2005). To proliferate or to die: Role of Id3 in cell 
cycle progression and survival of neural crest progenitors. Genes Dev. 19, 
744–755. 
Khattar, E., Kumar, P., Liu, C. Y., Akıncılar, S. C., Raju, A., Lakshmanan, M., 
Jean, J., Maury, P., Qiang, Y., Li, S., et al. (2016). Telomerase reverse 
275 
 
transcriptase promotes cancer cell proliferation by augmenting tRNA 
expression. J. Clin. Invest. 126, 4045–4060. 
Kim, H. K., Lee, Y. S., Sivaprasad, U., Malhotra, A. and Dutta, A. (2006). 
Muscle-specific microRNA miR-206 promotes muscle differentiation. J. Cell 
Biol. 174, 677–687. 
Knoepfler, P. S., Bergstrom, D. A., Uetsuki, T., Dac-korytko, I., Sun, Y. H., 
Wright, W. E., Tapscott, S. J. and Kamps, M. P. (1999). A conserved motif 
N-terminal to the DNA-binding domains of myogenic bHLH transcription 
factors mediates cooperative DNA binding with Pbx – Meis1 / Prep1. Nucleic 
Acids Res. 27, 3752–3761. 
Kok, F. O., Shin, M., Ni, C.-W., Gupta, A., Grosse, A. S., van Impel, A., 
Kirchmaier, B. C., Peterson-Maduro, J., Kourkoulis, G., Male, I., et al. 
(2014). Reverse Genetic Screening Reveals Poor Correlation between 
Morpholino-Induced and Mutant Phenotypes in Zebrafish. Dev. Cell 32, 97–
108. 
Köster, M., Dillinger, K. and Knöchel, W. (1998). Expression pattern of the 
winged helix factor XFD-11 during Xenopus embryogenesis. Mech. Dev. 76, 
169–173. 
Kuang, S., Kuroda, K., Le Grand, F. and Rudnicki, M. A. (2007). Asymmetric 
Self-Renewal and Commitment of Satellite Stem Cells in Muscle. Cell 129, 
999–1010. 
Kume, T., Deng, K.-Y., Winfrey, V., Gould, D. B., Walter, M. A. and Hogan, B. 
L. . (1998). The Forkhead/Winged Helix Gene Mf1 Is Disrupted in the 
Pleiotropic Mouse Mutation congenital hydrocephalus. Cell 93, 985–996. 
Kume, T., Jiang, H., Topczewska, J. M. and Hogan, B. L. (2001). The murine 
winged helix transcription factors, Foxc1 and Foxc2, are both required for 
cardiovascular development and somitogenesis. Genes Dev. 15, 2470–2482. 
Kutter, C., Brown, G. D., Gonçalves, A., Wilson, M. D., Watt, S., Brazma, A., 
White, R. J. and Odom, D. T. (2011). Pol III binding in six mammals shows 
conservation among amino acid isotypes despite divergence among tRNA 
genes. Nat. Genet. 43, 948–55. 
276 
 
Laferté, A., Favry, E., Sentenac, A., Riva, M., Carles, C. and Chédin, S. (2006). 
The transcriptional activity of RNA polymerase I is a key determinant for the 
level of all ribosome components. Genes Dev. 20, 2030–2040. 
Lagha, M., Brunelli, S., Messina, G., Cumano, A., Kume, T., Relaix, F. and 
Buckingham, M. E. (2009). Pax3:Foxc2 Reciprocal Repression in the Somite 
Modulates Muscular versus Vascular Cell Fate Choice in Multipotent 
Progenitors. Dev. Cell 17, 892–899. 
Langlands, K., Yin, X., Anand, G. and Prochownik, E. V (1997). Differential 
interactions of Id proteins with basic-helix-loop-helix transcription factors. J. 
Biol. Chem. 272, 19785–93. 
Laplante, M. and Sabatini, D. M. (2009). mTOR signaling at a glance. J. Cell Sci. 
122, 3589–94. 
Laplante, M. and Sabatini, D. M. (2012). mTOR signaling in growth control and 
disease. Cell 149, 274–293. 
Lasorella, A., Benezra, R. and Iavarone, A. (2014). The ID proteins: master 
regulators of cancer stem cells and tumour aggressiveness. Nat. Rev. Cancer 
14, 77–91. 
Lepper, C., Partridge, T. A., Fan, C.-M. and Gruss, P. (2011). An absolute 
requirement for Pax7-positive satellite cells in acute injury-induced skeletal 
muscle regeneration. Development 138, 3639–46. 
Li, H.-Y., Bourdelas, A., Carron, C. and Shi, D.-L. (2010a). The RNA-binding 
protein Seb4/RBM24 is a direct target of MyoD and is required for 
myogenesis during Xenopus early development. Mech. Dev. 127, 281–291. 
Li, D., Morales, A., Gonzalez-Quintana, J., Norton, N., Siegfried, J. D., 
Hofmeyer, M. and Hershberger, R. E. (2010b). Identification of novel 
mutations in RBM20 in patients with dilated cardiomyopathy. Clin. Transl. Sci. 
3, 90–97. 
Li, S., Guo, W., Dewey, C. N. and Greaser, M. L. (2013). Rbm20 regulates titin 
alternative splicing as a splicing repressor. Nucleic Acids Res. 41, 2659–
2672. 
277 
 
Li, M., Zhao, L., Page-McCaw, P. S. and Chen, W. (2016). Zebrafish Genome 
Engineering Using the CRISPR–Cas9 System. Trends Genet. 32, 815–827. 
Light, W., Vernon, A., Lasorella, A., Lavarone, A. and LaBonne, C. (2005). 
Xenopus Id3 is required downstream of Myc for the formation of multipotent 
neural crest progenitor cells. Development 132, 1831–1841. 
Lluís, F., Ballestar, E., Suelves, M., Esteller, M. and Muñoz-Cánoves, P. 
(2005). E47 phosphorylation by p38 MAPK promotes MyoD/E47 association 
and muscle-specific gene transcription. EMBO J. 24, 974–84. 
Lloyd, R. E., Foster, P.G., Guille, M. and Littlewood, D.T.J. (2012). Next 
generation  sequencing and comparitive analyses of Xenopus mitogenomes. 
BMC Genomics. 13, 496 
Macek, P., Cliff, M. J., Embrey, K. J., Holdgate, G. A., Nissink, J. W. M., 
Panova, S., Waltho, J. P. and Davies, R. A. (2018). Myc phosphorylation in 
its basic helix-loop-helix region destabilizes transient α-helical structures, 
disrupting Max and DNA binding. J. Biol. Chem. 293, 9301–9310. 
Maguire, R. J., Isaacs, H. V and Pownall, M. E. (2012). Early transcriptional 
targets of MyoD link myogenesis and somitogenesis. Dev. Biol. 371, 256–68. 
Maragh, S., Miller, R. A., Bessling, S. L., Wang, G., Hook, P. W. and 
McCallion, A. S. (2014). Rbm24a and Rbm24b are required for normal 
somitogenesis. PLoS One 9,. 
Marshall, L. and White, R. J. (2008). Non-coding RNA production by RNA 
polymerase III is implicated in cancer. Nat. Rev. Cancer 8, 911–4. 
Marshall, L., Rideout, E. J. and Grewal, S. S. (2012). Nutrient / TOR-dependent 
regulation of RNA polymerase III controls tissue and organismal growth in 
Drosophila. EMBO J. 31, 1916–1930. 
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Cell Biol. 
Maves, L., Waskiewicz, A. J., Paul, B., Cao, Y., Tyler, A., Moens, C. B. and 
Tapscott, S. J. (2007). Pbx homeodomain proteins direct Myod activity to 
promote fast-muscle differentiation. Development 3382, 3371–3382. 
Mayeuf-Louchart, A., Lagha, M., Danckaert, A., Rocancourt, D., Relaix, F., 
278 
 
Vincent, S. and Buckingham, M. (2014). Notch regulation of myogenic 
versus endothelial fates of cells that migrate from the somite to the limb. Proc. 
Natl. Acad. Sci. 111, 1–6. 
Mayeuf-Louchart, A., Montarras, D., Bodin, C., Kume, T., Vincent, S. D. and 
Buckingham, M. (2016). Endothelial cell specification in the somite is 
compromised in Pax3-positive progenitors of Foxc1/2 conditional mutants, 
with loss of forelimb myogenesis. Development 143, dev.128017-. 
McDermott, A., Gustafsson, M., Elsam, T., Hui, C.-C., Emerson, C. P. and 
Borycki, A.-G. (2005). Gli2 and Gli3 have redundant and context-dependent 
function in skeletal muscle formation. Development 132, 345–57. 
McQueen, C. and Pownall, M. E. (2017). An analysis of MyoD-dependent 
transcription using CRISPR/Cas9 gene targeting in Xenopus tropicalis 
embryos. Mech. Dev. 146, 1–9. 
Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E. and Rudnicki, M. A. 
(1996). MyoD is required for myogenic stem cell function in adult skeletal 
muscle. Genes Dev. 10, 1173–83. 
Miller, D. M., Thomas, S. D., Islam, A., Muench, D. and Sedoris, K. (2012). c-
Myc and Cancer Metabolism. Clin. Cancer Res. 18, 5546–5554. 
Mishima, Y., Abreu-Goodger, C., Staton, A. A., Stahlhut, C., Shou, C., Cheng, 
C., Gerstein, M., Enright, A. J. and Giraldez, A. J. (2009). Zebrafish miR-1 
and miR-133 shape muscle gene expression and regulate sarcomeric actin 
organization. Genes Dev. 23, 619–632. 
Moir, R. D., Lee, J., Haeusler, R. A., Desai, N., Engelke, D. R. and Willis, I. M. 
(2006). Protein kinase A regulates RNA polymerase III transcription through 
the nuclear localization of Maf1. Proc. Natl. Acad. Sci. U. S. A. 103, 15044–9. 
Mok, G. F., Lozano-Velasco, E., Maniou, E., Viaut, C., Moxon, S., Wheeler, G. 
and Münsterberg, A. (2018). miR-133-mediated regulation of the Hedgehog 
pathway orchestrates embryo myogenesis. Development 145, dev159657. 
Molkentin, J. D., Black, B. L., Martin, J. F. and Olson, E. N. (1995). Cooperative 
Activation of Muscle Gene Expression by MEF2 and Myogenic bHLH 
Proteins. Cell 83, 1125–1136. 
279 
 
Monsoro-Burq, A.-H., Wang, E. and Harland, R. (2005). Msx1 and Pax3 
Cooperate to Mediate FGF8 and WNT Signals during Xenopus Neural Crest 
Induction. Dev. Cell 8, 167–178. 
Moqtaderi, Z., Wang, J., Raha, D., White, R. J., Snyder, M., Weng, Z. and 
Struhl, K. (2010). Genomic binding profiles of functionally distinct RNA 
polymerase III transcription complexes in human cells. Nat. Struct. Mol. Biol. 
17, 635–40. 
Moriyama, E. N. and Powell, J. R. (1997). Codon Usage Bias and tRNA 
Abundance in Drosophila. J. Mol. Evol. 45, 514–523. 
Münsterberg, A. and Lassar, A. (1995). Combinatorial signals from the neural 
tube, floor plate and notochord induce myogenic bHLH gene expression in the 
somite. Development 121, 651–660. 
Münsterberg, A. E., Kitajewski, J., Bumcrot, D. A., McMahon, A. P. and 
Lassar, A. B. (1995). Combinatorial signaling by Sonic hedgehog and Wnt 
family members induces myogenic bHLH gene expression in the somite. 
Genes Dev. 9, 2911–2922. 
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., Nonaka, I. and 
Nabeshima, Y. (1993). Myogenin gene disruption results in perinatal lethality 
because of severe muscle defect. Nature 364, 532–5. 
Naidu, P. S., Ludolph, D. C., To, R. Q., Hinterberger, T. J. and Konieczny, S. 
F. (1995). Myogenin and MEF2 Function Synergistically To Activate the MRF4 
Promoter during Myogenesis. Mol. Cell. Biol. 15, 2707–2718. 
Nakamura, Y., de Paiva Alves, E., Veenstra, G. J. C. and Hoppler, S. (2016). 
Tissue- and stage-specific Wnt target gene expression is controlled 
subsequent to β-catenin recruitment to cis-regulatory modules. Development 
143, 1914–1925. 
Nakayama, T., Fish, M. B., Fisher, M., Oomen-Hajagos, J., Thomsen, G. H. 
and Grainger, R. M. (2013). Simple and efficient CRISPR/Cas9-mediated 
targeted mutagenesis in Xenopus tropicalis. Genesis 51, 835–43. 
Nakayama, T., Blitz, I. L., Fish, M. B., Odeleye, A. O., Manohar, S., Cho, K. W. 
Y. and Grainger, R. M. (2014). Cas9-based genome editing in Xenopus 
280 
 
tropicalis. Methods Enzymol. 546, 355–75. 
Nandan, M. O. and Yang, V. W. (2009). The role of Krüppel-like factors in the 
reprogramming of somatic cells to induced pluripotent stem cells. Histol. 
Histopathol. 24, 1343–1355. 
Narayanswami, S., Doering, J. L., Fokta, F. J., Rosenthal, D. S., Nguyen, T.-N. 
and Hamkalo, B. A. (1995). Chromosomal locations of major tRNA gene 
clusters of Xenopus laevis. Chromosoma 104, 68–74. 
Neuhold, L. A. and Wold, B. (1993). HLH forced dimers: Tethering MyoD to E47 
generates a dominant positive myogenic factor insulated from negative 
regulation by Id. Cell 74, 1033–1042. 
Newport, J. and Kirschner, M. (1982a). A Major Developmental Transition in 
Early Xenopus Embryos: I. characterization and timing of cellular changes at 
the Midblastula Stage. Cell 30, 675–686. 
Newport, J. and Kirschner, M. (1982b). A Major Developmental Transition in 
Early Xenopus Embryos: II. Control of the Onset of Transcription. Cell 30, 
687–696. 
Oelgeschläger, M., Kuroda, H., Reversade, B. and De Robertis, E. M. (2003). 
Chordin Is Required for the Spemann Organizer Transplantation 
Phenomenon in Xenopus Embryos. Dev. Cell 4, 219–230. 
Oficjalska-Pham, D., Harismendy, O., Smagowicz, W. J., Gonzalez de Peredo, 
A., Boguta, M., Sentenac, A. and Lefebvre, O. (2006). General repression 
of RNA polymerase III transcription is triggered by protein phosphatase type 
2A-mediated dephosphorylation of Maf1. Mol. Cell 22, 623–32. 
Oler, A. J., Alla, R. K., Roberts, D. N., Wong, A., Hollenhorst, P. C., Chandler, 
K. J., Cassiday, P. A., Nelson, C. A., Hagedorn, C. H., Graves, B. J., et al. 
(2010). Human RNA polymerase III transcriptomes and relationships to Pol II 
promoter chromatin and enhancer-binding factors. Nat. Struct. Mol. Biol. 17, 
620–8. 
Ott, M. O., Bober, E., Lyons, G., Arnold, H. and Buckingham, M. (1991). Early 
expression of the myogenic regulatory gene, myf-5, in precursor cells of 
skeletal muscle in the mouse embryo. Development 111, 1097–1107. 
281 
 
Otte, A. P. and Moon, R. T. (1992). Ectopic induction of dorsal mesoderm by 
overexpression of Xwnt-8 elevates the neural competence of Xenopus 
ectoderm. Dev. Biol. 152, 184–187. 
Owens, N. D. L., Blitz, I. L., Lane, M. A., Patrushev, I., Overton, J. D., Gilchrist, 
M. J., Cho, K. W. Y. and Khokha, M. K. (2016). Measuring Absolute RNA 
Copy Numbers at High Temporal Resolution Reveals Transcriptome Kinetics 
in Development. Cell Rep. 14, 632–647. 
Pan, Y., Bai, C. B., Joyner, A. L. and Wang, B. (2006). Sonic hedgehog 
Signaling Regulates Gli2 Transcriptional Activity by Suppressing Its 
Processing and Degradation Sonic hedgehog Signaling Regulates Gli2 
Transcriptional Activity by Suppressing Its Processing and Degradation †. 
Mol. Cell. Biol. 26, 3365–3377. 
Papin, C., van Grunsven, L. A., Verschueren, K., Huylebroeck, D. and Smith, 
J. C. (2002). Dynamic regulation of Brachyury expression in the amphibian 
embryo by XSIP1. Mech. Dev. 111, 37–46. 
Paquette, J., Tokuyasu, T., Salzberg, S., Altherr, M., Bredt, D., Blaxall, B., 
Adami, E., Rintisch, C., Dauksaite, V., Radke, M. H., et al. (2014). RNA-
binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA 
processing. Bioinformatics. 26, 285–286. 
Paule, M. R. and White, R. J. (2000). Transcription by RNA polymerases I and III. 
Nucleic Acids Res. 28, 1283–1298. 
Pavon-Eternod, M., Gomes, S., Geslain, R., Dai, Q., Rosner, M. R. and Pan, T. 
(2009). tRNA over-expression in breast cancer and functional consequences. 
Nucleic Acids Res. 37, 7268–80. 
Pavon-Eternod, M., Gomes, S., Rosner, M. R. and Pan, T. (2013). 
Overexpression of initiator methionine tRNA leads to global reprogramming of 
tRNA expression and increased proliferation in human epithelial cells. RNA 
19, 461–6. 
Penn, B. H., Bergstrom, D. A., Dilworth, F. J., Bengal, E. and Tapscott, S. J. 
(2004). A MyoD-generated feed-forward circuit temporally patterns gene 
expression during skeletal muscle differentiation. Genes Dev. 18, 2348–53. 
282 
 
Piccolo, S., Sasai, Y., Lu, B. and De Robertis, E. M. (1996). Dorsoventral 
Patterning in Xenopus: Inhibition of Ventral Signals by Direct Binding of 
Chordin to BMP-4. Cell 86, 589–598. 
Pinney, D., Pearson-White, S., Konieczny, S., Latham, K. and Emerson, C. P. 
(1988). Myogenic lineage determination and differentiation: Evidence for a 
regulatory gene pathway. Cell 53, 781–793. 
Plotkin, J. B., Robins, H. and Levine, A. J. (2004). Tissue-specific codon usage 
and the expression of human genes. Proc. Natl. Acad. Sci. 101, 12588–
12591. 
Pownall, M. E. and Emerson, C. P. (1992). Sequential activation of three 
myogenic regulatory genes during somite morphogenesis in quail embryos. 
Dev. Biol. 151, 67–79. 
Pownall, M. E. and Isaacs, H. V. (2010). FGF Signalling in Vertebrate 
Development. Morgan & Claypool Life Sciences. 
Pownall, M. E., Gustafsson, M. and Emerson, C. P. (2002). Myogenic 
Regulatory Factors and the Specification of Muscle Progenitors in Vertebrate 
Embryos. Annu. Rev. Cell Dev. Biol. 18, 747–783. 
Ramsköld, D., Luo, S., Wang, Y.-C., Li, R., Deng, Q., Faridani, O. R., Daniels, 
G. A., Khrebtukova, I., Loring, J. F., Laurent, L. C., et al. (2012). Full-length 
mRNA-Seq from single-cell levels of RNA and individual circulating tumor 
cells. Nat. Biotechnol. 30, 777–782. 
Rana, A. A., Collart, C., Gilchrist, M. J. and Smith, J. C. (2006). Defining 
synphenotype groups in Xenopus tropicalis by use of antisense morpholino 
oligonucleotides. PLoS Genet. 2, 1751–1772. 
Rathjen, T., Pais, H., Sweetman, D., Moulton, V., Munsterberg, A. and 
Dalmay, T. (2009). High throughput sequencing of microRNAs in chicken 
somites. FEBS Lett. 583, 1422–1426. 
Reina, J. H., Azzouz, T. N. and Hernandez, N. (2006). Maf1, a new player in the 
regulation of human RNA polymerase III transcription. PLoS One 1, e134. 
Renaud, M., Praz, V., Vieu, E., Florens, L., Washburn, M. P., L’Hôte, P. and 
283 
 
Hernandez, N. (2014). Gene duplication and neofunctionalization: POLR3G 
and POLR3GL. Genome Res. 24, 37–51. 
Rosenberg, M. I., Georges, S. A., Asawachaicharn, A., Analau, E. and 
Tapscott, S. J. (2006). MyoD inhibits Fstl1 and Utrn expression by inducing 
transcription of miR-206. J. Cell Biol. 175, 77–85. 
Rosenthal, D. S. and Doering, J. L. (1983). The genomic organization of 
dispersed tRNA and 5 S RNA genes in Xenopus laevis. J. Biol. Chem. 258, 
7402–10. 
Rossi, A., Kontarakis, Z., Gerri, C., Nolte, H., Hölper, S., Krüger, M. and 
Stainier, D. Y. R. (2015). Genetic compensation induced by deleterious 
mutations but not gene knockdowns. Nature 524, 230–233. 
Rudnicki, M. A., Braun, T., Hinuma, S. and Jaenisch, R. (1992). Inactivation of 
MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and 
results in apparently normal muscle development. Cell 71, 383–390. 
Rudnicki, M. A., Schnegelsberg, P. N. J., Stead, R. H., Braun, T., Arnold, H.-H. 
and Jaenisch, R. (1993). MyoD or Myf-5 is required for the formation of 
skeletal muscle. Cell 75, 1351–1359. 
Rudolph, K. L. M., Schmitt, B. M., Villar, D., White, R. J., Marioni, J. C., Kutter, 
C. and Odom, D. T. (2016). Codon-Driven Translational Efficiency Is Stable 
across Diverse Mammalian Cell States. PLoS Genet. 12, e1006024. 
Russ, A. P., Wattler, S., Colledge, W. H., Aparicio, S. A. J. R., Carlton, M. B. 
L., Pearce, J. J., Barton, S. C., Surani, M. A., Ryan, K., Nehls, M. C., et al. 
(2000). Eomesodermin is required for mouse trophoblast development and 
mesoderm formation. Nature 404, 95–99. 
Ryan, K., Garrett, N., Mitchell, A. and Gurdon, J. . (1996). Eomesodermin, a 
Key Early Gene in Xenopus Mesoderm Differentiation. Cell 87, 989–1000. 
Ryan, K., Garrett, N., Bourillot, P.-Y., Stennard, F. and Gurdon, J. . (2000). The 
Xenopus Eomesodermin promoter and its concentration-dependent response 
to activin. Mech. Dev. 94, 133–146. 
Sabourin, L. A., Girgis-Gabardo, A., Seale, P., Asakura, A. and Rudnicki, M. 
284 
 
A. (1999). Reduced differentiation potential of primary MyoD-/- myogenic cells 
derived from adult skeletal muscle. J. Cell Biol. 144, 631–43. 
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., 
Delp, S., Pomerantz, J. H., Artandi, S. E., et al. (2010). Short Telomeres 
and Stem Cell Exhaustion Model Duchenne Muscular Dystrophy in mdx/mTR 
Mice. Cell 143, 1059–1071. 
Saikia, M., Wang, X., Mao, Y., Wan, J. I., Pan, T. A. O. and Qian, S. (2016). 
Codon optimality controls differential mRNA translation during amino acid 
starvation. RNA 22, 1–9. 
Salghetti, S. E., Kim, S. Y., Tansey, W. P., Matsumoto, M., Nakamichi, I., 
Kitagawa, K., Shirane, M., Tsunematsu, R., Tsukiyama, T., Ishida, N., et 
al. (1999). Destruction of Myc by ubiquitin-mediated proteolysis: cancer-
associated and transforming mutations stabilize Myc. EMBO J. 18, 717–726. 
Sander, J. D. and Joung, J. K. (2014). CRISPR-Cas systems for editing, 
regulating and targeting genomes. Nat. Biotechnol. 32, 347–55. 
Sartorelli, V; Caretti, G. (2005). Mechanisms underlying the transcriptional 
regulation of skeletal myogenesis. Curr. Opin. Genet. Dev. 15, 528–535. 
Sasai, Y., Lu, B., Steinbeisser, H., Geissert, D., Gont, L. K. and De Robertis, 
E. M. (1994). Xenopus chordin: A novel dorsalizing factor activated by 
organizer-specific homeobox genes. Cell 79, 779–790. 
Sasai, Y., Lu, B., Steinbeisser, H. and De Robertis, E. M. (1995). Regulation of 
neural induction by the Chd and Bmp-4 antagonistic patterning signals in 
Xenopus. Nature 376, 333–336. 
Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M. and Kondoh, H. (1999). 
Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: 
implication of Gli2 and Gli3 as primary mediators of Shh signaling. 
Development 126, 3915–3924. 
Savage, J., Voronova, A., Mehta, V., Sendi-Mukasa, F. and Skerjanc, I. S. 
(2010). Canonical Wnt signaling regulates Foxc1/2 expression in P19 cells☆. 
Differentiation 79, 31–40. 
285 
 
Schmalbruch, H. and Lewis, D. M. (2000). Dynamics of nuclei of muscle fibers 
and connective tissue cells in normal and denervated rat muscles. Muscle 
Nerve 23, 617–26. 
Schmidt, E. V (1999). The role of c- myc in cellular growth control. Oncogene 18, 
2988–2996. 
Schmitt, B. M., Rudolph, K. L. M., Karagianni, P., Fonseca, N. A., White, R. J., 
Talianidis, I., Odom, D. T., Marioni, J. C. and Kutter, C. (2014). High-
resolution mapping of transcriptional dynamics across tissue development 
reveals a stable mRNA-tRNA interface. Genome Res. 24, 1797–1807. 
Schulte-Merker, S. and Stainier, D. Y. R. (2014). Out with the old, in with the 
new: reassessing morpholino knockdowns in light of genome editing 
technology. Development 141, 3103–4. 
Seale, P., Sabourin, L. A., Girgis-Gabardo, A., Mansouri, A., Gruss, P. and 
Rudnicki, M. A. (2000). Pax7 Is Required for the Specification of Myogenic 
Satellite Cells. Cell 102, 777–786. 
Shaw, P. H. (1996). The role of p53 in cell cycle regulation. Pathol. Res. Pract. 
192, 669–75. 
Sherr, C. J. and McCormick, F. (2002). The RB and p53 pathways in cancer. 
Cancer Cell 2, 103–112. 
Shor, B., Wu, J., Shakey, Q., Toral-Barza, L., Shi, C., Follettie, M. and Yu, K. 
(2010). Requirement of the mTOR Kinase for the Regulation of Maf1 
Phosphorylation and Control of RNA Polymerase III-dependent Transcription 
in Cancer Cells. J. Biol. Chem. 285, 15380–15392. 
Slack, J. M. W., Darlington, B. G., Heath, J. K. and Godsave, S. F. (1987). 
Mesoderm induction in early Xenopus embryos by heparin-binding growth 
factors. Nature 326, 197–200. 
Slack, J. M., Isaacs, H. V. and Darlington, B. G. (1988). Inductive effects of 
fibroblast growth factor and lithium ion on Xenopus blastula ectoderm. 
Development 103, 581–590. 
Smith, J. (1995). Mesodern-inducing factors and mesodermal patterning. Curr. 
286 
 
Opin. Cell Biol. 7, 856–861. 
Smith, W. C. and Harland, R. M. (1991). Injected Xwnt-8 RNA acts early in 
Xenopus embryos to promote formation of a vegetal dorsalizing center. Cell 
67, 753–765. 
Sokol, S. Y. (1993). Mesoderm formation in Xenopus ectodermal explants 
overexpressing Xwnt8: evidence for a cooperating signal reaching the animal 
pole by gastrulation. Development 118,. 
Sokol, S. Y. and Melton, D. A. (1992). Interaction of Wnt and activin in dorsal 
mesoderm induction in Xenopus. Dev. Biol. 154, 348–355. 
Soleimani, V. D., Yin, H., Jahani-Asl, A., Ming, H., Kockx, C. E. M., van Ijcken, 
W. F. J., Grosveld, F. and Rudnicki, M. A. (2012). Snail Regulates MyoD 
Binding-Site Occupancy to Direct Enhancer Switching and Differentiation-
Specific Transcription in Myogenesis. Mol. Cell 47, 457–468. 
Sölter, M., Köster, M., Hollemann, T., Brey, A., Pieler, T. and Knöchel, W. 
(1999). Characterization of a subfamily of related winged helix genes, XFD-
12/12′/12″ (XFLIP), during Xenopus embryogenesis. Mech. Dev. 89, 161–165. 
Sriskanthadevan-Pirahas, S., Deshpande, R., Lee, B. and Grewal, S. S. 
(2018). Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA 
polymerase III repressor Maf1 in Drosophila. PLOS Genet. 14, e1007202. 
Standley, H. J., Zorn, A. M. and Gurdon, J. B. (2001). eFGF and its mode of 
action in the community effect during Xenopus myogenesis. Development 
128, 1347–57. 
Stenico, M., Lloyd, A. T. and Sharp, P. M. (1994). Codon usage in 
Caenorhabditis elegans: delineation of translational selection and mutational 
biases. Nucleic Acids Res. 22, 2437–46. 
Stutz, F., Gouilloud, E. and Clarkson, S. G. (1989). Oocyte and somatic tyrosine 
tRNA genes in Xenopus laevis. Genes Dev. 3, 1190–1198. 
Sullivan, S. A., Akers, L. and Moody, S. A. (2001). foxD5a, a Xenopus Winged 
Helix Gene, Maintains an Immature Neural Ectoderm via Transcriptional 
Repression That Is Dependent on the C-Terminal Domain. Dev. Biol. 232, 
287 
 
439–457. 
Summerton, J. and Weller, D. (1997). Morpholino Antisense Oligomers: Design, 
Preparation, and Properties. Antisense Nucleic Acid Drug Dev. 7, 187–195. 
Sutcliffe, J. E., Brown, T. R. P., Allison, S. J., Scott, P. H. and White, R. J. 
(2000). Retinoblastoma Protein Disrupts Interactions Required for RNA 
Polymerase III Transcription. Mol. Cell. Biol. 20, 9192–9202. 
Suzuki, Y. and Brown, D. D. (1972). Isolation and Identification of the messenger 
RNA for silk fibroin from Bombyx mori. J. Mol. Biol. 63, 409–429. 
Sweetman, D., Rathjen, T., Jefferson, M., Wheeler, G., Smith, T. G., Wheeler, 
G. N., Münsterberg, A. and Dalmay, T. (2006). FGF-4 signaling is involved 
in mir-206 expression in developing somites of chicken embryos. Dev. Dyn. 
235, 2185–2191. 
Sweetman, D., Goljanek, K., Rathjen, T., Oustanina, S., Braun, T., Dalmay, T. 
and Münsterberg, A. (2008). Specific requirements of MRFs for the 
expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev. 
Biol. 321, 491–499. 
Tajbakhsh, S., Borello, U., Vivarelli, E., Kelly, R., Papkoff, J., Duprez, D., 
Buckingham, M. E. and Cossu, G. (1998). Differential activation of Myf5 and 
MyoD by different Wnts in explants of mouse paraxial mesoderm and the later 
activation of myogenesis in the absence of Myf5. Development 125, 4155–
4162. 
Takemoto, T., Uchikawa, M., Yoshida, M., Bell, D. M., Lovell-Badge, R., 
Papaioannou, V. E. and Kondoh, H. (2011). Tbx6-dependent Sox2 
regulation determines neural or mesodermal fate in axial stem cells. Nature 
470, 394–398. 
Tan, M. H., Au, K. F., Yablonovitch, A. L., Wills, A. E., Chuang, J., Baker, J. C., 
Wong, W. H. and Li, J. B. (2013). RNA Sequencing Reveals a Diverse and 
Dynamic Repertoire of the Xenopus tropicalis Transcriptome Over 
Development. Genome Res. 23, 201–216. 
Tapscott, S. J. (2005). The circuitry of a master switch: Myod and the regulation 
of skeletal muscle gene transcription. Development 132, 2685–95. 
288 
 
Therapy, G., Vol, M. B. and Schultz, M. C. (1999). Target of rapamycin ( TOR ) 
signaling coordinates tRNA and 5S rRNA gene transcription with growth rate 
in yeast Review Article. Gene Ther. Mol. Biol. 4, 339–348. 
Thisse, B., Pflumio, S., Fürthauer, M., Loppin, B., Heyer, V., Degrave, A., 
Woehl, R., Lux, A., Steffan, T. and Charbonnier, X. Q. (2001). Expression 
of the zebrafish genome during embryogenesis. ZFIN Direct Data Submiss. 
http://zfin.org,. 
Tichy, E. D., Sidibe, D. K., Tierney, M. T., Stec, M. J., Sharifi-Sanjani, M., 
Hosalkar, H., Mubarak, S., Johnson, F. B., Sacco, A. and Mourkioti, F. 
(2017). Single Stem Cell Imaging and Analysis Reveals Telomere Length 
Differences in Diseased Human and Mouse Skeletal Muscles. Stem Cell 
Reports 9, 1328–1341. 
Topczewska, J. M., Topczewski, J., Shostak, A., Kume, T., Solnica-Krezel, L. 
and Hogan, B. L. M. (2001). The winged helix transcription factor Foxc1a is 
essential for somitogenesis in zebrafish. Genes Dev. 15, 2483–2493. 
Topisirovic, I. and Sonenberg, N. (2014). Distinctive tRNA Repertoires in 
Proliferating versus Differentiating Cells. Cell 158, 1238–9. 
Tsang, C. K., Liu, H. and Zheng, X. F. S. (2010). mTOR binds to the promoters 
of RNA polymerase I- and III-transcribed genes. Cell Cycle 9, 953–7. 
Upadhya, R., Lee, J. and Willis, I. M. (2002). Maf1 Is an Essential Mediator of 
Diverse Signals that Repress RNA Polymerase III Transcription. Mol. Cell 10, 
1489–1494. 
Vannini, A., Ringel, R., Kusser, A. G., Berninghausen, O., Kassavetis, G. A. 
and Cramer, P. (2010). Molecular basis of RNA polymerase III transcription 
repression by Maf1. Cell 143, 59–70. 
Voronova, A., Coyne, E., Al Madhoun, A., Fair, J. V, Bosiljcic, N., St-Louis, C., 
Li, G., Thurig, S., Wallace, V. A., Wiper-Bergeron, N., et al. (2013). 
Hedgehog signaling regulates MyoD expression and activity. J. Biol. Chem. 
288, 4389–4404. 
Wagner, D. S., Dosch, R., Mintzer, K. A., Wiemelt, A. P. and Mullins, M. C. 
(2004). Maternal control of development at the midblastula transition and 
289 
 
beyond: mutants from the zebrafish II. Dev. Cell 6, 781–90. 
Walston, J. D. (2012). Sarcopenia in older adults. Curr. Opin. Rheumatol. 24, 
623–627. 
Wang, L.-H. and Baker, N. E. (2015). E Proteins and ID Proteins: Helix-Loop-
Helix Partners in Development and Disease. Dev. Cell 35, 269–280. 
Wang, Y. and Jaenisch, R. (1997). Myogenin can substitute for Myf5 in promoting 
myogenesis but less efficiently. Development 124, 2507–2513. 
Wang, Z. and Roeder, R. G. (1997). Three human RNA polymerase III-specific 
subunits form a subcomplex with a selective function in specific transcription 
initiation. Genes Dev. 11, 1315–26. 
Wang, D., Valdez, M. R., Mcanally, J., Richardson, J. and Olson, E. N. (2001). 
The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 
proteins during skeletal muscle development. Development 128, 4623–4633. 
Wasserman, W. W. and Fickett, J. W. (1998). Identification of regulatory regions 
which confer muscle-specific gene expression. J. Mol. Biol. 278, 167–181. 
Weintraub, H., Davis, R., Lockshon, D. and Lassar, A. (1990). MyoD binds 
cooperatively to two sites in a target enhancer sequence: occupancy of two 
sites is required for activation. Proc. Natl. Acad. Sci. U. S. A. 87, 5623–7. 
Weintraub, H., Davis, R., Tapscott, S., Thayer, M., Krause, M., Benezra, R., 
Blackwell, T. K., Turner, D., Rupp, R., Hollenberg, S., et al. (1991). The 
myoD gene family: nodal point during specification of the muscle cell lineage. 
Science 251, 761–6. 
Welcker, M., Orian, A., Jin, J., Grim, J. E., Grim, J. A., Harper, J. W., 
Eisenman, R. N. and Clurman, B. E. (2004). The Fbw7 tumor suppressor 
regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc 
protein degradation. Proc. Natl. Acad. Sci. U. S. A. 101, 9085–9090. 
White, R. J. (2004). RNA polymerase III transcription and cancer. Oncogene 23, 
3208–16. 
White, R. J. (2005). RNA polymerases I and III, growth control and cancer. Nat. 
Rev. Mol. Cell Biol. 6, 69–78. 
290 
 
White, R. J. (2008). RNA polymerases I and III, non-coding RNAs and cancer. 
Trends Genet. 24, 622–9. 
White, R. J. (2011). Transcription by RNA polymerase III: more complex than we 
thought. Nat. Rev. Genet. 12, 459–63. 
White, R. J., Stott, D. and Rigby, P. W. (1989). Regulation of RNA polymerase III 
transcription in response to F9 embryonal carcinoma stem cell differentiation. 
Cell 59, 1081–1092. 
Williamson, D., Lu, Y.-J., Fang, C., Pritchard-Jones, K. and Shipley, J. (2006). 
Nascent pre-rRNA overexpression correlates with an adverse prognosis in 
alveolar rhabdomyosarcoma. Genes, Chromosom. Cancer 45, 839–845. 
Wilusz, J. E. (2015). Removing roadblocks to deep sequencing of modified RNAs. 
Nat. Methods 12, 821–2. 
Winter, A. G., Sourvinos, G., Allison, S. J., Tosh, K., Scott, P. H., Spandidos, 
D. A. and White, R. J. (2000). RNA polymerase III transcription factor TFIIIC2 
is overexpressed in ovarian tumors. Proc. Natl. Acad. Sci. U. S. A. 97, 12619–
24. 
Wolffe, A. and Brown, D. (1988). Developmental regulation of two 5S ribosomal 
RNA genes. Science (80-. ). 241, 1626–1632. 
Wong, E. H. M., Smith, D. K., Rabadan, R., Peiris, M. and Poon, L. L. M. 
(2010). Codon usage bias and the evolution of influenza A viruses. Codon 
Usage Biases of Influenza Virus. BMC Evol. Biol. 10, 253. 
Wong, R. C.-B., Pollan, S., Fong, H., Ibrahim, A., Smith, E. L., Ho, M., Laslett, 
A. L. and Donovan, P. J. (2011). A novel role for an RNA polymerase III 
subunit POLR3G in regulating pluripotency in human embryonic stem cells. 
Stem Cells 29, 1517–27. 
Wood, W. M., Etemad, S., Yamamoto, M. and Goldhamer, D. J. (2013). MyoD-
expressing progenitors are essential for skeletal myogenesis and satellite cell 
development. Dev. Biol. 384, 114–127. 
Wormington, W. M. and Brown, D. D. (1983). Onset of 5 S RNA gene regulation 
during Xenopus embryogenesis. Dev. Biol. 99, 248–57. 
291 
 
Yan, B., Neilson, K. M. and Moody, S. A. (2009a). Notch signaling downstream 
of foxD5 promotes neural ectodermal transcription factors that inhibit neural 
differentiation. Dev. Dyn. 238, 1358–1365. 
Yan, B., Neilson, K. M. and Moody, S. A. (2009b). foxD5 plays a critical 
upstream role in regulating neural ectodermal fate and the onset of neural 
differentiation. Dev. Biol. 329, 80–95. 
Yang, J., Hung, L.-H., Licht, T., Kostin, S., Looso, M., Khrameeva, E., 
Bindereif, A., Schneider, A. and Braun, T. (2014). RBM24 Is a Major 
Regulator of Muscle-Specific Alternative Splicing. Dev. Cell 31, 87–99. 
Yao, Z., Farr, G. H., Tapscott, S. J. and Maves, L. (2013a). Pbx and Prdm1a 
transcription factors differentially regulate subsets of the fast skeletal muscle 
program in zebrafish. Biol. Open 2, 546–55. 
Yao, Z., Fong, A. P., Cao, Y., Ruzzo, W. L., Gentleman, R. C. and Tapscott, S. 
J. (2013b). Comparison of endogenous and overexpressed MyoD shows 
enhanced binding of physiologically bound sites. Skelet. Muscle 3,. 
Yin, H., Price, F. and Rudnicki, M. A. (2013). Satellite cells and the muscle stem 
cell niche. Physiol. Rev. 93, 23–67. 
Zetser, A., Gredinger, E. and Bengal, E. (1999). p38 Mitogen-activated Protein 
Kinase Pathway Promotes Skeletal Muscle Differentiation. J. Biol. Chem. 274, 
5193–5200. 
Zheng, G., Qin, Y., Clark, W. C., Dai, Q., Yi, C., He, C., Lambowitz, A. M. and 
Pan, T. (2015). Efficient and quantitative high-throughput tRNA sequencing. 
Nat. Methods 12, 835–7. 
Zhu, Z. and Miller, J. B. (1997). MRF4 can substitute for myogenin during early 
stages of myogenesis. Dev. Dyn. 209, 233–241. 
 
